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Title: Collaborations, Connections & Participation: An ethnographic study of dementia 
research in the UK 
 
Author: Sally Ann Atkinson 
This thesis examines the question: How is biomedical research in the field of dementia enacted? 
I address this question using ethnographic fieldwork, interviews and document analysis 
conducted between September 2010 and March 2014, which examine the relations involved in 
the emergence of a national dementia research agenda in the UK. Over the last decade in the 
UK ‘dementia’ has become characterised as the public health crisis of our time. The sense of crisis 
around the conditions covered by this umbrella term is exacerbated by a global trend toward 
increased longevity and acute awareness of the limitations of existing treatments. In 2011 the 
UK Department of Health, in collaboration with national research organisations, announced 
the launch of an integrated dementia research strategy. Taking a historical and emergent 
perspective on research into aging, neurodegenerative diseases and the concept of ‘dementia’, 
this examination demonstrates how the evolving research initiative marks a shift in the process 
of co-production which exists between science, policy and publics in the UK.  
Using a detailed examination of linguistic and visual material from the perspective of science 
policy and practice, the thesis demonstrates how shifts in biotechnology make conditions 
described under the umbrella of ‘dementias’ differently visible. The scientific narratives which 
accompany this changing visibility, present dementias as a challenging target for social and 
scientific intervention. In response to this complexity, the research agenda focuses on the 
relationships and interactions between the multiple stakeholders involved. A rhetoric-based 
analysis demonstrates how researchers use such collaborations to try and remake the connections 
between aging, dementia, science and social responsibility. I argue that this process of breaking 
and remaking such connections is part of persuasive attempt to embed patients, participants and 
publics in the conduct of clinical research. 
This ethnographic description demonstrates how this process of embedded engagement is not 
without challenge. Researchers feel increasingly exposed to public expectations and frustrations 
which exist beyond the control of the ‘citadel’ of science (Martin 1998). Thus through cyclical 
re-workings of narratives of success and failure, hope and possibility, researchers involved in the 
development of new interventions for dementia diagnosis and treatment attempt to balance the 
tension between the rhetoric of future potential products and their day-to-day experience of the 
scientific process. Thus the thesis demonstrates how the development of new interventions is a 
continual negotiation of uncertainties and anxieties for both researchers and their participants. 





Collaborations, Connections and Participation:            













Sally A. Atkinson 
Thesis submitted for the degree of Doctor of Philosophy 






Table of Content 
Table of figures ............................................................................................................................ 5 
List of Acronyms ......................................................................................................................... 7 
Acknowledgements ..................................................................................................................... 8 
Chapter 1 Introduction: Complexity in the study of biomedical research ....................... 9 
An overview of the thesis. .................................................................................................... 22 
Chapter 2 Dementia science in context .............................................................................. 27 
Age, chronic disease and emergent technologies ................................................................. 28 
Dementia: A brief historical perspective .............................................................................. 31 
An evolving pathology: pre-senile dementia and twentieth century neurophysiology, 
laboratory cellular imaging techniques ................................................................................. 34 
The Diagnostic Standard Manual and the International Classification of Disease ........... 39 
Neuroscience: Heading toward ‘The Decade of the Brain’ ................................................. 43 
Dementia research in the context of the UK National Health Service: health economics, 
standards and regulations ..................................................................................................... 49 
Chapter 3 The emergence of the ‘field’ ............................................................................... 63 
A turn of events: the national dementia research call ......................................................... 63 
A complex field of multiple stake holders .................................................................................... 66 
Developing relations and addressing access: working inward and studying up ............................... 67 
Experts & elites ........................................................................................................................ 68 
DeNDRoN and the NMR Centre ............................................................................................. 70 
Social relations in clinical research....................................................................................... 73 
Government, industry and the market in dementia research ........................................................ 74 
Negotiating access to NHS dementia research: capitulating to the hydra ...................................... 75 
DeNDRoN as a gatekeeping institution ..................................................................................... 80 
Unexpected connections: the role of ‘para-scientific’ relations ....................................................... 81 
The virtual and visual in dementia research ............................................................................... 82 
Conclusion: on the thickness and thinness of ethnographic data ...................................... 84 
Chapter 4 The burden of dementia - a ‘problem’ for science and society? ........................ 86 
Rhetoric and rhetorical analysis in anthropology and science studies ................................ 86 
The language of burden in dementia research. ..................................................................... 88 
Tracing the etymology of burden ................................................................................................ 96 
4 
 
Perceived problems in dementia science: barking up some wrong trees .......................... 102 
Research involving cognitive impairment, aging and chronic disease ........................................... 114 
Challenges in research organisation and infrastructure .............................................................. 118 
The burdens of dementia research ....................................................................................... 121 
Chapter 5 The rhetoric of risk: the construction of a persuasive crisis. ........................... 125 
‘The impending storm’: dementia & the language of urgency and emergency ................ 127 
Dementia as flood ............................................................................................................... 129 
Scales of risk ........................................................................................................................ 139 
Creating research responsibility ......................................................................................... 155 
Chapter 6 Making and breaking connections in dementia research. .............................. 157 
Breaking connections: Restructuring relations with dementia ......................................... 158 
This is not normal aging ..................................................................................................... 158 
Changing Age ........................................................................................................................ 161 
The economics of later life ....................................................................................................... 163 
Remaking connections: Imagining ‘publics’, ‘participants’ and ‘collaborators’ ............... 169 
Dementia engagement and science as a social good. .................................................................. 175 
The pervasive and everyday nature of engagement strategies ...................................................... 175 
Brains are good to think with: connections of potential, hope and futurity ................................. 177 
The rhetorics of brain donation and research participation: altruism and gifting......................... 182 
The limits of rhetoric .......................................................................................................... 188 
Chapter 7 Anxieties, contradictions & expectations in dementia research ..................... 190 
A ‘poison chalice’: Anxious conversations about research ................................................ 190 
Defining good knowledge, good science, and successful research .................................... 197 
The vaccine and the cascade: contesting causation. .......................................................... 200 
Participation and expectation ............................................................................................. 204 
‘Science takes time, I think the public understand that’ ................................................... 207 
Conclusion: clinical research at play - managing the borderlines of science .................... 211 
Chapter 8 Conclusion: tension and suspension in a community of research ................. 215 
Transgressive relations: boundary crossing in the interplay between science and society 216 
Engaging, persuading and collaborating ............................................................................ 219 




Table of figures 
Figure 1: Key relationships emerging in a study of a dementia research community ................. 13 
Figure 2: Relations within a clinical trial ...................................................................................... 21 
Figure 3: Continual process of emergence ................................................................................... 32 
Figure 4: Cycle of proliferating classifications ............................................................................ 38 
Figure 5: Phases of the clinical trial. ............................................................................................. 55 
Figure 6: Diagram of the ARUK Dementia research strategy ..................................................... 56 
Figure 7: Advert for the Charlie Crowe Scanner Appeal ............................................................ 72 
Figure 8: MRI Images used on the NMRC Website .................................................................... 83 
Figure 9: Comparison of use of burden in dementia articles ........................................................ 95 
Figure 10: Illustration of rates of publication 2000-2014 ............................................................ 95 
Figure 11: Illustration of increasing use of burden in dementia publications .............................. 96 
Figure 12: Cycle and proliferation of complexity....................................................................... 110 
Figure 13: National television campaign "This is my Dad" - Fading .......................................... 136 
Figure 14: National television campaign "This is my Dad" - Returning .................................... 137 
Figure 15: -Statistics of scale for dementia ................................................................................. 140 
Figure 16: Comparing scales of funding and resources ............................................................. 141 
Figure 17: Relating scale of dementia to space and place .......................................................... 144 
Figure 18: The dementia World Cup ......................................................................................... 145 
Figure 19: Relating risk of dementia to the passage of time ...................................................... 146 
Figure 20: Mind Over Matter ..................................................................................................... 150 
Figure 21: “I have dementia I also have a life” Campaign, ........................................................ 151 
Figure 22: “I get by with a little help with my friend”. Public Health England (2014) ............ 154 
Figure 23: Our brains Campaign, ARUK .................................................................................. 156 
Figure 24: "What is Dementia?" .................................................................................................. 159 
Figure 25: "Defining Dementia" ................................................................................................. 160 
Figure 26: The North East Charter for Changing Age. ............................................................. 162 
Figure 27: Living North (2011) ................................................................................................... 165 
Figure 28: “Changing Age for Business” .................................................................................... 165 
Figure 29: The bench case study. ................................................................................................ 169 
Figure 30: Alzheimer's Society pin .............................................................................................. 175 
Figure 31: Alzheimer's Society fundraising for clinical trials ..................................................... 176 
Figure 32: Promotional banner for the Lion's Face opera ......................................................... 177 
Figure 33: DeNDRoN “Brain Arcane” Exhibition. ................................................................... 178 
Figure 34: Marketing a cure: the ‘pill’ as a representation of hope. .......................................... 181 
Figure 35: Social media framing research engagement as altruism. .......................................... 185 
Figure 36: Mobilising kinship and futurity to support dementia research. .............................. 186 
Figure 37: 'Our brains in their hands' campaign. ...................................................................... 187 
Figure 38: Re-narrating the failure of clinical trials (ARUK 2012) ........................................... 202 
Figure 39: When is a failed clinical trial not a failure (ARUK 2013) ....................................... 203 
Figure 40:  MRC 2009-2014 Strategic Review ........................................................................... 211 
6 
 





List of Acronyms 
 
AD Alzheimer’s Disease 
ARUK Alzheimer’s Research UK 
BOLD Blood Oxygenation Level-Dependent 
CCG Clinical Commissioning Group 
DALY Disability Adjusted Life Years 
DeNDRoN Dementias and Neurodegenerative Disease Research Network 
DLB  Dementia with Lewy Bodies 
DSM Diagnostic Standards Manual 
DSM-IV-TR Revised fourth edition of the Diagnostic Standard Manual 
EBM Evidence Based Medicine 
fMRI Functional Magnetic Resonance Imaging  
IADL Instrumental Activities of Daily Living 
ICH-GCP International Council for the Harmonisation of Good Clinical Practice 
ICD International Classification of Disease 
IRAS Integrated Research Assessment System 
MAGDR Ministerial Advisory Group for Dementia Research 
MRI Magnetic Resonance Imaging 
MRC Medical Research Council 
NHS National Health Service 
NHSE National Health Service England 
NICE National Institute of Clinical Excellence 
NINCDS –
ADRDA 
National Institute of Neurological and Communicative Diseases and Stroke 
/ Alzheimer’s disease and Related Disorders 
NMR Nuclear Magnetic Resonance  
NMRC Newcastle Magnetic Resonance Centre 
PCT Primary Care Trusts 
PET Positron Emission Tomography 
QALY Quality Adjusted Life Years 
RAFT Recruitment and Feasibility Tool 
RCT Randomised Control Trial  
REC Research Ethics Committee 
R&D Research & Development 
RfPB Research for Patient Benefit 
SEM Scanning Electron Microscopy 
SPECT Single Photon Emission Tomography 
UKCRNP UK Clinical Research Network Portfolio 
UKNSC UK National Screening Committee 
VaD Vascular Dementia  






This thesis has involved a lot of collaborations and has benefited from the making of many 
invaluable connections. Many of the debts are unrepayable, but I offer my thanks and gratitude 
to those who have worked with me and kept me going through this process. I have not named 
individual informants, with the exception of the key policy makers who spoke at public forums. 
To all those scientists, health care practitioners, public participants and who have talked with 
me, and let me listen to them, I offer my thanks, and hope I have produced something which 
reflects, at least in part, what makes them participate in the challenges of dementia research.  
I would like to acknowledge the funding of the Economic and Social Research Council, and the 
British Women’s Graduate Federation whose funding made this piece of work possible. I would 
also like to thank the academic staff of the Durham University Department of Anthropology, 
and particularly the Public Culture in Practice and Theory Group, especially Michael Carrithers, 
Gareth Hamilton and Rachel Douglas-Jones. Without the support staff this piece of work 
wouldn’t exist and I want to thank Kate, Paula, Rosie and Judith for their unflappable support. 
I would also like to thank the European Neuroscience and Society Network for their intellectual 
support and for opening up to me the world of social studies of neuroscience. In particular I’d 
like to thank Nikolas Rose and Des Fitzgerald, without whose smartphone I may never have 
known about the NIHR meeting in time. To the Medical Anthropology At Home Group who 
let me share my early data, when even I wasn’t sure what it was, my great thanks, particularly to 
Grace Akello who sped through my paper at very short notice. Also to my colleagues in medical, 
evolutionary, development anthropology and even the archaeologists, thank you for letting me 
chat about my brains with you. 
In particular I would like to thank my supervisors Bob Simpson and Yulia Egorova. Some debts 
will always be too great to pay. For their unending patience, belief, and support I have complete 
admiration and respect. Your untiring willingness to discuss and debate with interest and 
enthusiasm has kept me going.  
Those who have helped me as friends and family, thank you, we got there in the end. In particular 
Penny and Charlie your grace and generosity never ceases to astound me. To Joanna Simpson 
for taking me into your home and letting me take over the kitchen table, thank you for making 
me so welcome. So many have come and gone since I started, Julia, Carla, Katie, Sam, Emilie, 
Gareth, Rachel thank you for all your support along the way. My family, patience is your middle 




Chapter 1 Introduction: Complexity in the study of 
biomedical research  
 
Biomedical research into dementia is a rapidly growing phenomenon.  Yet, little is known about 
the social and cultural relations that make this growth possible.  How is biomedical research in 
dementia enacted? To answer this question I conducted an ethnographic study of the emergence 
of a dementia research community in the UK. By focusing on the relational nature of bioscience, 
my work emphasises the everyday interactional performances which make research happen. This 
work thus provides a novel contribution to the anthropological study of knowledge production 
and the understanding of social practices in the biosciences. One of the main challenges in the 
research was to capture and clearly articulate the complexity of the relations in biomedical 
research, whilst providing a systematic representation of the messy nature of the processes, scales 
and connections involved. In this introduction I outline why an approach focused on complexity 
is important I argue that ethnography is recognised as an important tool in capturing complexity 
and addressing the types of messy social relations apparent in the study of dementia research. By 
tracing the formation of relations, connections and interactions I attempt to capture this 
complexity at work. I argue for the need for a study of dementia which focuses explicitly on 
research and research relations. I end the chapter by providing an overview of the content of the 
thesis. 
 
Anthropology of science and social studies of science and technology. 
 
This thesis developed out of a broader interest in the relationship between concepts of mental 
health and emerging biotechnologies, such as neuroimaging. Developments in imaging have 
radically altered the trajectory of the field of neuroscience (Beaulieu 2001, 2002, Cohn 2004, 
2008, Dumit 2004, Andreasen 1989). The potential to examine processes inside a living brain 
represents one of the most influential shifts in conceptualising, understanding, diagnosing and 
developing treatments related to brain functionality including a broad spectrum of mental 
illness, cognitive disorders, neurodegenerative diseases, learning disabilities and acquired brain 
injuries. Biotechnological developments, such as imaging have radically altered western 
biomedical models of brain anatomy, neuronal development, molecular and neurochemical 
processes and brain function. Biotechnologies in neuroscience play a pivotal role in the 
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development of new models and definitions of ‘normal’ brain structure, function, development 
and aging (Hogle 2007; Jones & Higgs 2010; Williams et al. 2012). 
 
Social scientists have recognised and traced how biomedical research has had a fundamental 
impact on the role of the brain in representations of health, well-being, personhood and identity, 
particularly across Western European and Northern American societies (Rose 1991, 1996).1 The 
development of knowledge about the brain has been driven by changing cultural understanding 
of the mind and the role of science (Jasanoff 2004). Conversely, natural scientists developing 
knowledge about the brain are continually re-evaluating and redefining the concept of ‘mind’, 
shaping how science proceeds and how knowledge about the brain and mental health is socially 
defined (Blakemore & Greenfield 1987, Herholz et al 2001). Therefore, this thesis is influenced 
by Jasanoff’s (2004) theory of co-production. From this perspective, developments in the 
neurosciences are both a result of, and driving force for, shifting social perceptions of mind, 
brain and mental health. 
 
My approach in this thesis has been influenced by the accumulation of research in the 
neurosciences as well as biotechnologies more broadly. In particular, this includes field such as 
new genetic and reproductive technologies (Franklin 2003, Franklin & Ragone 1998, Ginsburg 
& Rapp 2004, Strathern 1992a, Gibbon & Novas 2008). Social research in these fields 
demonstrates how biotechnologies can force deep critical reflection on the nature of 
personhood, culturally conceived ‘natural’ categories and what it fundamentally means to be 
human. My decision to focus upon dementia as a case study was prompted by the growing 
prominence of the syndrome in public and media discourse. As a disease related to ageing and 
the end of life, dementia concerns some of the most profound questions concerning human 
identity and personhood. At the same time, however, changing knowledge about the conditions 
which cause dementia are fundamentally changing how the syndrome is characterised in research 
and clinical practice. By reflecting on the medical background of causes of ‘dementia’, such as 
Alzheimer’s disease, I demonstrate the important role of interaction and collaboration in 
                                                 
1 In a critical analysis of the concept of the ‘normative’ brain Rose (2007) has discusses extensively how new 
neuroscientific biotechnologies and pharmaceuticals are linked with the construction of governance and state bio 
power in contemporary understanding of the ‘self’. 
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scientific practice. Such relations, I argue, are central to understanding the complexity of the 
changing landscape of dementia research. 
 
An ethnographic approach to complexity: developing an study of the UK dementia research 
agenda 
 
Contemporary ethnographers haves developed a fascination with complexity, particularly in 
relation to developments in technoscience and biomedicine. For example, complexity is located 
in human and non-human networks (Latour 1987, 1999; Latour & Woolgar 1986), in hybridity 
(Harraway 1991), in the pervasive processes of definition and classification (Bowker & Star 2004, 
Martin 1992, 1998; Mol 2002), in multi-sitedeness and virtuality (Marcus & Fischer 1986, 
Marcus 1995, Rabinow et al. 2008, Wouters et al. 2008), and in the relations through which it is 
shaped and enacted (Mol & Law 2002, Strathern 1992a, 1992b, 1995a, 1995b). 
 
What can a study of dementia neuroscience research contribute to this extensive body of 
literature? This study presents a unique and timely description of a period between 2010 and 
2014 when the emergence of national dementia research agenda marked a fundamental shift in 
the public, political and scientific awareness of this group of conditions in the UK. My approach 
to the study of biomedical and biotechnological research in dementia neuroscience is focused on 
the interweaving social relations and scientific knowledge which formed the everyday processes 
of making this shift happen. As I became familiar with the field of dementia research in the UK 
it became clear that this was site of immense connectivity and complexity. The participants visible 
in the study, that is, clinicians, research scientists, research staff, publics, and industrial 
organisations were all integral to the processes taking place. These characters operate in a tangled 
web of relations, in which aims, goals and motivations overlap and connect them, whilst also 
becoming the cause for tension between them.  
 
First, I wish to clarify my decision to use the term ‘dementia’ and ‘dementias’ when referring to 
conditions which cause the symptoms classed as dementia syndrome. Dementia is a concept 
which, as I go on to demonstrate, has historically undergone radical redefinition. Today we 
understand dementia not itself as a condition, but as a title for a range of symptoms including, 
but not limited to, memory loss, behavioural changes, difficulty with communication, and visual 
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processing, and problem solving. As I go on to discuss in the following chapter, these symptoms 
result from progressive damage to the brain caused by specific neurodegenerative disease 
processes. There are over one hundred conditions which can cause symptoms of dementia. Of 
these the most common forms, include: AD, Vascular Dementia (VaD), Dementia with Lewy 
Bodies (DLB), and Parkinson’s disease dementia (PDD). These are the conditions most 
commonly referenced in this thesis.  In both social and scientific research on dementias there is 
a tendency to focus on one specific disease pathology, and in particular on AD, as the most 
dominant disease group. However, the researchers and participants with whom I was involved 
were concerned with a range of dementia causing conditions. In addition, in the process of public 
engagement and the politicisation of dementia as a cause for social and political mobilisation, 
my participants almost inevitably talk about ‘dementia’, ‘dementias’ and ‘dementia research’, 
treating dementia as discrete object in discussion about research, policy, funding, and public 
awareness. As a result, throughout the thesis I use the term ‘dementia’ as it is used in this context, 
in the awareness that it conflates a wide range of conditions, and that it has become a politically- 
oriented concept beyond its current, formal, biological definition. 
 
During the study, it became apparent, that the language and imagery used to represent dementia 
as a field of scientific, governmental and public concern were of vital importance to understand 
the kind of relations being formed, and how they were enacted. In particular, the concept of 
‘dementia’ was framed by a peculiar combination of acute urgency and emergency. Through the 
use of the terms urgency and emergency I try to capture the development of dementia as both a 
site of a public health crisis, and an environment in which knowledge, opinions, relations and 
connections rapidly and continually evolved and intersected. A preliminary attempt at capturing 
the most salient issues and relationships in dementia research is illustrated in figure 1. 
 
Implicit in this simple diagram are multiple, cross-cutting connections which it is the aim of this 
thesis to describe ethnographically. For example, when looking at how the members of a research 
group worked together on a dementia project, it was important to acknowledge the role of 
institutional affiliation, participation in local, national and international research and policy 
frameworks, and connections with wider national and transnational research networks. At the 
same time I was exploring where research data came from, how projects went about recruiting 
participants and how they disseminated or implemented their findings. Considering these basic 
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questions about how research happens, I draw attention to the overlaps and interactions between 
government organisations, health care institutions, and commercial groups. Through this 
process I bring into focus that research does not happen outside of social and cultural influence. 
Rather when exploring research the perceived emotions and anxieties of publics, patients, carers 





Figure 1: Key relationships emerging in a study of a dementia research community 
 
Becoming aware of the nature of these complexities as my fieldwork developed, I found it 
increasingly unsatisfactory to conduct a study which separated or excluded the messiness of 
interconnections. Indeed, these aspect of dementia research became central to addressing the 
core question about the kinds of relations in which dementia research took place. As a result, 
this is a study which explores how those working in dementia research were aware of, subject to 
and involved in the messy, pluralistic and entangled processes which occur in making dementia 
as a disease, an object of research and, significantly, an item on the political agenda. In short, my 




















of social relations in technoscience (Fischer 1996, 2007; Jasanoff 2004, 2005; Martin 1992, 1994, 
1998; Nowotny, Scott & Gibbons 2001, 2003, 2005; Traweek 1988).  
 
An ethnography of connections and relations. 
 
Capturing the relations and connections at work in the development of the dementia research 
agenda is an important but challenging aspect of this study. Throughout the thesis I try to 
maintain a balance between providing clear and meaningful narratives, and ensuring they reflect 
the processes fundamental to the performance of dementia research. There is ample evidence 
from the anthropology of science and technology, that ethnography provides a uniquely valuable 
method for accessing and describing human interactions in the dispersed and entangled field of 
science and knowledge production (Marcus 1995, 1998; Knorr Cetina 1999, Konrad 2002). To 
develop this ethnographic approach, I immersed myself in the work and worlds of biomedical 
researchers in order to understand how they viewed their research practices. By attending 
research events I was able to observe how researchers experience, work with and make use of the 
connections between people, places and institutions. Being able to manage such relations is a 
fundamental part of scientific practice. Such relations were frequently nationally and even 
globally dispersed, but nonetheless shaped by researchers’ local practices.  
 
Becoming immersed in this way prompted reflections about how scientific knowledge is created, 
valued and validated. It caused me to consider how I, as an anthropologist, went about creating 
my own knowledge and understanding. By employing a grounded theory approach,  I allowed 
the research to emerge from the data (Glaser & Strauss 1967). Observing how researchers 
constructed and talked about the challenges and aims of their work challenged my own 
perceptions of biomedical science. Whilst regulation and governance was extremely rigorous, 
knowledge practices and research development often proceeded in an open-ended and contested 
manner. The research processes I describe in this thesis, parallel those adopted by Nowotny, 
Scott and Gibbons (2001, 2003) in the development of the idea of mode II science. Whereas 
mode I science focuses on the idea of knowledge as discrete and contained within clear 
disciplinary boundaries, the Mode II approach is characterised by knowledge which is 
transdisciplinary and socially distributed; a temporary cohesion of ideas which are continually 
under scrutiny and subject to change (Nowotny, Scott and Gibbons 2001: 48). The characteristics 
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of Mode II science illustrate that far from being driven by transparency and certainty, scientific 
knowledge production is fraught by complexities which function at all scales. Strathern (1995a) 
demonstrates how ethnographic research traces relations as a means of accessing social order out 
of everyday complexity. However, by a systematic focus on the nature of relations, she shows how 
complexity is replicated and repeated across scales, escaping from and crossing between domains 
of social life. In this thesis, by analysing the relations between people, conceptual connections 
and rhetorical devices involved in the development of the UK dementia research agenda, I 
demonstrate the convergence and divergence of ideas and motivations which are shaping current 
practices in dementia science. 
 
The study of complex relations in dementia research 
 
In working in the field of contemporary dementia research, I am locating this study not only 
within anthropologies of science and science studies, but within the wider social and social 
scientific literature which addresses the conditions which cause dementia from a wide range of 
perspectives. From current biomedical descriptions, specific disease pathways affect the 
transmission of messages between neurons.  Over time they cause over neuronal damage, 
resulting in the progressive symptoms of dementia. A person experiencing the effects of dementia 
will develop progressive cognitive impairment which affects global mental processing including 
everyday function, personality, and behaviour (Ballard et al. 2011; Blennow et al. 2006; Burns et 
al. 2002; Burns & Iliffe 2009). There are a wide range of critical approaches to the social study 
of dementia, particularly in the fields of social psychology and social gerontology. Within these 
approaches there is a large body of work around the themes of care, disability, personhood and 
social marginalisation (Baldwin 2008; Davis 2004; Dewing 2008; Cohen 2014; Innes et al. 2004; 
Innes 2009). In this work, questions are raised about the impact of the symptoms of dementia 
and a dementia diagnosis on the social relations within which life is experienced. 
 
The examination of dementia diagnoses and the diagnostic processes is an area of particular 
interest for this thesis. The ‘need’ for timely and accurate diagnosis has received significant 
attention in the biomedical community (Hansen et al. 2008; Van Gorp & Vercruysse 2012; 
Chatterji 1998; Baldwin 2008). The characteristics of the conditions which cause dementia, and 
their interaction with the structures and biochemistry of the brain are seen to present a 
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physiological barrier to early diagnosis. The complexity of disease processes combine in the 
earliest stages of the disease with the brains capacity for plasticity. As a result, initial symptoms 
can be highly variable and fluctuating.  
 
In both social and scientific studies of dementia, researchers have emphasised the stigmatisation 
involved in seeking help for, or receiving a diagnosis of dementia. This stigma, it is argued, is 
rooted in deeply embedded social fears (Garand et al. 2009; Vernooij-Dassen et al. 2005). From 
a functionalist perspective this fear is located around the loss of control of mind and body, 
leading to progressive restrictions on independence and self-determination (Higgs & Jones 
2009). From an interactionist approach a dementia diagnosis affects not only the person 
involved, but their relationships with family, friends and colleagues. Dementias can therefore be 
seen as conditions which threatens inter-personal relationships such as those that exists within 
families, between life partners, and between the person and society (Innes 2009; Werner & 
Heinik 2008; Werner et al. 2012). This perspective is reflected in the current guidance provided 
by the NHS on the effect of receiving a diagnosis: 
 
 Being diagnosed with dementia will have a big impact on your life. You and your family 
may worry about how long you can care for yourself, particularly if you live alone. People 
with dementia can remain independent for some time, but will need support from family 
and friends. 
Staying independent with dementia 
http://www.nhs.uk/Conditions/Dementia/Pages/living-with.aspx 
 
Regardless of symptomatic experience, the very act of receiving the diagnostic label, is understood 
to have a detrimental impact upon the identity of the person (Goffman 1990). Thus social stigma 
is understood to be an important factor in compounding the process of social isolation and 
detachment experienced as a result of the symptoms of dementia itself.  
 
One research response to the question of threatened identity and personhood in dementia 
treatment and care has been the development of a person-centred approach (Kitwood 1997, 
McLean 2007). Through experiencing the symptoms, stigmas and a lack of understanding about 
dementia, an individual’s identity risks become sumbsumed by the condition itself. This loss of 
identity is compounded by the affect of these conditions on a persons capacity for interpersonal 
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communication. The increasing damage to a persons capacity to interact in accepted and 
expected ways can make it difficult to sustain the connections of  empathy and relationality 
involved in compassionate care. The person-centred approach attempts to put the person back 
into the condition, stressing first and foremost ongoing respect for the humanity, history and 
identity of the individual, regardless of the impact of the condition on their ability to 
communicate these relations in a socially ‘normative’ manner. This approach has developed 
significant traction in the field of dementia care and care research. However, the achieveability 
of embedding this approach in to day-to-day care has come under question (Brooker 2004).  
 
In contrast, a different response to the social implications of dementia diagnoses has been to 
questions the concept of dementia itself (Bond 1992). Vincent et al. (2008) challenge the role of 
diagnostic categories of dementia given that the biomedical understanding of these conditions 
remains uncertain and changeable. This leads the writers to ask to what extent diagnostic labels 
perform a social function, containing and explaining behaviour which is understood to be 
outside of the dominant social norm. In particular this perspective leads to questions about the 
value and role of early diagnosis given the lack of existing treatment efficacy. This argument 
reflects a wider shift in social science to question the social implications of the increasing 
biomedicalisation of aging dementia itself (Kauffman, Shim & Russ 2004). 
 
However, in neurology, old-age psychiatry and within patient advocacy groups, failure to provide 
early and accurate differential diagnosis is understood to delay and impede a person and their 
family’s access to the treatment and support systems which are currently available (Vernooij-
Dassen et al. 2005). Whilst the exact causes and disease pathways involved remain contested, 
existing treatments such as cholinesterase inhibitors have been shown in randomised control 
studies to slow down the progress in Alzheimer’s disease dementia (Singh & O’Brien 2009). A 
firm diagnosis which conforms to current National Institute of Clinical Excellence (NICE) 
criteria, therefore, represents a critical gateway to accessing care and treatment. 
 
However, treatments such as that described above, do not work for all patients and their 
effectiveness tends to decrease over time. In effect dementias remain incurable. The lack of more 
effective treatments is interpreted by specialist clinicians as a key factor in the reluctance amongst 
many GP’s to refer patients for specialist assessment as soon as dementia is suspected (Hansen et 
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al 2008). In contrast, GP’s feel a responsibility to weigh the impact of diagnostic label against the 
possible benefits of existing and accessible treatment and support (Iliffe, Manthorpe & Eden 
2003). 
 
As the prevalence of dementia increases with age, people presenting with subjective memory 
complaints are often over the age of sixty-five. As a result, many live with a range of chronic and 
co-morbid disorders. This overlapping of conditions can complicate the process of receiving a 
firm diagnosis (Burns & Iliffe 2009). Without a firm diagnosis a person may have little or no 
access to support and no access to services, resources or treatments which can improve their 
quality of life. This is reflected in the language of patient advocacy groups such as the Alzheimer’s 
Society, illustrated below: 
 
Many people with dementia face a wait of months and even years for a diagnosis and 
fewer than half ever receive one. This means hundreds of thousands of people are living 
in a state of limbo without access to treatment and support to live well. This government 
funding has the potential to reduce the wait for a diagnosis, give GPs the confidence to 
diagnose and reflects a commitment from the government to tackling dementia. 
 
“Government announces cash to cut dementia diagnosis times” 05 November 2012 
http://www.alzheimers.org.uk/site/scripts/news_article.php?newsID=1385 
 
Of the members of the public whom I spoke with at research events, a number described how 
their involvement with patient advocacy and disease research groups had resulted from searching 
for support which had not be available to them from main stream health care. Similarly, doctors 
and clinicians described sign-posting patients to advocacy groups as a primary source of help, 
local support networks and information for people with dementia and their families.  
 
Why focus on research and research relations? 
 
As I have briefly illustrated above, the personal and social impact of living with, being diagnosed 
with, or caring for, someone with dementia has received significant attention in current 
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literature, and from a wide range of perspectives. With some notable exceptions (Hedgecoe & 
Martin 2003; Lock 2001, 2013; Moreira & Bond 2008; Moreira, May & Bond 2009), relative 
little attention has been paid to the scientific practices and research infrastructures which play 
pivotal roles in redefining the nature of dementia itself. This thesis, therefore focuses on 
dementia researchers in the research process. This approach is motivated by the need for better 
understanding of the changing nature of biomedical research design, practice, infrastructure and 
governance, and how such changes are being managed by the researchers, clinicians and scientists 
working in this environment. The practices and processes of research have a direct impact upon 
how the nature of dementias are conceptualised, and how new treatment approaches are 
developed. Throughout the thesis, therefore, the core issues under scrutiny are the relations and 
connections through which the dementia research agenda is developed and enacted.  
 
The public, although not the focus, are a critical part of the landscape of the research relations 
examined in this thesis. They appear as participants, advocates, fund-raisers and lobbyist, and as 
the imagined publics to which researchers and research group’s appeal in the development of 
public engagement. In particular I look at the role of public patient involvement (PPI) and public 
engagement as these practices are framed by researchers as part of, albeit a challenging and at 
times unwelcome part, of the research process. I demonstrate how in governance and scientific 
and biomedical policy the public are framed as a resource required to make biomedical research 
feasible, sustainable and socially acceptable. There are important questions to be raised here 
regarding power relations and the enrolment of the public into the process of biomedicalisation. 
However, as I demonstrate at the start and the end of the thesis, these publics are not quiet, 
compliant and passive. Public participants play a key role in resisting, countering and even 
challenging the dominant narratives of science which I draw out of my observations of the 
dementia research community. The study of an increasingly public oriented future for scientific 
research has given rise to what Jasanoff has referred to as ‘civic epistemologies’. I take this term 
to describe knowledge production which combines the complexity of emerging scientific practice 





The environment of drug development and clinical research in the UK National Health 
Service 
 
In addressing the relations within which dementia research takes place I pay particular attention 
to the cross-cutting nature of the political, governmental, economic, scientific, academic, 
industrial and health care institutions involved in the research process. Throughout my research 
I was made aware of the concerns around the limited advances made in drug development for 
treatment of the disease processes involved in, and symptoms of, dementia over the last twenty 
years. In an open letter to the drug companies the British Association for Psychopharmacology 
expressed concern that a trend was emerging for the international pharmaceutical industry to 
withdraw investment from dementia research and development (R&D) because of its high cost 
and low success rate (British Association for Psychopharmacology 2010). The researchers and 
clinicians I worked with pinpointed a lack of investment in human, technical and financial 
resources for the failure to gain traction over the highly complex nature of the disease processes 
involved. I examine how these narratives of failure and the burdens of dementia are constructed 
and the kinds of relations implicated in that process. 
 
As a result, I reflect upon the process of clinical trials and drug development as socially embedded 
processes. Staff involved with in-human trials (phases I – IV) are both personally and 
professionally committed to the research process. In particular, early career clinical researchers 
with whom I spoke saw the clinical research dimension of their work as a time consuming but 
necessary element of their long-term career development. In working with progressive diseases 
and their modification rather than cure, clinicians collaborating with clinical trials were never 
working towards the discharge of the patient, but sign-posting patients and their families or care 
givers towards the future treatment or care services they might require as their condition 
progressed. Under these circumstances clinicians such as old-age psychiatrists and gerontologists 
acquired a long-term interest in the progression of the patients’ condition. 
 
Decisions by clinicians to work with, or indeed as, researchers in clinical studies have to be 
understood in the highly complex web of relations involved in NHS in the UK. In chapters two 
and three I explore how these relations operate across a number of scales: local, national and 
transnational. For example, to work with NHS patients, staff and facilities, approval is required 
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from the regional ethics committee (REC). The research conducted follows protocols based on 
internationally agreed classifications of the disease and its phases. Due to the complex nature of 
capacity, the regulation of clinical trials for people with dementia is closely scrutinised, 
particularly in relation to the process of informed consent. Further economic, ethical and legal 
relations are implicated by funding agreements with pharmaceutical companies and national 
research organisations. A clinical trial will often involve multiple recruitment sites and 
engagement with other researchers and clinicians across the UK (see figure 2). Researchers have 
to manage inter-site hospital relations and the infra-structural requirements for the successful 
recruitment, testing and monitoring of the efficacy of any intervention. And throughout, the 
clinician and research team will have to engage with the immediacy of personal encounters as 
they struggle to work with patients who are experiencing the practical and emotional strain of a 
progressive chronic condition. 
 
Figure 2: Relations within a clinical trial 
 
In this introduction I have situated this thesis broadly as an ethnographic study of complex and 
shifting relations which are fundamental to the construction of the UK’s national dementia 
research agenda. I have emphasised a focus on researchers and the research process, situated 
within wider social, cultural, political, economic and scientific relations. Such relations play a 
























conditions. By shifting focus from care or the products of research on to research relations and 
processes I represent the dynamic and creative culture of biomedical research which takes us 
beyond the well-worn triptych of science, politics and society. 
 
An overview of the thesis. 
 
This thesis has three broad sections. In the first section, comprising of chapters two and three, I 
provide a historical contextualisation of the study of dementia in the biosciences, and discuss the 
emergence of contemporary dementia research and the current research community on which 
this ethnography is based. In the second section, chapters four and five provide the core of the 
thesis, where I explore how language and rhetoric are used in research and research engagement 
to construct dementias as a specific problem for science and society. In the final section, chapters 
six and seven reflect on how the efforts to ‘re-make’ dementias illustrate the ongoing evolution 
of the relationship between clinical research and society in the UK. I conclude in chapter eight 
by reflecting how the relations illustrated by the thesis can be characterised as transgressive and 
boundary crossing, managing and maintaining science which is in a perpetual state of tension 
and suspension. Below is an in-depth chapter overview. 
 
The history and emergence of dementia research and a research community 
 
In the first part of the thesis I provide an overview of ‘dementias’ as a concept which is neither 
‘natural’ nor ‘neutral’, but historically situated in the continual evolution and interaction 
between social perception and biomedical practice. This overview is accompanied by a review of 
the theoretical and methodological approach taken in this case-study to examine the 
contemporary scientific practices and discourses by which dementias have become classified. This 
new visibility is part of a process of categorizing a group of conditions in a manner which makes 
them amenable to scientific study and intervention.  
 
Chapter two explores the concept of dementia as a disease and an object of research as it has 
developed over time. I examine how the history of the disease concept is characterised through 
uncertain and stigmatised definitions which underpin its emergence as a problem disease for 
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science and society. In this history I examine the roles of standardisation, institutional relations 
and political economic infrastructures shaping dementia as a disease concept. I draw on the work 
of Fischer (2009) and Jasanoff (2004, 2005, 2011) to provide insight into how scientific 
knowledge and practices need to be understood as assemblages of technical, ethical, economic, 
legal, political, governmental and cultural relations. To understand these assemblages I begin by 
mapping examples of such relations as they have developed over time. I consider not just 
organisational and technical developments but the cultural dynamics of biomedical research into 
dementias. In doing this I employ Jasanoff’s idea of science as an embedded civic epistemology, 
rather than a set of isolated technoscientific practices. Using this approach, I illustrate how the 
UK dementia research community is continuing to evolve under particular social and economic 
circumstances. 
 
Chapter three delves further into the structure and working of the dementia research 
community. This dispersed site of research shaped the methodological conduct of my work. By 
examining the procedures needed to negotiate access and approval ethnographically, I highlight 
the organisational convolutions and relations involved in developing biomedical research. I 
describe how my failure to access the laboratory setting facilitated a different sort of research 
approach, one attuned to the importance of dispersed processes, practices and relationships 
which are integral to making dementia research happen. I argue that my experience of 
negotiating access revealed the key role played by language, imagery and classification in the 
exchanges between scientists, participants in science and the general public. I illustrate how the 
dispersed nature of the research community is realised across multiple real-world and virtual 
sites. Thus, working on contemporary science practice as a social scientist, I argue, both benefits 
from and challenges a classic understanding of ethnographic field work (c.f. also Prainsack et al. 
2010, Prainsack & Wahlberg 2013).  
 
The language and rhetoric of dementias as a problem for UK science and society 
 
The second section of the thesis focuses in in-depth examination of the language and narratives 
around dementia which have developed amongst an emerging research community. These 
narratives act as a response to the historical under-resourcing highlighted in the earlier chapters, 
perceived by clinicians and neurologists to be bound up with key characteristics of 
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neurodegenerative conditions which result in the symptoms of dementia. I frame these narratives 
as persuasive rhetorical acts which form part of a wider effort in the dementia research 
community to change perceptions of ‘dementia’ to enable new momentum for scientific and 
social engagement. 
 
Chapter four introduces the role of rhetoric in bringing dementia into focus as a contemporary 
problem. I analyse how the idea of dementia as ‘burden’ features in the language pathology, 
practice and policy of dementia science. Language is used by those working in dementia research 
to make links between dementia as a condition experienced by people in society, on the one 
hand, and dementia as an object of scientific research on the other. In this chapter, I outline the 
ways in which perceptions of dementia are seen to have a negative effect on scientific practice. 
The condition is often linked to the inevitability of ageing and therefore is likely to be seen as a 
research field in which success will be less ‘heroic’, as one dementia researcher put it. The chapter 
highlights how researchers seek to remedy the failure of dementia research to become a priority 
for research. I describe how researchers engage in a process of identifying and objectifying the 
impediments and barriers to successful research. Such impediments include: the complexity and 
lack of understanding about dementia causing pathologies; the difficulties of working with 
people with cognitive impairments; the stigmas of age and chronic disease; and the weaknesses 
in the UK research infrastructure. 
 
In chapter five, I look at how these issues, classified as ‘burdens’ of dementia and dementia 
research, are externalised through a rhetoric of risk. Here my emphasis shifts onto how scientists 
capture public and political attention and construct dementia as a national crisis. By using a 
rhetoric-based approach to the language and imagery of dementia research, I demonstrate how 
stakeholders convey a scale of urgency and emergency in the ‘dementia crisis’. Attempts to raise 
the profile of the disease oscillate between the intimacy of specific pathologies, to the gross scale 
of national statistics, probabilities and projections of future prevalence. The chapter concludes 
that these strategies of risk and crisis combine to form a dementia social movement akin to that 
observed in other disease movements, but one explicitly enmeshed with the needs and aims of 




Remaking dementias and the relationship between clinical research and society in the UK: 
anxieties, tensions & suspension. 
 
The final section of the thesis uses material gathered during public engagement events to 
demonstrate how dementia is being reshaped as a condition with a particular social and scientific 
future, as a researchable, treatable and manageable set of conditions. I explore how such 
engagements mark the ongoing evolution in the relationship between clinical research, national 
health care and society. I argue that this is a relationship of tensions in which different rhetorical 
devices are balanced against one another. I use examples of participant-researcher interaction to 
examine the anxieties and fault lines which emerge in this process, which becomes in a sense 
part of the self-perpetuating mechanism of biomedicine in which outcomes are permanently 
suspended. 
 
Chapter six examines the strategies used within the research community to create a new kind of 
relationship between society and research science. The making of this relationship involves 
breaking existing stigmatised associations between dementia and age. Scientists are then involved 
in constructing a community of publics, patients and participants to support the dementia 
research agenda. I argue that this strategy is employed to strike a balance between the gravity of 
risk and the possibility of hope, innovation and the potential for future drug development. I 
suggest that scientists are working to naturalise the link between the problem of dementia and 
the solutions which biomedical science would like to offer. Essential to this link is the cultivation 
of trust in science, scientists and the research process. I conclude by reflecting on the limits of 
the rhetorical devices used, as they reveal internal anxieties about the nature of dementia 
research. 
 
In chapter seven, I focus on how these anxieties are portrayed by researchers and how they 
manage expectations and limitations of their science, questioning the concept of a ‘cure’ and 
reflecting that research often proceeds down what, are in effect, blind alleys. Such reflections 
lead scientists to debate the nature of success and failure in dementia research. I describe how 
researchers talk about these anxieties with members of the public and how they share the 
difficulties they are facing. Using notions such as the time taken to undertake research, the 
complexity the disease and the rigours of the scientific process, scientists attempt to control and 
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direct public expectation. These discussions illustrate the tensions and contradictions which lie 
at the heart of the evolving dementia research agenda. 
 
My conclusion steps back from interpersonal processes and micro-level communications of 
public-science engagement, returning to the original question posed by this study: Through what 
kinds of relations is dementia research enacted? Drawing on Nowotny, Scott and Gibbons (2001) 
description of transgressive institutions, I argue that the kinds of examples I have given in the 
thesis can be usefully thought of as transgressive relations. That is relations which cross, collapse 
and continually remake the boundaries between science and society. Such relations, play a vital 
role in maintaining suspension in the process of scientific knowledge production. I consider how 
connections made through institutions, technologies, practices and discourses play a vital role, 
conveying the potentiality of research innovation, in spite of the uncertain, complex nature of 
the scientific process. I conclude by asking about the implications of this process for the ongoing 
relationship between biomedical research and society.2 
 
  
                                                 
2 Prior to starting the study I completed the University of Durham, Department of Anthropology’s ethics review 
process. The Ethics Committee reviewed my research approach and confirmed that I had appropriately considered 
potential ethical concerns. Due to time constraints I decided not to continue with the NHS REC process, and 
worked with interstitial organisations who facilitated my contact with the researchers and the public who became 
involved in this project. As my project changed I updated the departmental ethics committee with the changes to 
my research approach. 
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Chapter 2 Dementia science in context 
 
“So, let me ask you a question”, my companion asked as we drove up the hill. 
 
“What’s the difference between Alzheimer’s Disease and Dementia?” He had asked me 
what I was studying during my PhD, and I had explained in my usual, imprecise way that 
I was looking at the social impact of new technological developments in mental health 
research, how they might be changing how we thought about the brain and the mind. I 
described how I had come to focus on the use of medical imaging in the developing dementia 
research agenda. I paused cautiously to consider my answer, 
 
“Well I’m a social scientist. I only have a lay understanding of the conditions which cause 
dementia. I’ve never been trained in the biosciences. But, as I understand it Alzheimer’s 
Disease is one of the main subtypes of dementia. The largest proportion of people in the UK 
diagnosed with dementia are diagnosed with Alzheimer’s Disease. That’s the one we hear 
about most often. It has a specific disease pathway associated with the development of 
plaques and tangles in the brain. But there are many other types which I’ve heard 
researchers talk about during the project, vascular dementia or dementia with Lewy bodies 
for instance.” He looked at me significantly unimpressed, 
 
“So what’s dementia then?”  
 
I was torn. Do I talk about my uncertainty? How the meetings I had been attending, and 
the articles I had been reading over the last 18 months had consistently expressed concern 
about what we didn’t yet know about dementia. How do I explain that the boundaries of 
the disease and the pathways of its development remain a topic of contestation by the experts 
themselves? 
 
During my field work I became acutely aware of the complex and contested nature of dementias 
as a disease group. When people heard what I was researching I was frequently asked to give 
definitions or provide insight into the facts of ‘dementia’. From my research I was aware that 
there were many potential routes I could take to an answer: I could talk about the historical 
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development of dementias as a category, the emergence of contemporary diagnostic definitions, 
general public awareness, and the role these factors all played in the development of the dementia 
research agenda I was observing in the making.  
 
In this chapter I address the uncertain nature of dementia by contextualising this study within 
the current context of aging populations and changing health care systems. In particular, I 
explore how aging is a key risk factor in current social and biological perceptions of dementia. I 
then reflect on the historical and social networks which shape these perceptions. I present a brief 
outline of the history of the development of the idea of dementia from antiquity through to the 
first formal classifications of the disease. This account of contemporary neuropathology centres 
on the molecular definition of the disease pathway of a specific dementia causing condition 
attributed to Alois Alzheimer. AD was the first pathology specifically identified and named. As 
such it plays a predominant role in this history, and in public discourse it is frequently 
synonymous with the broader range of conditions which cause dementia. Following this account 
I explain how this history resonates with the concerns discussed by current dementia researchers.  
 
Age, chronic disease and emergent technologies 
 
People are living longer. This is a global trend, all-be-it one which is occurring highly unevenly. 
Disparities in access to and development of health care systems, in different settings combine 
with other socio-economic factors to limit life expectancy (Baer, Singer & Susser 2003). Changes 
in medical and technological developments such as vaccination, drug therapies, transplantation, 
and artificial implants have played a significant role in increasing life expectancy (Lock 1996, 
Lock & Nguyen 2010). In North America and Western Europe, increasing access to such 
biotechnologies enable people to survive acute illness, and live longer with chronic ill health, 
that is, with conditions for which there are no definitive cures and which require long term 
management.  
 
In medical anthropology the spread of intensive therapeutic interventions has led to an 
increasing focus on the long term processes and relationships involved in the diagnosis, care, 
treatment, rehabilitation, technological intervention and research of chronic conditions (Cohn 
et al. 2013, Graffy et al. 2010). Areas of particular focus include chronic lung and heart diseases 
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(Hunt et al 2001, Goldsmith et al 2000), long term cancer treatments (Fergusen & Kaspar 2000, 
Fosket 2004, Lock 1998, Perusek 2012), diabetes, endocrine and metabolic disorders (Cohn 
1992, 1995, 2000) and mental health conditions (Kleinman 1988, Martin 2009). Developments 
in biotechnologies which target the brain, such as neuroimaging and biomarker research, have 
led social scientists to consider how the burgeoning discipline of neuroscience may affect out 
social and biological understanding of mental and neurological health (Dumit 2004, Lock 2013, 
Moreira & Bond 2008, Rose 1996, 2007) 
 
Chronic conditions, including neurological disorders, become more prevalent as people age. 
People over the age of sixty-five are increasingly likely to experience not one, but multiple chronic 
conditions (Schubert et al 2006). New health research provides hope to ameliorate the physical 
and mental deterioration, discomfort and uncertainty experienced by an increasing number of 
people who live into their eighth and ninth decades (WHO 2011). As I reflect in this thesis, 
aging populations raise challenging questions for national states and global institutions around 
the personal, ethical, legal, economic and governmental responsibility to facilitate long-term 
health care provision in later life.  
 
In dementias specifically, progressive changes in the structure of brain tissue are associated with 
global deterioration in a person’s cognitive state. This affects not only a person’s ability to 
process, reason and recall, but can have devastating effects on those most personal of qualities 
which we associate with the self: mood, personality and behaviour. Thus, in dementias, biological 
and mental health care intertwine. A key element in our contemporary understanding of 
dementia is the role played by age. Age remains the primary known risk factor in the development 
of the most common dementia causing conditions, including AD, VaD and DLB (Holmes 2012). 
In the UK, epidemiologists currently estimate that one in twenty over the age of sixty-five will 
develop symptoms of dementia. This estimate rises to one in five of those over the age of eighty-
five (O’Brien 2005). The link between aging and dementia means that a study on dementia 
research as a socially embedded process must address the current and changing social attitudes 
to age within this cultural context. On the one hand, ethnographic studies have suggested that 
across many cultures older members of societies are valued as powerful holders and arbitrators 
of accumulated experience, knowledge and understanding (Keith 1979). On the other hand, 
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social researchers have observed age to be associated with a loss of control over physical, mental 
and social well-being (Cohen 1994, Leibing & Cohen 2006, Whitehouse et al 2005). 
 
From the moment of conception we age, develop and change, aging is implicit to human 
existence. Transitions over the life course are a feature of many classic ethnographic accounts 
from Malinowski (1961) to Evans-Pritchard (1971) and Turner (1974). Given the importance of 
aging, it is significant that until recently, old-age and later life received less ethnographic 
recognition than might be expected (Cohen 1994, Clarke 1967, Keith 1980). In the last two 
decades the field of anthropology of gerontology has become more coherent (Cohen 1994, Albert 
& Cattell 1994).  
 
The aging of the human brain connected with increased risk of neurodegenerative disease 
connects the study of dementia research with anthropology’s increasing attention to later life and 
the end of life. This is evident in the increasing number of social studies on the state of well-
being and care in later life (Binstock, et al 2007, Johnson 2005, Kitwood 1997, McLean 2007). 
During my UK based fieldwork amongst dementia researchers, age was presented in a complex 
range of ways. It was a stigma and a challenge to be overcome; a vulnerability to be protected and 
the object of social action and the fight for rights and recognition. These different 
interpretations, as I show in subsequent chapters, have all been used to support and mobilise a 
national dementia research agenda. This is an agenda focused around four areas, the ‘cause, cure, 
care and prevention’ of conditions which cause dementia (Alzheimer’s Society 2014). This 
agenda emphasises innovative treatments and technologies which many hope will hold the clue 
to slowing down, stopping or potentially curing dementia.  
 
Cutting edge developments in the biosciences intersect with the most intimate points of human 
social life, from conception and birth to aging and death. From gene therapies to novel brain 
imaging technologies, developments in biomedicine are rapidly expanding and increasingly affect 
everyday experience. Through the dialogue between science and society, mediated by clinical 
encounters, governmental initiatives, media campaigns, industry and health activism, the 
language of biomedicine is becoming an increasingly familiar. This familiarity inevitably shapes 
how we currently understand and experience aging. This study is therefore located in a wider 
field of anthropological work in science and technology studies, which demonstrate how 
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emerging technologies reveal common aspects of life in a new light (Ginsberg & Rapp 2004, 
Lock 2001, Rapp 1999, 2001). In the rapidly expanding field of neuroscience such technologies 
interrogate our thoughts, feelings, behaviours and emotions, reconfiguring the boundaries of the 
‘normal’ and ‘abnormal’, what constitutes well-being and ill health (Williams, Katz & Martin 
2011). Such biomedical developments have the potential to incite both immense hope and deep 
seated social anxiety (Rose 2007).  
 
However, there is relatively little social science research focused on the current development of 
biotechnologies specifically for people with, or at high risk of developing dementia (Lock 2013, 
Moreira & Bond 2008). This study therefore offers a timely opportunity to explore the hopes 
and anxieties involved in the cutting-edge developments in biomedical research into conditions 
which cause dementia. Conditions which cause dementia involve the uniquely intimate space of 
the human mind, and throw into relief the Cartesian mind and body duality which continue to 
underpin dominant western philosophies of science and medicine (Pickstone 2000). These 
diseases combine the changing physical body with complex, culturally specific perceptions of age 
and aging. In this thesis, through the ethnographic analysis of developments in dementia 
research practices and the political agenda which shapes them, I develop an understanding of 
the role of biotechnological research in the co-construction of knowledge about dementias and 
ageing in UK society.  
Dementia: A brief historical perspective 
 
Interest in and understanding of mental and behavioural changes associated with later life have 
a long and convoluted history. The development of a classification of dementia as a specific 
syndrome resulting from a particular group of disorders, which have distinct and identifiable 
disease pathways, is a relatively recent phenomenon. The stabilization of disease categories in the 
face of shifting and uncertain knowledge is a key feature of current dementia science. As Bowker 
and Star (1999) discuss, there is a continual tension between evolving knowledge and the 
construction of stable, workable categories. For instance, Sontag (1994) and Martin (1994) both 
argue in the context of the immune system and HIV that as a disease category and the biological 
systems in which they are thought to act become more concrete, so the disease becomes a tangible 
object for strategic scientific investigation and intervention. As Fischer (2009) describes it is 
useful to therefore to think of classifications of disease and developments in treatments and 
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technologies, as in a continual process of emergence. This is illustrated by the simple cycle in 
Figure 3: What we understand today as emergent soon becomes established and eventually 
historical as it is superseded by newer forms of knowledge. This process is central to my reading 
of dementia as a concept. Over time, the understanding of dementia has evolved from a set of 
behavioural observations, to be defined by an increasingly specific set of pathologies. These 
pathologies are themselves the site of current debate and reconfiguration, and are by no means 
fixed. To illustrate this processual approach to the concept of dementia I provide a brief overview 
of the historical influences which have shaped contemporary western3 knowledge of these 
conditions to the present day.  
 
 
Figure 3: Continual process of emergence 
 
 
I frame the history of conditions which cause dementia as a continual process of construction 
and contestation, what Jasanoff (2004) describes as a process of co-production. By using the term 
co-production I suggest that knowledge about dementia is shaped through the interaction of 
cultural beliefs, scientific and technological innovation, changing medical practice, 
infrastructure, government policy and public and patient interests.  
 
                                                 
3 As my case study addresses specifically dementia neuroscience in the UK, this history is biased towards the 
influences pertinent to this Western biomedical context. Such an account acknowledges, albeit briefly, the non-
western influences which are integral to this history of neuroscience, although there is not space to expand upon it 






Taking an embedded historical approach to conditions which cause dementia, I first locate them 
in the broader history of our beliefs about the mind, and the evolution of the contemporary 
biomedical model of the brain (Young 1970). There have been radical changes in our 
understanding of the human brain and mind, with the location of the mind ‘wandering’ between 
different organs of the body such as the heart, lungs and brain (Boller & Forbes 1998, Clarke, 
Dewhurst & Aminoff 1996: 2, Smith 2014). In relative terms, it is only recently in human history 
that the brain has been understood as the ‘organ’ of the mind. As a result, historical descriptions 
of dementia differ radically from the conditions we would recognise today. As a result, historical 
descriptions of dementia differ radically from conditions we would recognise today. However, 
Boller and Forbes (1998) persuasively argue that over time there has been a persistent 
preoccupation with the role of aging in changes of mental function. Finger (2000: 13-14) 
describes archaeological evidence from the Edwin Smith Surgical Papyrus of twenty-seventh 
century B.C.E Egypt which illustrate the cumulative effects of trauma and illness associated with 
the head and brain matter. Boller and Forbes suggest as early as 2000 B.C.E. such Egyptian 
archaeological evidence also associates aging with progressive impairment of memory and 
cognition (1998: 125). The historical shaping of dementia continues to be felt in contemporary 
perceptions of the condition.4 This leads the authors to suggest that the observation of what 
today we call describe as the symptoms of dementia, are ‘probably as old as mankind itself’ (Boller 
& Forbes 1998: 125).  
 
In the ‘Golden Age’ of fifth century B.C.E. Greece, during the rise of democracy and the concept 
of individual rationality, there is evidence in the work of Hippocrates that the brain begins to be 
located as ‘the major controlling centre for the body’ (Finger 2000: 29). However, it is important 
to note, this hypothesis was far from dominant, and throughout antiquity the location of the 
mind and soul were a matter of continuous debate (Smith 2014). In spite of contention around 
the nature of the brain itself, during this period, Plato, Horatius and Cicero are all described as 
recording observations which link aging in later life with cognitive degeneration (Boller & Forbes 
1998). Moving toward the common era, Galen is credited with developing experimental methods 
                                                 
4Writers looking at the history of medicine caution against the over-interpretation of terminology, explicitly 
differentiating the evolution of a word from the evolution of a concept. Concepts must be viewed in context, and 
may not be directly comparable through time as knowledge and thinking change and evolve (Berrios 1987, 1995, 
Foucault 1973). With this in mind the evidence I focus on here is the broad association between observed 
descriptions of aging and of changes in behaviour. This does not assume equivalence between the ways in which 
cognition, mental functioning, the brain or dementia are conceptualised in their specific historical contexts.  
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to demonstrate what his predecessors Hippocrates and Aristotle had hypothesised, that the brain 
was the definitive organ of the mind (Finger 2000: 46). The work of Galen and later Celsus 
radically expanded the theory of localised brain function and produced the first attempts at 
systematic accounts of cognitive change. Aretaeus in the second century AD is recorded as 
making a specific differentiation between acute changes in behaviour, and those which followed 
a chronic course. This differentiation as linked to the first specific reference to a progressive 
course of, ‘irreversible impairment of higher cognitive functions’ (Boller & Forbes 1998: 127).  
 
It is only in the late fourteenth century that the concept of dementia came into common usage 
in Western Europe (Berrios 1987). The first modern psychiatric definitions of dementia as a 
disease affecting cognition, are attributed to Esquirol and Pinel in France in the late eighteenth 
century (Berrios 1987, Boller & Forbes 1998). These early definitions of dementia senilis still lack 
what we would recognise as an empirical description or medical case history today. There is also 
no clear distinction between the neurological, biological, psychiatric or functional nature which 
we recognise in contemporary definitions of neurodegenerative conditions (Boller & Forbes 
1998). Berrios also suggests that during this period the concept of dementia was not itself 
associated with a specific age group, nor limited to cognitive changes (1987: 829). Lock (2013) 
on the other hand, supports the idea that the association of later life with observable, chronic 
and irreversible changes in thought, memory and behaviour is a theme which has remained 
persistent across time, and continues to underpin popular perception of dementias. The 
historical evidence presented here suggests, that whilst complex and context specific, early 
definitions and associations of dementia do demonstrate an enduring association between aging 
and potential cognitive decline. This relationship would remain a topic of contention over the 
next two centuries, and continues to be an issue with complex social and scientific implications 
for contemporary dementia researchers.  
 
An evolving pathology: pre-senile dementia and twentieth century 
neurophysiology, laboratory cellular imaging techniques  
 
Between the seventeenth and eighteenth century there was renewed interest in and increasing 
acceptability of human dissection and pathology in medical science and teaching. Combined 
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with a shift in technological sophistication and increasingly anatomical definitions of disease 
concepts, the practice of pathology revolutionised understanding of the structures of human 
anatomy, including the brain (Duffin 2010: 32-33). The Edinburgh school of dissection in 
particular played a major role in furthering the social acceptability of human dissection and the 
legal procurement of human cadavers for research and teaching (Duffin 2010: 35). This was in 
part made possible by social, philosophical and religious shifts during the period, evidenced and 
reproduced in the work of Descartes and Willis, which constructed a separation between the 
material body and the concept of the immortal, rational soul (Clarke, Dewhurst & Aminoff 
1996: 74-79, Grand & Feldman 2007). In this period, the understanding of neurological systems 
and the interaction of brain and body were experimentally mapped. This represented the first 
steps in neuro-anatomical approaches to brain function and solidified the identification of the 
brain as the seat of the mind and, in turn, the person (Finger 2001, Whitaker, Smith & Finger 
2007). 
 
In the nineteenth and twentieth centuries the concepts of senile dementia came under systematic 
scrutiny and observation by clinicians, undertaking research into the clinical and pathological 
features of dementia (Hodges 2006). These clinician-researchers systematically recorded 
psychiatric case histories on their wards. Intriguingly, these observations did not privilege old 
age, but focused on ‘dementia like’ neuropsychiatric cases involving younger people. These were 
people under the age of sixty-five years, the lower age threshold after which dementia senilis was 
believed to present. This interest in the anomaly of younger people presenting with dementia 
senilis-like symptoms led some clinicians and researchers to question what organic factors other 
than ageing might be involved in the development of these dementia disorders (Berrios 1990). 
This focus on the organic cause of mental disorders coincided with increasingly detailed 
documentation of the transmission of sexually transmitted illness throughout Europe (Boller & 
Forbes 1998). Diseases such as ‘neurosyphillis’, were strongly associated with chronic 
deterioration in mental health. The work of Alzheimer in Germany on dementia at the turn of 
the twentieth century, coincided with the increasing emphasis on identifying the organic causes 
of psychiatric disorders (Boller, Bick & Duyckaerts 2007).  
 
In describing the work of ground-breaking neuropathologists such as Alzheimer, Nissl and 




[W]e are reminded of the difficult issues that were involved in defining the 
conceptual boundaries of this disease - issues that remain daunting despite the 
tremendous progress that has been made in the last few decades. 
(Whitehouse, Maurer & Ballinger 2000: 3-4). 
 
Alzheimer's work presents an important moment in the evolution of the discipline of 
contemporary neuroscience. Whilst a practising psychiatry in the first decade of the 20th century, 
Alzheimer used new cell staining techniques developed by Bielschowski in 1903 for microscopy, 
to analyse the histopathology, orcell structures, of brain tissue from deceased patients (Förstl 
2000: 72). This was the first time that staining had been used in neuro-anatomy and Alzheimer 
created images of the ‘plaques’ and’ tangles’ which are still referenced today in describing the 
pathology of AD. Combining this information with clinical observations, Alzheimer developed 
a combined clinical and laboratory base approach which marked a major shift in the practice of 
neuroscience (Maurer, Volk & Gerbaldo 2000: 6 - 9).  
 
In the research which finally led to the identification of AD, Alzheimer emphasised that the 
pathology he was describing most likely represented only one subset of a larger range of 
neurodegenerative diseases. He stressed that the extent and nature of this subtype was not fully 
understood. Alzheimer therefore warned against the simple acceptance of a single and 
unquestionable classification. This risked, he felt, the false categorisation of a potentially much 
more complex range of conditions into a single undifferentiated syndrome. He wrote: 
 
[W]e must not be satisfied to force it [AD] into an existing group of well-known 
disease patterns. It is clear that there exist many more mental diseases than our 
textbooks indicate. In many such cases, a further histological examination must be 
affected to determine the characteristics of each single case. We must reach this 
stage in which the vast, well-known disease groups must be subdivided into many 
smaller groups, each one with its own clinical and anatomical characteristics. 
 




The scientific, clinical and academic environments of key German universities, laboratories, 
hospitals at this time made possible rapid advances in the identification of neurodegenerative 
diseases. The relationship between Kraeplin and Alzheimer is of particular note. Kraeplin, 
Alzheimer’s former mentor and later professional colleague, was a great supporter of his 
innovations in laboratory practice and cell staining techniques. In publications and 
presentations, it was Kraeplin, a ‘classificatory optimist’ (Förstl 2000: 74), and a senior figure in 
German neuroscience, who coined the term Alzheimer’s disease. This was in the context of 
shifting relationships between competing senior scientists, laboratory groups and increasing 
access to international journals in multiple languages. Based in Munich, Alzheimer’s and 
Kraeplin developed one of the largest and most influential groups of international 
neuroscientists at that time (Förstl 2000: 74). There was emerging professional consensus that 
AD was a specific disease category. Over the next decade AD became an increasingly common 
concept and a dominant theme in dementia research journals. As a result of these emerging 
social and scientific relations, and contrary to Alzheimer’s instinct, across Europe AD became 
increasingly synonymous amongst lay people with all dementias. Significantly today, the usage of 
AD has also become a lingua franca or short hand for scientists when communicating in the 
public arena and working on the politics of raising awareness of dementia research. This legacy 
is apparent in the names of the dominant dementia research charities both globally, Alzheimer’s 
Europe and Alzheimer’s Society, and here in the UK, where Alzheimer’s Society and Alzheimer’s 
Research UK (ARUK) are the dominant dementia charities. Although both organisations deal 
with a much wider range of dementia causing conditions that AD, the decision to unify their 
work under the banner of the single and most common dementia pathology is of note.  
 
Thus in the classification of conditions which cause dementia a paradox emerges: in the process 
seeking to define the concrete homogeneity of a disease category, there occura a proliferation of 
classifications (figure 4). Alzheimer, himself, emphasised that his findings marked the 
burgeoning complexity of a heterogeneous classification of dementias from observations of cases 
in which there was an earlier than usual age of onset and a specific pattern in cellular 
degeneration. However, rather than expanding outward, the prevailing research environment 
pulled inward, towards a single concrete classification which could become a focus for research. 
The success of the category of Alzheimer's disease speaks both to the social and political nature 
of the scientific relationships developed between neuroscientists in Europe during the early 
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twentieth century (Boller & Forbes 1998). In a world in which scientific reputation, publishing 
and research design were increasingly part of a growing and interconnected international 
scientific community, Alzheimer's cell images and case histories provided the foundation for the 
construction of a concrete disease entity. This movement toward the dominance of AD 
demonstrates the functional importance of having a named disease when it comes to the 
development research networks. Having a clear object of research attached to systematically 
diagnosed subjects, plays an important strategic role in the development of dementia studies. 
The expansion of research interest and infrastructure, in turn, enabled scientists and clinicians 
to map the complex heterogeneity which existed within this disease category, which undermine 




Figure 4: Cycle of proliferating classifications 
 
As AD came into focus as an object, an organic disease which could be targeted by science, 
researcher’s understanding of what dementias were, how they might be studied and treated was 
undergoing radical redefinition. As new tools and technologies emerged, knowledge expanded 























perpetuated. As I go on to discuss later in this thesis, the boundaries between dementia subtypes 
and their variations continues to evolve as a matter for contention in the neuroscientific 
community (Dubois et al. 2010).  
 
At the core of contemporary scientific epistemology is an ongoing tension between scientific 
certainty and the imperatives of replication, testing and falsification. Certainty is necessary in 
order to create the structures – conceptual, institutional, and relational – which enable research 
to take place. Within these structures the experimental process is used to render such knowledge 
as fragile, uncertain and contested. Science and technology can thus appear to produce 
homogenous and concrete explanation, what Latour refers to as a ‘black-boxed’ knowledge 
(Latour 1987). Inevitably, when we look more closely at any given concept within context, it is 
revealed to be a composite and pluralistic artefact, involving contributions from a diverse range 
of actors, combining distributed information which is continually disputed (Latour & Woolgar 
1986). Social and historical studies of science demonstrate, therefore, that the development of 
science should be viewed not as isolated practices, but practices which take place within changing 
and complex social relations and specific cultural and historical contexts (Bowler 1989, 1990, 
Gould 1992, Latour & Woolgar 1986). In the section which follows I illustrate this tension with 
reference to the continued evolution of dementia disease classifications, and in particular the 
development of dementias within the Diagnostic Statistical Manual (DSM) and the International 
Classification of Disease (ICD). Both publications are used internationally as guidance for the 
formal diagnosis of conditions which cause dementia. 
The Diagnostic Standard Manual and the International Classification 
of Disease 
 
A specific interest in the collection of information on the instance of disease has been traced 
back to seventeenth century England and Europe (Greenwood 1948). As Foucault argued in his 
account of biopower, recording information about the health of populations has become an 
integral part of the operation of the modern nation state (Foucault 1990, 2002). In the United 
States in the mid-eighteenth century, a more complete and systematic collection of census 
information went hand in hand with the accumulation of information on verifiable incidents of 
a disease which could be classified by defined criteria (Strand 2011). Such data was developed to 
enable physicians to systematically identify the signs and symptoms of a particular disease. As in 
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the case of AD, observed symptomatic data could then be posthumously correlated with material 
evidence of the pathological changes caused by the condition. Consequently in 1855 the 
International Statistical Congress in Brussels developed the first versions of the International 
List of Causes of Death. This was based on the records developed by Farr and D’Espine 
(Greenwood 1948). The work of the Congress’s 1893 committee, chaired by Bertillon, Chief of 
Statistical Services of the City of Paris, led to the development of the International Classification 
of Causes of Death list. Under the aegis of the World Health Organisation (WHO) in the US 
these early attempts at a systematic nomenclature eventually evolved into the International 
classification of Disease and Related Health Problems (ICD) (WHO 2014). The ICD was widely 
used in Europe to classify and diagnose mental health disorders but did not find favour in its 
home nation. Increasingly it was the DSM which became the commonly used system in the UK 
and US for categorising mental health conditions and diseases of the nervous system (Jetté et al 
2010, WHO 2014). 
 
The development of the DSM is linked to the development of the international scientific 
community in the early part of the twentieth century. Researchers and clinicians increasingly 
looked to forms of evidence from large scale samples which were conceptualised as more reliable 
and robust, allowing comparison across time and place. As the case of Alzheimer’s work 
illustrates, the role of clinicians maintaining and exchanging patient records and case histories 
became central to this process. Clusters of cases were identified and ‘written up’ into accounts 
which could be readily exchanged amongst the wider neuroscientific community. This exchange 
took place through private communication and increasingly through publication in the 
expanding number of specialised biomedical journals. Better regulation, standardization and 
recording practices facilitated communication and provided the basis for discouraging potentially 
harmful practices from a newly professionalising medical community (Busch 2011) 
 
The routes of this classificatory preference are to be found in the routine health screening of 
army recruits in the United States during and after the Second World War. This unique context 
provided an opportunity for physicians and psychiatrists to observe illness in a large and relatively 
controlled population (Blashfield, Flannigan & Riley 2010). Menninger, a US military physician 
working with service personnel and their records, developed the Medical 203 document, which 
provided procedures for the large scale statistical monitoring of psychiatric diseases and set 
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precedence for the further systematisation of disease categories (Houts 2000). Such efforts 
underpinned the American Psychiatric Association statistical record of the US hospital inpatient 
population. It was from these records that statistically significant mental disease groups were 
identified and classified. This data formed the basis for the Diagnostic and Statistical Manual of 
Mental Disorders, commonly called the DSM (Rogler 1996, Cooper 2005). For those working 
in the field of psychiatry, the DSM provided an officially recognised name, numerical code and 
description of the explicit mental and physiological criteria the patient had to display in order to 
fit the diagnostic category. The guide included a list of symptoms, their duration, and the 
common alternative conditions to be excluded, in order for a diagnosis to be considered firm. 
 
The first edition, the DSM I, was released in 1952, and the second edition, DSM II, appeared in 
1968. At this time, records suggest that the guidance was little used by practising psychiatrists 
(Cooper 2005). However, by the third edition (DSM III) which appeared around 1980, the 
resource is described as ‘embedded in [US] mental health at every turn’ (Cooper 2005: 1). By the 
1980s, there was increasing professionalization and regulation of scientific and biomedical 
research. At the same time, there was rapid development of the transnational scientific 
community, with increasing connection to global pharmaceutical industries and markets. 
Cooper notes: ‘research papers are couched in DSM terminology and pharmaceutical companies 
list the DSM diagnoses that their drugs treat' (Cooper 2005: 1). Within this context the DSM 
became the fundamental guide to the classification of mental health worldwide.5  
 
From its inception the capacity of the DSM to define disease has come under challenge. Far from 
a neutral and purely empirical process, the DSM has been shown to be subject to commercial, 
political and cultural influences and interests (Rogler 1996).6 Some of the categories of disease 
                                                 
5 Although outside the scope of this particular history, it is important to note that this professionalization and 
regulation of medical and bio-scientific research occurred in the context of emerging ethical standards developed 
through a series of multi-national documents: the Nuremburg Code, 1947, the Universal Declaration of Human 
Rights, 1948, the Declaration of Helsinki, 1964, the International Covenant on Civil and Political Rights, 1966, 
the Belmont Report, 1979, and the 1996 International Conference on Harmonisation Good Clinical Practice(ICH-
GCP). These ‘milestones’ were historic in the development of multi-national ethical framework, defining the 
acceptable limits of medical research with human subjects and in the role of voluntary participation and informed 
consent for research participation (Bhatt 2010). 
6 In the United States where health care is primarily privately funded, with relatively limited state support available, 
medical insurance policies, and the companies that supply them are the primary conduit for citizens to pay for to 
health care at the point of need. Insurance and pharmaceutical companies are significant part of the US economy. 
As a result, lobbyists have significant power in the political arena. In the area of research which informs the 
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described in earlier DSM manuals are today understood to be purely historical and cultural 
phenomena rather than legitimate diagnoses. In particular, the role of the DSM in legitimising 
the classification of homosexuality as a mental disorder has been critiqued. This classification is 
seen to have contributed to stigma and discriminatory legacy which continues to be experienced 
within lesbian, gay, bisexual and transgendered communities today (Jutel 2011). The evidence of 
such classifications demonstrate how each edition of the DSM should be thought of very much 
as products of their time and reflective of the dominant values of the cultures in which they are 
constructed. As a result changes in cultural understanding can have a profound impact on the 
kinds of social behaviour which are classified as evidence of a ‘disorder’ of the mind (Cooper 
2005). In short, the use of rigid definitions and boundaries based on standardised statistical 
calculations, have the effect of constructing rather than describing disease realities. The utility of 
this construction is described by Berrios and Porter: ‘Diagnostic categories are about creating 
something which can be acted upon with beneficial outcomes’ (Berrios & Porter 1995: xvii). This 
process highlights the way in which diagnostic labels function as a tool of science as well as a 
means of social control and the exercise of biopower (Foucault 1990, Rose 1996, 2007). As 
societies themselves are subject to continual change, both the ICD and the DSM continue to be 
revised and rewritten in response to shifts in not only science, but also changing cultural, 
commercial and political interests. The shifting nature of disease categories once more highlights 
a paradox: changing evidence has the potential to both consolidate and compromise the 
bounded concept of disease categories, including those used to define conditions which cause 
dementia. 
 
In my own study, dementia researchers and research projects often referred to the patients 
diagnosed using the classifications outlined in the textual revision of the fourth edition (DSM-
IV-TR), released in 2000.7 The category provided by DSM-IV-TR was often combined in research 
protocols with the ICD 10, released in 1994. For dementia, however, more important is the 
additional disease classification developed by the National Institute of Neurological Disorders 
and Stroke–Alzheimer Disease and Related Disorders (NINCDS–ADRDA), published in 1984. 
Whilst the DSM classification describes a ‘probable diagnosis’ of AD based on clinically observed 
                                                 
construction of the DSM health industries play a significant role. As a result, diagnostic practices and concepts 
demonstrate the interrelation of health care, health industry, economy, political structures and scientific practices. 
7DSM V was published May 2013. Consequently the most recent amendments in the diagnostic criteria for 
dementias fall outside the limits of this thesis. 
43 
 
signs and symptoms; the NINCDS-ADRDA classification allows for a definitive diagnosis with 
the inclusion of imaging data. Additionally the NINCDS-ADRDA classification can be informed 
by histopathological evidence to specify the particular condition and the pathology involved in 
causing dementia. 
 
At the time of the initial development of the NINCDS–ADRDA and the DSM IV, common 
access to information about the histopathology of the dementias was still limited to post-mortem 
analysis. With the advent of new technologies such as imaging and bio-marker tests, the capacity 
to observe disease processes in vivo has led to a fundamental change in the diagnostic categories 
of conditions which cause dementia. As Dubois et al. write: 
 
The NINCDS–ADRDA and the DSM-IV-TR criteria for Alzheimer’s disease (AD) are 
the prevailing diagnostic standards in research; however, they have now fallen behind the 
unprecedented growth of scientific knowledge. Distinctive and reliable biomarkers of AD are 
now available through structural MRI, molecular neuroimaging with PET, and 
cerebrospinal fluid analyses. This progress provides the impetus for our proposal of 
revised diagnostic criteria for AD. 
Dubois et al. (2007: 734 (my emphasis)) 
 
As I discussed in the history of dementia, advances in research continually render existing 
diagnostic standards limited. Frequently throughout history the DSM has been found to be 
playing catch-up with evolving research knowledge.  For instance although imaging technologies 
began to be developed in the 1970s, and used in dementia research since the 1990s they were 
not included in the 2000 DSM criteria.  
Neuroscience: Heading toward ‘The Decade of the Brain’8 
 
Having considered the categories by which conditions causing dementia are defined, I now move 
on to discuss how the development of these new biotechnologies have changed biological and 
                                                 
8The idea of a ‘decade of the brain’ originated in the US between1990-1999 and was launched by President Bush 
(Abi-Rached 2008). However, the concept of a decade dedicated to the brain and brain science spread to many other 
organisational bodies, including the EU. The decade became a trope to capture and capitalise on the potential of 




biochemical understanding of the brain and its process. Such changes reflect the continuing 
shifts which occur between knowledge and practice. Just as Alzheimer’s use of cell staining 
techniques radically changed how researchers understand a range of dementia conditions in the 
early twentieth century, today new technologies of neuroscience are having a similar 
transformative impact on the fields of clinical research, clinical trials and health care practices. 
By tracking changes in research design, changes in inclusion and exclusion criteria for research, 
and infrastructural development of research facilities, it is possible to see this relationship 
evolving in practice. The criteria which are developed in the categorisation processes described 
above must change as new biological evidence becomes accepted by the majority of those who 
make up the dementia research community.  
 
As Dubois et al. (2007) indicate a key development in the evolution of current dementia disease 
categories was the emergence of ‘in vivo’ brain imaging, particularly the development of Magnetic 
Resonance Imaging (MRI) (O’Brien 2005). The technique of MRI was first published by, and 
remains largely attributable to, Mansfield and Lauterbur in 1974 (Geva 2006). As with all major 
advances in science, however, there remains a degree of contention about the primary 
international contributors to the development of the technique (Filler 2009). The development 
of such imaging technologies in the 1980s required a synthesis of novel advances in a range of 
disciplines including engineering, medical physics and computer programming techniques and 
technologies. It was only during the later development of the technology that it became apparent 
the potential MRI would have in human biomedicine. As a result, the range of technologies used 
to create visualisations of living brain tissue structures and processes classed as neuroimaging are 
still considered a relatively young and emerging field in medical physics. The first MRI scan of 
human tissue of a live human subject took place in the UK in 1984. The synthesis of disciplinary 
techniques and willingness of key scientists to work across disciplinary boundaries enabled the 
development of equipment to image soft tissues in the living body, including the brain. Over the 
last 30 years new developments in this technological field have been rapid. New imaging 
approaches have resulted in multiple modalities being in use in health research and care today 
(Farah &Wolpe 2004). The most common of these, and the ones used by researchers in this 
study included MRI, functional MRI (fMRI), Photon Emission Tomography (PET), Scanning 
Photon Emission Computer Tomography (SPECT), used to image the brain in vivo, and 
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Scanning Electron Microscopy (SEM) used to image post-mortem brain tissue at very high 
resolution. 
 
(F)MRI, MRI and PET are the most common imaging tools used in clinical practice. The 
techniques for most gross neuroimaging techniques are based on the measurement of variations 
in the oxygenation or metabolism of brain tissue. In structural imaging (MRI) the measurement 
of metabolism is correlated with tissue density in order to map the physical brain structure. The 
primary data produced by these methods are translated through mathematical algorithms to 
construct two dimensional or three dimensional visual representations. In fMRI metabolic 
changes are correlated with specific changes in activity when a controlled stimulus, such as a 
language processing task, is experienced. Thus fMRI can be used to map brain activity in action, 
over time, providing a four-dimensional representation. PET uses a radioactive isotope marker 
that is taken up by selected cells in the brain. The rate of uptake of the isotope provides a 
secondary measure of metabolism which is correlated with brain activity. Other technologies that 
are in common use in dementia research include: Scanning Photon Emission Computer 
Tomography (SPECT) which focuses on measuring variation in photon emission; Blood-
Oxygenation-Level-Dependent (BOLD) (Jezzard & Clare 2001).9 The large scale collection and 
comparison of such data enables researchers to construct an aggregate model of structures and 
processes which are understood to make up the ‘average’ living human brain. By extension, these 
processes then enable researchers to identify potentially abnormal structures or disease processes 
which correlate with disorders in physical and mental function. The collection of these data 
informs the construction of disease categories, becoming part of the process of diagnosis, and 
central to the development and practice of research and treatment.  
 
As well as the gross scale of imaging the structure and function of the brain in techniques of MRI 
and PET, current advances in dementia research involve working at the cellular and molecular 
level. This is related to the development of SEM which allows the imaging of posthumous brain 
tissue at extremely high resolution. This technology allows researchers to visually examine disease 
processes at the cellular level which has been central to the accurate differentiation between 
                                                 
9 Farah & Wolpe (2004) provide further overview of the main imaging technologies in common use in clinical 
practice and clinical neuroscientific research. For a fuller technical overview of the MRI and fMRI see also 
D’Esposito 2006, Durvernoy 1999, Gjedde 2001 and Glover 2001. 
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dementia conditions such as DLB and VaD. By identifying and trying to understanding the 
biochemical and bimolecular processes occurring at the cellular level, researchers are developing 
a new picture of how specific disease processes work, and how more refined treatment protocols 
could be developed to intervene more effectively and earlier in course of the condition (Lock 
2013). 
 
Unsurprisingly, in such a rapidly developing field there are vibrant debates in the imaging 
community about the relative value and efficacy of different techniques for particular patients 
and for particular conditions (Jackson & Purandare 2007). Within the dementia research 
literature, MRI, fMRI and PET dominate research into dementia condition diagnoses and 
treatments. Although these are widely accepted techniques, a number of writers have drawn 
attention to the lack of standardized protocols for interpreting data produced by these 
technologies (Jezzard & Buxton 2006). The absence of standard procedures there is concern 
about the over-interpretation of data produced by non-comparable processes (Andreasen 2001, 
Beaulieu 2002, Dumit 2004, Joyce 2005). Joyce (2005) suggests that the variable processing of 
data can lead to idiosyncratic inference and interpretation at various stages in the production of 
imaging data. 
 
In this thesis scientific images and images of science play an important role in the evolution of 
dementia research in the UK both practically and rhetorically. I examine MRI and fMRI and 
SEM images are used by scientists not simply as evidence of their findings, but also, as a means 
of conveying their knowledge, interests and concerns beyond the scientific domain. This includes 
the use of imaging data in the fields of policy, patient recruitment, public awareness and research 
advocacy. This places the scientific image in both the scientific and political arenas. There is an 
extensive body of literature which examines the complex processes by which medical images are 
formed and the relations and connections they elicit (Burri & Dumit 2008, Cohn 2008, Dumit 
2004, Joyce 2005, Prasad 2005). This literature amply demonstrates how images used in medicine 
and biomedical sciences have helped define and critique basic categories in scientific and 
biomedical discourse (Lynch 1985). Developments in scientific imaging have been shown to have 
the capacity to reshape, challenge and completely alter people’s cosmologies of health and illness. 
Taking this approach I am locating scientific images as an important artefact through which 
people come to know the world, understand its working and conceptualise the role they play 
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within it. This has been demonstrated particularly in the construction of diagnostic categories 
and labels, which can have important implications for the identity, behaviour and social relations 
of the people which receive them (Kilshaw 2008, Greco 2012).10 
 
Scientific images can thus play a vital role in fixing both social and medical realities. However, it 
is important to note that often such images become disconnected from the scientific mode of 
production. Portrayals of science in action have led social scientists to examine how biomedical 
images (including technical diagrams, illustrations of disease processes, medical images and 
images of science) are used in diverse locations, for a complex range of purposes and by a variety 
of differently positioned actors. For instance, such images play important roles not only in peer 
reviewed academic journals (Daston & Galison 1992), but also in public health campaigns (Löwy 
& Krige 2001, McCool et al. 2012). The reproduction of images in this case are clearly motivated 
by, and produced within, different contexts. However, one feature in the contemporary age of 
biomedicine is the abiding fascination with visualisations of the human body. Galison (1997) 
suggests that images provide unrestricted access to information with an incredible level of 
immediacy. Images, he argues move fluidly between domains, by-passing the technical, scientific 
and social complexities of their production (Daston & Galison 1992, Galison 1997). In short, 
images are forms of knowledge which are flexible, porous, and open to multiple uses and 
interpretations. Such interpretations therefore, can rapidly move the image away from its original 
signifier, in sometimes unexpected ways.11 
 
The expansion and growing sophistication of biotechnologies, such as imaging, have shifted how 
scientific research groups are shaped and constructed. Increasingly dementia research groups will 
bring together researchers with a range of disciplinary specialisms. Therefore scientific images, 
                                                 
10 The role of diagnostic categories in reshaping or challenging people’s sense of identity has been drawn into 
particular relief in the case of emergent conditions which do not have accepted boundaries or classifications. The 
cases of chronic fatigue syndrome (CFS) known also as Myalgic Encephalopathy (ME) and Post Traumatic Stress 
Disorder (PTSD), are high profile examples where the contested nature of the conditions, crossing organic and 
psychiatric boundaries, have made them sites of potent political and personal conflict (Clarke & James 2003, Dumit 
2005). This sort of identity making and contestation is also particularly apparent in the narratives of other 
neurodegenerative and chronic conditions, where the boundaries between being ‘sick’ and being ‘well’ fluctuate and 
blur (Monks & Frankenberg 1995, Marenderani, Locock & Powell 2012). 
11Simultaneous developments in the digitisation of data and the incorporation of information communication 
technologies (ICT’s) into the process of neuroimaging, facilitates the development of large scale and transnational 
data comparison. This has resulted in transnational scientific endeavours such as the Human Brain Project. For a 
more in depth examination of the role played by ICT’s in the development of contemporary neuroscience see 
Beaulieu (2001, 2004).  
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such as neuroimaging, are not only a product of increasing trans-disciplinarity, but also an 
important tool for facilitating these kinds of transdisciplinary working relationships. As such 
medical imaging can be a powerful tool. Imagines provide a shared object and language within a 
research group, one which can operate across and beyond disciplinary boundaries. For instance, 
neuroimaging data constructed during an fMRI project to improve diagnostic accuracy between 
AD and VaD, would be used both within the specific project, and also presented to specialist 
audiences from different fields. These fields may include: clinical practice, disease pathology, 
biochemistry, statistical programming and digital modelling. Such images may then also be used 
in future research presentations, proposals and documents involved in the development of the 
research infrastructure. The same images also appear in patient documents to explain diagnostic 
processes and treatment options. Such images may appear again in material to recruit 
participants to clinical trials and in media content to raise awareness of dementia conditions at 
public engagement events. This is a far from an exhaustive list, but illustrates how an image may 
be used to facilitate the scientific process across different domains. 
 
In the early 1990s the growing variation of modalities of data production, operating within 
different scientific communities, resulted in large quantities of data on an increasing number of 
neurological and neurodegenerative conditions. However, different approaches within research 
groups and specialisms, and variations between national scientific policies led to different 
imaging techniques becoming dominant in different localities. This is apparent in the use of 
technologies such as PET, particularly as they relate to availability, access to and control of the 
radioactive materials required. As a result, there exists a great variation, nationally and 
internationally on the types of data available for the comparison of particular conditions such as 
AD. This variation raised concerns among the scientific community worldwide (Beaulieu 2004). 
Some scientists considered the lack of systematisation, synthesis and collaborative sharing of data 
to be limiting the success of the field of dementia research. The perceived lack of coordination 
was understood to restrict the effective application of data to advance research and clinical 
practice. In response to this flaw in research structure, groups of senior scientists worked within 
their national systems of science policy, developed strategies to attempt to maximise the 




Beaulieu (2004) has compared the strategies which subsequently developed in North America 
and Western Europe. North America scientists focused on how infrastructure could be 
developed to take advantage of the burgeoning, geographically dispersed, data-rich digital 
research community. Capturing the popular imagination was considered crucial to the success 
of the enterprise. The US ‘Decade of the Brain’ was launched by President Bush in the 1990s. 
This led to initiatives such as the Human Brain Project (HBP). Such initiatives, following the 
precedent of the Human Genome Project (HGP), were designed to integrate data and increase 
research productivity and application. This was achieved by capitalising on national social and 
political enchantment with scientific understanding of the human condition, enlisting a sense 
of national pride to build public and political support (Beaulieu 2004).  
 
In contrast, neuroscience researchers in Europe and the UK focused not on the coordination of 
data management systems, but on the networks of scientists, researchers and clinicians involved. 
UK and EU policy suggests that dementia neuroscience lacked the people with the appropriate 
range of clinical and technical research expertise to work across disciplines. Beaulieu argues that 
in these regions, the dominant issue was perceived to be a lack of sufficiently qualified cross-
disciplinary scientific personnel required to take full advantage of and develop new technologies 
in this field (Beaulieu 2004). Simply put, UK and European dementia research policy, upon 
which this anthropological study is based, foregrounded the importance of technical expertise 
and relations. As a result, developments in the UK dementia research community have focused 
on initiatives to raise the profile of dementia neuroscience and to recruit high quality, young 
scientists from across a range of disciplines. This focus is apparent in the Medical Research 
Councils’ (MRC) 2008 Strategic Report on Neurodegeneration: “When judged against other 
countries, a particular weakness in the UK is the relatively fragmented research effort, with small 
research teams” (MRC 2008: 5). 
 
Dementia research in the context of the UK National Health Service: 
health economics, standards and regulations 
 
Moving on from the state of contemporary dementia neuroscience, in order to understand the 
shape of dementias and dementia research in the UK it is necessary to locate research efforts 
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within the context of a national health service (NHS) and the wider national system of health 
and social welfare. Although shaky at its inception in 1948, Klein describes how the NHS 
developed into “a tax funded service that provides comprehensive, universal health care that is 
free at the point of delivery” (Klein 2010: v). This service was underpinned by an ethos of 
collectivism and public confidence in the structure of state planning. However, by the 1970s, 
economic and political climates were changing both globally and nationally. At this time, notions 
of health research and ‘public’ science were reshaped along increasingly market-oriented 
principles (de Chadarevian 2011).12 Klein argues that the NHS quickly became a monolith of 
technocratic rationalism (2010: 46-75). As a result, in the early 1980s a parliamentary review of 
the NHS recommended greater investment in public health and health services research to 
increase productivity and rationalise expenditure (Black 1997). In 1991 this led to the UK 
becoming the first European country to officially integrate a national research and development 
program into the health system, heralding a new era in health research and health care (Klein 
2010).  
Over the last twenty years, across consecutive governments, the marketization of the NHS has 
continued, with patients reconfigured as ‘consumers’, and the language of choice and 
individualism entering every aspect of the health care relationship. However, the NHS has shown 
great resilience, existing throughout ‘policy drama and organisational turbulence […] in a cocoon 
of institutional and cultural continuity’ (Klein 2010: v). Whilst public opinion is frequently 
frustrated by unequal or inconsistent quality and availability of care, the NHS remains ‘a much 
loved, if also much criticised, national treasure’ (Klein 2010: v). However, the commercialization 
and marketization of national health care, has accompanied a decline in public trust in the 
medical profession and by extension the biomedical research community. As a result, there is 
increasing demand for transparency and accountability within biomedical research. This 
                                                 
12 De Chadarevian suggests that whilst the commercialisation of health research started in the UK, it was perfected 
in the United States, where the practice of patenting new developments had become central to the growth of 
emerging health-care markets. The UK research system continues to be criticised for failing to make effective use of 
patent law to control intellectual property developed through the national research infrastructure. As a result, 
measures have been put in place to ensure that all new project funding agreements address how intellectual property 
rights will be protected (de Chadarevian 2011). Klein (2010) suggests that one reason academic and clinical 
researchers have been, and remain reluctant to engage with the commercial research practices relates to the collective 
and paternalistic ethics and politics which underpin the history of the NHS. There remains a tension between with 
the logic of the market and the ethos which underpins the health service. 
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accountability is realised through complex processes of audit, regulation, and a responsive 
approach to the concerns of the ‘patient /consumer’.  
UK biomedical researchers, thus work within a complex set of structural, bureaucratic, ethical 
and regulatory frameworks. Alongside these frameworks, UK biomedical research sits within 
wider European and transnational structures such as the EU Clinical Trials Directives. These 
directives in turn sit within international ethical, commercial and scientific regulatory structures, 
for example, those provided by the WHO (ICH 2010). These multiple, and often competing 
frameworks, must be harmonised in order for research and experimentation to proceed. It 
should be noted that whilst the challenges of new modes of accountability are reshaping clinician 
/ patient relations, they have not dis-assembled the long standing hierarchical power relations 
which largely persists.  
As the field of biomedical research is vast, I begin by outlining the kinds of dementia research 
involved in this project, and situate these in the national context of funding and regulation. 
Black (1997) identifies four broad tiers of research supported within the NHS: Basic, clinical, 
health service and public health. In this project I looked at studies in two main areas of dementia 
research, basic and clinical. Basic research is laboratory based, focusing on the proof of principle 
in relation to understanding of dementia subtypes and their pathologies in relation to the ageing 
brain. This may involve human cell line and animal cell or subject studies.13 Second, I considered 
clinical research, also known as applied research, which involves living human subject. Clinical 
or applied research is divided into two main areas: observational and interventional. 
Observational studies do not involve any physical intervention in the subject’s treatment. Rather, 
they use diagnostic technologies (ranging from imaging to psychological tests) and patient records 
to understand and monitor the disease pathways of specific dementia subtypes in the individual 
or, within larger population groups. Interventional studies research the effect of technologies, 
medicines, therapies and practices on human participants. Hackshaw pinpoints four main targets 
for interventional research: 
 
                                                 
13 I am particularly concerned with study implications of experimenting with human tissue. However, it is important 
to acknowledge the controls and regulations involved in animal based studies of dementia. The background and 
implications of such regulations are a considerable topic of interest, but beyond the scope of this thesis. For a 




-to diagnose or detect disease 
-to treat an existing disorder 
-to prevent disease or early death 
-to change behaviour, habits or other lifestyle factors  
(Hackshaw 2009: 7) 
 
Currently in dementia research one of the main targets for interventional studies are to develop 
methods of early identification, to slow the organic progression of the condition, maintaining or 
improving the cognitive capacity or quality of life of the recipient.  
 
UK biomedical research is overseen by the National Institute of Health Research (NIHR) which 
is the core research arm of the NHS. The NIHR works alongside the discipline specific research 
councils. In the case of biomedical and biotechnological research, this includes the Medical 
Research Council (MRC), the Engineering and Physics Research Council (EPSRC), and 
increasingly the Economic and Social Research Council (ESRC). The councils fund and provide 
guidance and regulations for funded studies. Such guidance is both responsive and anticipates 
future directions and issues arising from research. As a result such organisational bodies are 
involved in shaping future research design and foci. The national research councils, such as the 
MRC, work alongside specific academic and industry research centres. It is through these centres 
that research projects are developed and conducted. In order to access human research subjects, 
data or tissue, an academic research group must have, or create links between, academic 
institutions and regional NHS facilities. Access to, and ethical approval for, research with a 
patient population is administrated by regional Research and Development (R&D) and Research 
Ethics Committees (REC).14 These are organised and administered at the level of Primary Care 
Trusts (PCT), the regional umbrella organisation under which NHS services are collected and to 
a degree coordinated.15 
 
                                                 
14A more in-depth description of the structures and processes involved in NHS R&D and REC approval is given 
in chapter two. 
15 The PCT system of regional organisation was replaced by the Clinical Commissioning Group (CCG) in April 
2013 (Great Britain, National Health Service England (NHSE) 2013). The CCG devolved commissioning power 
for regional NHS services from the top-down PCT structure to regional collectives of General Practitioners. 
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In the UK applied pharmaceutical and biotechnological research studies involve a tightly 
regulated and high cost research process. Industry plays a major role in providing finance and 
resources for projects which are based in the NHS. UK government policy increasingly 
emphasises the academic-commercial partnerships as the natural basis for biomedical research 
(Sheard et al 2006). Internationally the UK is also located within highly competitive 
transnational health markets. As a result biomedical research and industry is positioned by 
current government as a key resource in the UK economic recovery and future expansion (Great 
Britain, Department for Business, Innovation and Skills 2011). There is a significant branch of 
anthropological work focused on the global nature of biotechnological research.16 Therefore, 
whilst throughout this thesis I make reference to the transnational and collaborative connections 
which shape national research practices, primarily I am focused upon how such relations are 
realised and enacted within the national scientific, social and political-economic networks. 
 
In the last six decades, one of the main challenges for the NHS has been to respond to the 
shifting demographics of an ageing population. As a result, decisions on resource allocation and 
priorities determined by the Department of Health are moving away from the classic targets of 
infectious disease, toward chronic degenerative health conditions such as dementias (but also 
conditions such as arthritis, metabolic, endocrine, cardiovascular and cardiopulmonary 
conditions). As the NHS is increasingly called upon to help manage and treat such conditions, 
so it also confronts the anxieties, needs and expectations of an aging public. As a consequence, 
one of the core policy frameworks which dominate current NIHR and research council strategy 
is that of ‘Research for Patient Benefit’ (RfPB) (Great Britain, NIHR 2013, 2014). The RfPB 
initiative launched in 2006 is described by the NIHR as a ‘response-mode programme’ focused 
on research which can improve delivery of front-line health services in the short to medium term 
(Great Britain, NIHR 2008: 2). 
 
With increasing emphasis on rapid response to outcomes and patients benefit, how do funders 
and policy makers identify and assess the value of biomedical research across a broad range of 
potential interventions? The principles of Evidence Based Medicine (EBM) are widely used to 
                                                 
16 For an overview of the main debates on the practical, political and ethical issues related to the transnational nature 
of biotechnological development, in particular in pharmaceutical trials see in particular Lock & Nguyen 2010 and 
Ong & Collier 2008.  
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evaluate research and demonstrate the clear and quantifiable benefit of any treatment 
programme. As Timmermans and Berg note, the concept of EBM can have a variety of 
interpretations, such as a process of ‘critical self-evaluation, the production of evidence through 
research and scientific review, and/or the ability to scrutinize presented evidence for its validity 
and clinical applicability’ (Timmermans & Berg 2003: 3). The fundamental meaning of EBM for 
research is that any new intervention must ‘be more effective than another or that it has a similar 
effect, but is safer, cheaper or more convenient to administer’ (Hackman 2009: 8). Evidence of 
efficacy and utility must be demonstrated through ‘proper statistical analysis’ which provides 
robust and objective evidence’ (Hackman 2009: 8). As such research must refer to national and 
transnational clinical standards and guidelines, which define how diagnostic and therapeutic 
strategies are objectively ‘proven’ to be better than their alternatives. 
 
The internationally recognised ‘gold standard’ for assessing the efficacy of a clinical intervention 
is the Randomised Control Trial (RCT). The concept of controlled experimentation can be 
traced back to antiquity, but the structure we recognise today first emerges in the mid-eighteenth 
century in the work of James Lind on scurvy (Hacksaw 2009, Bhatt 2010). Controlled testing, 
involves comparing the outcomes of a group who receive the experimental intervention to groups 
which receive: no intervention, an alternate treatment or a placebo. However, the knowledge 
that one is receiving an experimental drug has been shown to have a psychological impact, which 
significantly biases the results of the trial. As a result, in 1943, the UK MRC designed and funded 
the first double-blind comparative trial of patulin to treat the common cold (Timmermans & 
Berg 2010). Blinding attempts to address bias through the alternate allocation of subjects to 
intervention or non-intervention group, where neither clinician nor subject knows which group 
the subject is assigned to. Although the concept of randomisation had been considered since 
1928 (Hackshaw 2009), it was the 1948 testing of streptomycin for pulmonary tuberculosis, again 
under the auspices of the MRC, which marked the first recognised randomised trial. Here, 
participants were assigned random numbers to further minimise the potential for bias, by 
preventing any prediction of which treatment group a participant would be assigned to. The 
combination of randomised and double-blind protocols enabled complex data to be subjected to 
relatively simple statistical tests (Lesaffre & Verbeke 2005).17 Clinical trials, like the disease 
                                                 
17 Where variables were continuous this requires a t-test, where the variables are categorical a chi-squared test 
(Lesaffre & Verbeke 2005). 
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categories upon which they intervene, continue to evolve. However, from this point onward 
clinical trials acquired the key characteristics we associate them with today: meticulous design 
and implementation, systematic enrolment criteria and systematic data collection (Bhatt 2010). 
These principles of a systematisation and control remain the backbone of the authority claimed 
by the knowledge and products which result from the clinical trial process.  
 
In the case of clinical drugs trials Lesaffre and Verbeke (2005) describe how a study will be 
divided into four phases illustrated in figure 5. The classic trial structure is reiterated in the 
ARUK 2013 research strategy illustrated in figure 6. This diagram also demonstrates how basic 
research and clinical research are particularly closely interlinked in dementia science. The need 
to improve understanding of the basic disease mechanisms involved in the specific conditions 
which cause dementia remains a high priority in the development of better drug targets and 
diagnostic tools for clinical trial. 
 
 
Figure 5: Phases of the clinical trial.  
Lesaffre &Verbeke (2005)  
 
The inclusion and exclusion criteria for trials in dementia research employ the disease category 
continually developed thought DSM, ICD and NINCDS/ADRDA. These criteria enable 
researchers to define the ‘right patient’ to recruit for a specific trial (Dubois et al 2007). 
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response to the intervention can be considered comparable. As such phase I and II trials involve 
‘ideal’ patients. These studies explore the response of a very specific disease pathway within that 
specific sub-sample of patients. Thus the RCT both creates and acts upon the ‘ideal’ research 
subject (Timmermans & Berg 2010). This is again illustrated by the ARUK research strategy 
illustration (figure 6). 
 
 
Figure 6: Diagram of the ARUK Dementia research strategy 
 
This research approach has been dubbed ‘right patient, right drug, right time’ (Ashley-Webb 
2013). This image illustrates the feedback which takes place between the changing categorisation 
of the condition, the types of treatment and diagnostic targets which are adopted, and the trial 
design. Thus the trial process, in working to protect the participant, and the quality of the data 
produced, continually modifies and increases the emerging complexity of the disease. This cycle 
between research and diagnosis perpetually reinforces the idea of a fixed and controlled set of 





Although clinical research functions within these categories, a major concern for research is that, 
like other age related chronic illnesses; those affected with conditions which cause dementia are 
highly likely to have other co-morbid disorders. As a result researchers struggle with the very 
controlled limits of the RCT structure, in the content of a disease which render the recruitment 
of a ‘pure sample’ increasingly problematic. This was reflected at a discussion I observed at a 
meeting of clinicians, scientists and the public involved in the Alzheimer’s Society Research 
Network: 
 
Chair of meeting: What I was going to ask you about was one of the debates 
about the sort of heterogeneity of AD, you know, the fact that there are a lot of 
different types of pathology in the brain. A lot of people particularly perhaps once 
they are past the age of 80 have vascular changes and other things going on, and 
it feels like there has been a debate with some people arguing that we should be 
doing initial trials on fewer, purer groups who have particular imaging or, you 
know biomarker changes, that we know have got AD but not much else. But on 
the other hand people would argue if we do that, then the trials aren’t 
generalizable to anyone except people who meet those very tight criteria. Do you 
have any views on that? 
Epidemiologist: Yes, yeah I have pretty firm views on that, because it is true of 
other disease other than dementia as well. Clinical trials are a very pure form of 
experiment, and generally people who design trials want their trial population to 
be less… problematic, really (laughs), and so they ideally want them to have no 
other diseases, and therefore the very old people are excluded from trials, often 
just because, not because of age but because they often have co-morbidities, and 
so you end up testing a drug, any drug on a population that ultimately it won’t 
be given to. Because when it’s then put out wider, it is given to very old people 
that have got [other] conditions, and we’ve see the results of that with some drugs 
where they have been interacting with others, with other drugs. So yes, ok maybe 
we could focus on particular populations of particular forms of dementia, but I 
would say I wouldn’t rule out the other co-morbidities at all. And I think yes it 
would be great if we could intervene earlier but, but we’re then looking at 
following people up for a very long time, and we have to judge a really delicate 
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balance of designing trials that don’t have downsides where people need 
following up for 10 years. It is just not feasible to do this. And of course we’re in 
a really tricky area and I don’t think there is a simple solution 
Creating a synthesis between recognised standards, demonstrating comparable efficacy across 
therapies, and trial protocols with results that can be replicated and compared across different 
nations has led to complex efforts to ‘harmonise’ clinical guidelines transnationally. Since 1990, 
the UK, along with Europe, the United States and Japan, participate in the International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use (ICH 2010). The organisation provides bi-yearly updates, developed by 
representatives of regulatory agencies and the pharmaceutical industry, with the aim of 
constructing collective standards of practice in clinical trials. Regularly updated training in ICH 
guidelines for Good Clinical Practice (ICH-GCP) is a requirement for investigators conducting 
research within the UK NHS (NJRO 2014). Thus the structures of trial practice and therefore, 
the categories used to understand diseases are embedded in a wider transnational process of 
construction and debate. 
 
The National Institute for Clinical Excellence (NICE) is the arm of the NHS tasked with 
providing national guidance on clinical, social care and public health guidelines and medicines 
practice (Great Britain, NIHR 2014a). In providing guidance on the use of newly available 
medicinal products, NICE uses an EBM approach. This approach is informed by the ‘best 
available evidence’ based on expert opinion and measures of efficacy, safety, patient need and 
cost-benefit (Great Britain, NIHR 2014b). Collapsing the complex benefits posed by an 
experimental treatment into a manageable and universally approved system of comparison has 
generated its own field of complex calculations and classifications of benefit. This system is used 
not only by those approving therapies for NHS use, it inevitable informs how researchers define 
and test the benefits of the treatments in development, and how the disease itself is objectified. 
EBM has thus spawned a wide range of secondary measures which are used to quantify the 
efficacy of interventions for complex dementia conditions (Katona et al 2007).  For example, 
outcomes in dementia research can include multidimensional measures such as MRI evidence, 
behavioural symptoms, tests of cognition and global function, and activity of daily living 
functions (O’brien 2003: 94-95). Measures such as the instrumental activities of daily living scale 
(IADL) and Quality Adjusted Life Years (QALY) place a numerical score on the benefits a 
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treatment has the potential to provide. Such scores become powerful ‘expert’ evidence in the 
subsequent fiscal comparisons which form part of the NICE consultation process (Katona et al 
2007). The NICE website emphasises that their reports are guidance and not legislature, giving 
individual physicians flexibility and ultimate responsibility for practice decisions (Great Britain, 
NICE 2004c; Moreira 2011). However, with clinical commissioning and budgeting 
responsibilities devolved to the local CCG in 2013, in an economic climate which asks the NHS 
to make efficiency savings of £20 billion, such guidance has significant authority (Nuffield Trust 
2011). This is particularly true in cases such as existing treatments for dementia, which 
demonstrate how difficult it is to capture both efficacy and benefit (Moreira 2011). During public 
consultation on NICE guidelines, inevitably less quantifiable assessments of benefit and cost are 
brought into play, thus the development of such guidance can become political and highly 
contested (O’Brien 2006). 
 
The successful development of scientific innovations, therefore, requires researchers not only to 
understand the potential for novel medical technologies, but also to be aware of the national and 
transnational methods by which the efficacy and value of such technologies will be measured. 
Thus when preparing their research design to include accepted, quantifiable means of assessing 
the quality and efficacy of scientific discoveries, scientists are already deeply engaged with the 
social and political-economic factors which shape the domain of clinical research.  
 
The prioritisation of patient expressions of need was a source of concern for some of the 
researchers I spoke with during this project. On the one hand, they feared that the NHS was 
becoming a demand driven service which would become unsustainable in the current fiscal 
climate. On the other hand, researchers and clinicians were sceptical as to whether there 
currently exists enough knowledge about the aetiology of conditions which cause dementia to 
develop the products which might meet the increasing demand for effective, outcome-based 
interventions. 
 
MRI techniques and technologies are a case in point. The potential of these technologies has 
fundamentally altered our understanding of neurodegenerative disease processes in the living 
brain. However, the costs of fitting and running MRI technology are substantial. Having 
personnel to run, analyse and interpret imaging data is a significant and ongoing cost. Today the 
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application of MRI diagnostics within the NHS has reached an unprecedented scale, becoming 
the largest growing field of imaging and radiodiagnostics (Great Britain, Audit Commission for 
Local Authorities in England and Wales, National Audit Office, 2011; Svenson & Steele 2013). 
Indeed, its applications have moved far beyond what was imagined in the early days of its funding 
and development. As I learned in my fieldwork, whilst clinicians and publics are enchanted by 
these technologies, clinical researchers and epidemiologists are increasingly wary of their 
potential over-application. This is particularly true in relation to proposals for a national 
dementia screening strategy. 
 
A mode II study of dementia from a risk society perspective 
 
Within the field of neuroscience the role of imaging technologies has altered the kinds of 
knowledge available to understand both the ‘normal’ aging processes of the human brain, and 
the processes involved in specific degenerative disease pathways (O’Brien 2005, Frisoni et al 
2010). However, as understanding of neurology and knowledge about neurodegenerative 
conditions has developed, it has revealed the extent of what we do yet know about the biology 
of conditions which cause dementias. Indeed, the gap between what is known, but not yet 
understood would appear to be widening with each new discovery. As such, a core issue explored 
in this study is the relationship between perceived health risks, uncertainty and the accumulation 
of medical and scientific knowledge driven by public and political expectation as much as 
scientific curiosity.  
 
My argument here comes close to that of Beck and Giddens about the nature of risk in 
contemporary society (Beck 1992, 1994, Giddens 2013). These writers argue that, rather than 
mitigating risk, emerging science and technologies have seen risk and uncertainty proliferate. As 
knowledge expands so the boundaries of knowledge grow. As a consequence society becomes 
increasingly concerned about the expanding realm of the unknown (Beck-Gernsheim 2000). This 
in turn feeds a sense of being at risk, not only at the level of the individual, but also at the level 
of public perception and awareness of the community. Dementia research provides an excellent 
example of the dynamics of a risk environment in practice, and the responses that emerge. As I 
go onto show in chapter three, public support for dementia research has become a lynch pin in 
efforts amongst the scientific community to prioritise dementia research at a national level. 
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Dementia researchers are aware of the huge pressure to deliver knowledge, and more 
importantly, treatments which fulfil the social contract between science and the public. This is a 
social contract that is built on the premise that more research will provide better outcomes for 
those with complex dementia syndromes. 
 
This picture of contemporary experimental neuroscience fits with what has been described by 
Gibbons et al as the second mode of science: namely characterised as ‘socially distributed, 
application-oriented, trans-disciplinary, and subject to multiple accountabilities’ (Nowotny 2003: 
179; cf also Gibbons et al 1994, Nowotny et al 2001, 2006). Nowotny suggests that those most 
inclined to involve themselves in mode II science are those least established and with most to 
gain (2003). In the case of dementia, research is on the one hand well established with a long 
and complex history. On the other hand dementia science is perceived amongst current 
researchers to be highly underfunded and under-resourced, having failed to achieve significant 
traction on the disease processes involved in dementia. Many of the techniques and technologies 
which are becoming increasingly central to the development of new dementia diagnostics and 
treatments remain relatively new and rapidly emerging. These characteristics are particularly 
apparent in the development of new imaging technologies and biomarkers (Lock 2013).  
 
The emergent characteristics of dementia neuroscience which I have outlined above illustrate 
two key features upon which this thesis is focused. Firstly, I focus on the challenges and problems 
scientists and researchers experience in trying to address the complexities which surround 
dementia research. This complexity, I suggest, is rooted in the particular way dementia causing 
conditions continue to be highly plural, problematic and changing disease objects, which 
researchers struggle to define. Such struggles take place in an environment of clinical research 
which is enmeshed both biomedical, and social, political and economic relations, which 
themselves are continually evolving. I argue, therefore for a theoretical approach located in the 
theory of co-production, in which the dementia research community is examined as an example 
of civic-epistemology. By using this term I suggest that dementia science can useful be examined 
not as separate from, or outside of social relations. Rather this is a case study of dementia science 
as a process of knowledge production which takes place within social relations. Secondly I 
consider how dementia research is emerging as a very public site of science. Public engagement, 
I will show, is embedded in the emergence of the dementia research agenda, which is attempting 
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to addresses specific challenges attributed to dementia researcher by researchers and policy 
makers. This thesis, therefore, explores the dementia research agenda as a novel re-emergence of 
mode II science, and aims to understand the implications of this changing sense of relationality 




Chapter 3 The emergence of the ‘field’ 
 
In this thesis I provide a novel qualitative understanding of the connections that are shaping 
contemporary dementia neuroscience practice and policy. Over the course of the study I have 
followed a grounded approach, that is, the project has evolved in response to constraints and 
possibilities as these presented themselves in the course of the research. In this chapter I describe 
the research process, participants, and methods. I reflect on how I moved from a simple and 
coherent concept of dementia research, to a study which had to confront the much more 
convoluted realities of science as it is embedded in social, political and economic relations. In 
particular, I look at the process of negotiating access to different groups in the research 
assemblage, including public and patient participants, academic and clinical researchers and 
research organisations. This overview illustrates how the process of gaining access shaped the 
kind of methods I was able to use to shed light on dementia research practice.  
 
I then go on to consider the main problems and anxieties articulated by those who helped me 
develop this project and the issues of access which we all had to negotiate. These issues are 
important because they demonstrate a key methodological premise of the study, that is, how 
people make and break relations in research. Thus, on the one hand, scientists and their publics 
have overlapping aims and interests and could forge relations and make connections to facilitate 
advancement of their mutual goals. At the same time, competing interests or perspectives 
amongst the same groups could create friction and uncertainty which could lead to connections 
being reconfigured. In this regard, the relation between science and society is dispersed and 
fragmented rather than linear and clearly situated. What I observed were groups operating 
organically and rhizomatically, rather than in tree-like networks (Deleuze & Guattari 1997). I 
describe how the spreading of connections between scientists and publics led me to take an 
analytical approach based on linguistic and visual imagery and rhetoric as a strategy for observing 
the relations and collaborations that make up a ‘research community’.  
 
A turn of events: the national dementia research call 
 
I conducted research between October 2010 and March 2014. By chance, my entry into the 
world of dementia research occurred at a time when the profile of dementias in UK medical, 
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scientific, governmental and ‘public’ was rising rapidly. In March 2012, I observed the media 
announcement by Prime Minister David Cameron, of the ‘National Dementia Challenge’. This 
was outlined in a Department of Health press release as, 
 
(T)he Government’s ambition to increase diagnosis rates, to raise awareness and 
understanding and to strengthen substantially our research efforts so we can help 
those living with dementia have a better quality of life. 
 
 (Lansley, Department of Health, March 26, 2012) 
 
For neuroscientists’, psychiatrists, biomedical and clinical researchers specialising in the field, 
the pledge of investment in financial, human, technical and social resources at such a high level 
marked the culmination of more than twenty years debate and lobbying (Fox 1989, Keen 1993). 
These efforts were directed at the under-resourcing and under-representation of dementia 
disorders in the UK, and world health research agenda.  
 
Key landmarks preceded Cameron’s statement. One such landmark was reached at a Dementia 
research workshop I attended in January 2011. Presented by the UK’s National Institute of 
Health Research (NIHR) and the Ministerial Action Group on Dementia Research (MAGDR), 
this event brought together a wide range of researchers: Clinical, biomedical, qualitative and 
quantitative. Also in attendance were senior National Health Service (NHS) and Department of 
Health (DH) officials who announced a ‘call’ for applied health research on dementias (Great 
Britain NIHR 2014a). Key speakers at this event were the UK’s Chief Medical Officer and 
Director General of Research and Development Professor Dame Sally Davies who was also the 
chair of the UK Clinical Research Network (UKCRN), Paul Burstow Minister of State for Care 
Services, Alistair Burns, the National Clinical Director for Dementia in the Department of 
Health, himself a Professor and Honorary Consultant of Old Age Psychiatry.  This was a 
formidable line-up of senior, clinically trained, politically active health policy-makers whose 
connections with the scientific community made them extremely powerful drivers of a dementia-




Joining the political, clinical and scientific representatives were members of the UK’s two main 
dementia advocacy groups: the Alzheimer’s Society and the Alzheimer’s Research Trust which, 
significantly, rebranded itself as Alzheimer’s Research UK (ARUK) in 2010. The change of name 
suggested an intensification of efforts to market dementias, using the dominant brand of 
Alzheimer’s, as a major public health concern for which public and political mobilisation was 
required. Barbara Woodward-Carlton, a representative for the Alzheimer’s Society and member 
of the Quality Research in Dementia Group (later renamed the Research Network), was 
scheduled to give a presentation at the event. She represented the Society’s ‘lay’ members, the 
patients, carers, and former carers who wished to be involved in ‘actively shaping the research 
programme’ (Alzheimer Society 2012). As the day progressed, key contributions were made by 
the chair of Neurosciences and Mental Health Board of the Medical Research Council (MRC), 
UK’s leading governmental funder of clinical research and the Director of the Dementias and 
Neurodegenerative Research Network (DeNDRoN). This powerful assembly of advocates for 
dementia research serves as a useful example of the processes and relations that I had been 
following over the last year. The NIHR meeting acted as evidence of what had emerged as a 
highly active social-scientific movement which had developed around specific issue related to 
working on dementia. 
 
During Woodward-Carlton’s presentation the room became quiet, uncomfortably so. She 
described caring for her mother, who had dementia and had recently passed away. She did not 
hold back. This was her platform, and she had a clear point that she wanted to communicate. 
She explained her position with a graceful clarity to over 300 researchers and health care 
practitioners from across UK universities, NHS trusts, research networks, research centres, 
private research companies, and medical charities. She explained that the public experience of 
dementia research had stagnated. People who experience the impact of dementia, she argued, 
had not benefited from the knowledge that research had produced. She criticised the failure to 
disseminate or implement research findings beyond or even across the health and social care 
sector. In particular, she drew attention to the lack of research dissemination and research 
informed training amongst primary and acute services.  
 
There followed a vacant pause, and then applause. When the question and answer session began, 
it was the tension that struck me, the feeling of discontinuity between Barbara’s concerns and 
66 
 
the questions which followed. Researchers, who made up the majority of the audience, fell into 
a discussion which, I would come to recognise as reflecting their long standing and well-rehearsed 
frustrations: Why were researchers still failing to gain access to appropriate patient groups or 
data sets? Why was a national neurodegenerative disease register not up and running to facilitate 
research recruitment? Why were projects not being reviewed by subject appropriate panels?  
 
Despite the applause Barbara had received, I could not but help noticing the absence of 
discussion about her concerns about the failure to implement existing research knowledge. Were 
her comments so incommensurate with scientists’ wider research concerns? This led me to 
consider just what is the relationship between the public voices that are expressed at research 
meetings and the actual practices involved in the scientific process?  
 
A complex field of multiple stake holders 
 
This example acts as a useful reflection on the nature of the field site in which I was working. It 
demonstrated how multiple players, with diverse perspectives, interests and goals come together 
in the research process. Significantly, it draws attention to the way that beneath the superficial 
sharing of an agenda, there was a tension between the need to carry out more research and to 
use existing research for direct patient benefit (fPB). What response would result from such 
meetings? Often uneasy exchanges and competing perspectives revealed the explicit and implicit 
shaping of the logistics and the context of research, as it was understood by differently situated 
actors. It was this context which led me to adopt an analytical perspective in which laboratory 
and clinical practice needed to be understood in relation to the social entanglements though 
which the UK dementia research agenda was being shaped.  
 
Undertaking ethnography at this interface resulted in an often chaotic sense of the field. Actors 
could be from a wide range of institutions, from diverse locations across the UK, with radically 
different statuses and power to influence and control the development of research. On occasions 
such as the NIHR meeting they shared physical space, however, they had competing ways of 
understanding and knowing dementia, and different ideas about how ‘good’ dementia research 
should look, and what it should do. This chaos provided a rich context in which to observe 
contemporary entanglements of science and society. Such research meetings and events became 
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a key site for my conduct of ethnographic research. These settings providing unique 
opportunities to observe how scientists viewed and responded to relations outside of, but critical 
to the funding, recruitment and dissemination of their work in hospitals and laboratories.  
 
In the following sections, I introduce the main actors in the field including research institutions 
(NMR Centre), research infrastructure organisations (DenDRoN, NIHR, and UKCRN), 
government representatives (DH), the pharmaceutical industry, public and patient participants 
and patient advocacy groups (Alzheimer Society, Alzheimer Research UK). 
 
Developing relations and addressing access: working inward and studying up  
 
Whilst an awareness of multiple stakeholders is essential to this study, it is important to 
emphasise that throughout these networks are primarily explored from and understood within 
the clinical and scientific perspectives on dementia research. In other words, I focused on tracing 
the interaction of the social and the scientific primarily from the perspectives of researchers. I 
particularly look at how scientists and clinicians understood, framed and interacted with the 
growing visibility of, and interest in their work. In order to do this I had to examine not only 
researchers in isolation but researchers in their interactions with other stakeholders in the 
research process. However, locating and accessing clinical research in this context presented a 
major challenge in this study.  
 
There were two main issues: defining a location and negotiating access. The entanglement 
between clinical research and publics which I found so intriguing made the idea of a site specific 
study a less than satisfactory way of proceeding. Yet, if I wasn’t to focus on one location, how was 
I to define my site of study, and how would I negotiate access and conduct ethnographic field 
work? 
 
The second issue revolved around access and power relations in the field. The project was 
scrutinised and approved by Durham University’s Anthropology Department Ethics Committee. 
However, to work on NHS sites and with NHS staff required a second tier of approval. As many 
researchers have found, working with the NHS for non-NHS researchers is a notoriously 
challenging prospect (Simpson 2011, Lewis & Russell 2011). Gaining access involves a lengthy 
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administration process and the development of good ties with a regional NHS research and 
development group. This is particularly difficult for a non-clinically trained, qualitative 
researcher who has never worked in the field before. As has been discussed by anthropologists 
doing ethnographic studies within the NHS, working with medical and scientific professional 
groups such as neuroscientists carries its own peculiar set of challenges. As I explore below, these 
include restricted access, limited availability, and limited tolerance for the qualitative research 
approach and methodology.  
 
Experts & elites 
 
Understanding the particular challenge of working with elites was fundamental to the research I 
undertook. The issue of how to manage power relations in research encounters which involve 
elite and expert groups or what Nader referred to as ‘studying up’ has a long history in 
anthropology (Conti & O’Neil 2007, Konrad 2002, Nader 1972 also cf. Nugent & Shore 2002). 
When ‘studying down’ the power of the researcher, (both consciously and unconsciously, 
assumed and ascribed) is recognised as having an effect on interaction with participants, 
requiring the exercise of reflexivity and awareness.  The often paternalistic assumptions which 
underpin this approach were challenged by ethnographers especially when they began to turn 
their gaze onto their own communities, and those groups which hold and exert power in the 
contemporary world.  
 
In Science and Technology Studies (STS), where informants are often academic and clinical 
researchers and practitioners, with high levels of formal and technical knowledge, the practice of 
ethnography takes on particular characteristics. To access organisations, such as the NHS, which 
are hierarchical and have explicit definitions of expertise, the approach of the ethnographer has 
to be framed accordingly. This is particularly true where the researcher’s own expertise (as an 
ethnographer) do not easily translate into the epistemic foundations upon which the definitions 
of the community are built. Traweek (1998) describes this as entering a culture of ‘extreme 
objectivity’, or more precisely one in which the ideals of research are based upon explicit ideas 
about the nature of knowledge and validity. I go on to demonstrate, that although this epistemic 
ground was certainly a challenge I encountered, in my interactions with members of the dementia 
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research community, participants were often highly aware of the importance of social relations 
in the process of research and knowledge making. 
 
The researchers with whom I hoped to work were often highly pressurised and practicing under 
severe time constraints. They combined academic, clinical, and administrative workloads in 
addition to their role as principle investigators. This was particularly true for those identified as 
leaders in the development of the national dementia research agenda. The main strategies I 
adopted to manage this process are those described by STS scholars as a willingness toward 
acclimatisation and negotiation (Nader 1972, Knorr Cetina 1999, Boyer 2008). My own 
experience, like theirs was a perpetual process of adaptation. 
 
I had prepared myself to use both participatory and more structured data collection practices 
such as semi-structured interviews. These would enable me to choose the most suitable tool for 
the context and the nature of the participants. For elites in particular, I believed that the semi-
structured interview would be most beneficial, allowing as it does for a fixed time and location 
to fit the participant’s schedule. Furthermore, a pre-emptive outline of questions would help 
them to contextualise what was expected in the meeting. Curiously, I found that during formal 
interviews, participants were often reticent in discussing any issue which they saw as falling 
outside their technical domain. They deferred to others, whose point of view on a particular issue 
they would describe as having greater validity than their ‘opinion’, which they didn’t feel had a 
place in an interview.  
 
My experience therefore echoes that described by Rabinow (1999) where informal rather than 
formal encounters as a participant-observer, yielded far richer and fuller conversations about how 
researchers understood the changing research environment. These settings included events such 
as research meetings, symposia and workshops. In these more informal settings the same 
participants who during interview stated they were unable to comment on a technological, 
clinical or economic issue, freely initiated discussions and raised their concerns about the wider 
issues of dementia research and how they might impact upon research work.18 In this project, 
                                                 
18 Participants in these informal contexts were always informed or reminded of my role as a researcher of these 
events and I received verbal consent to use our discussion to inform my project. As such I always adhered to the 
guidelines on maintained consent outlined by the ASA 
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such occasions captured the finer-grain of social interaction and negotiation that occurs in 
dementia research environment far more fully than the formalised interviews.  
 
I found that to work with experts in this environment, I could not ignore the role played by non-
scientific participants. In working across the public-science interface, I also increasingly 
encountered the ‘expert-patient’. On the one hand the concept of the ‘expert-patient’ is a rhetoric 
construct developing within NHS and Department of Health policy making. On the other hand, 
expert-patients were those with dementia and those who cared for them who had acquired a very 
different kind of ‘expert’ knowledge about the research process. Thus, the role and identification 
of ‘downstream’ as well as ‘upstream’ expertise, and their potential to exert force or power are 
an important feature of this study (Evans & Collins 2002: 609, Kerr et al 2007). I use accounts 
of key episodes, such as the presentation made by Barbara Woodward-Carlton’s at the NIHR 
meeting given at the start of this chapter, to represent these ‘downstream’ expert voices in action.  
 
These episodes show participants vocally resisting the ‘upstream’ narratives about research 
presented by scientists and clinicians. In particular this is apparent in accounts of the uneasy 
negotiations which taking place between Public Patient Involvement groups and dementia 
researchers. This reflection on power relations situates my analysis of dementia research in the 
flow of day to day social relations. In reflecting on the multiple flows of power, my aim is not 
imply an equal control of power between researchers and other participants. Neither the expert-
patient, nor the social-expert in the form of the anthropologist, can be said to stand on an equal 
footing with clinicians and scientists in the domain of clinical research. 
 
DeNDRoN and the NMR Centre 
 
Having been primed by accounts of STS research to encounter resistance in negotiating access 
to the laboratory context, I was surprised to find genuine interest and enthusiasm for my work 
amongst the scientists and clinicians I met. By making links with the North East branch of 
DeNDRoN, I developed good contacts with leading neuroscientists and medical imagers based 
in Newcastle. Initially, through contacts within DeNDRoN I was put in touch with the Newcastle 
Medical Resonance Centre (NMRC). My research into how DeNDRoN’s administration of the 
Clinical Research Network Portfolio (UKCRN) demonstrated that the two Magnetic Resonance 
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Imaging (MRI) scanners and functional MRI (fMRI) techniques based at the NMRC, made it a 
crucial technological hub for a number of observational dementia projects. These studies 
explored the aetiology of specific dementia types and has a particular interest in the study of 
Dementia with Lewy Body (DLB). They also specialised in interventional phase III trials 
examining drug efficacy and diagnostic procedures.  
 
I put together a proposal for research and put this to the senior management of the NMRC and 
in September 2010 met with one of the centre’s directors. We discuss how a project examining 
dementia research might work, and how I might make contact with researchers in order to 
observe imaging practices in the context of dementia research. Whilst waiting for our meeting I 
looked around the corridors, like my own department I observed the conference posters which 
showed different aspects of their centres research. From the work I had already done, I recognised 
the names of some of the researchers involved. Unlike in my own discipline where single authors 
were common, I was struck by the long lists of authors involved in each project. This reflected 
the shape of research in this field which frequently required the collaboration of people from 
different technical specialties, a diverse support team, and the involvement of multiple senior 
researchers to enable a project to take place.  
 
Other posters told the story of a fundraising project centred on a local man, Charlie Crowe, who 
was in the late stages of Alzheimer’s disease (AD) (figure 7). Charlie sadly passed away in February 
2010. A former Newcastle football player, images from Charlie’s life and footballing career 
collected by him and his family became the focal point for a campaign to raise funds for a new 
multimillion pound MRI scanner to extend the centre’s capacity as a leader in imaging research 
and diagnostics for dementia and metabolic syndromes. 
 
I was shown around the centre’s first floor and introduced to people from the many specialists 
involved in imaging research. In one room medical physicists, mathematicians and computer 
programmers worked alongside one another. In another room, I met men and women involved 
in neuroscience, old age psychiatry and psychology. In yet another office the administrative team 
negotiated issues such as funding, research governance and approval. I was made aware of how 




Figure 7: Advert for the Charlie Crowe Scanner Appeal 
 
The director talked extensively about the process of attracting and recruiting internationally 
excellent scientists. He emphasised that for him the administrative team was a focal point for 
enabling research to actually take place, negotiating the complex layers of bureaucracy involved 
in working between regional NHS organisation, academic institutions and national funding 
bodies. The director of the NMRC talked about his role in ensuring the high scientific profile of 
the unit, working with both the local community, Newcastle University and regional NHS 
organisations. Maintaining the reputational capital of the centre was clearly important when 
furthering research activity both nationally and internationally.19 
 
                                                 
19 The role of reputational capital in scientific communities has long been a concern in social studies of science 
(Merton 1968, Mulkay 1976). 
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Downstairs were the rooms for the clinical research team of nurses and imaging technicians who 
were involved in ensuring that research participants completed safety questionnaires and consent 
processes. They also prepared people for the scanning process itself. The director expressed his 
anxiety about this situation, explaining that he really wanted this office on the same floor as the 
others, to ensure that there was no sense of disparity between the different groups involved. 
However, this was not possible as the unit was starting to outgrow the original purpose built 
facility that he had helped designed.  
 
Social relations in clinical research  
 
Finally, I was introduced to the scanning suite itself. At the centre was an imposing, stark white 
machine with the iconic moulded, circular, polo-mint shaped entrance. A familiar low hissing, 
pumping noise filled the room, as the gas compressor continually fed helium to super-cool the 
coils forming the magnet bore. A bed where the participant would lie could be raised from sitting 
height to slide them into the machine. Surrounded by reinforced concrete to shield the magnet, 
the room was windowless and gently lit. The relative silence combined with the rhythmic hiss 
seemed to me both clinical and calm. Unexpectedly on the wall was projected an image of 
Newcastle football club. The director explained that by using a periscope mirror inside the 
scanner people could see out. This reduced their feeling of claustrophobia when they were fully 
inside the bore of the scanner. This, he said had been found particularly useful when working 
with people with dementia who might become easily disoriented and anxious. The slide show of 
images projected on the wall provided patients with familiar scenes, often related to the history 
and landscape peculiar to the city. The director described how earphone defenders were used to 
shield the patient from the loud noise made by the magnetic coils vibrating during different 
stages of the scan. These headphones were also connected to the scanning booth so that the 
technicians could engage participants in conversation during the scan. This helped to reassure 
anxious participants and helping them to remain as calm, comfortable and, importantly as still 
as possible. The technique of MRI requires that the subject remains still for the duration of each 
scan in order to collect effective data. It was clear from this initial encounter that this was not 





The ways in which the social was an integral part of the scientific had been poignantly illustrated 
by the creative and considered use of visual imagery to help a person with dementia feel secure 
and calm whilst having a structural MRI. The social quite literally made the scientific possible. 
The use of such imagery, however, was not only directed at research participants but was a 
significant element in fund raising campaigns. Working with iconic regional figures, 
organisations and businesses, the NMRC employed such imagery as part of efforts to secure 
funding for a more powerful Tesla scanner to improve data acquisition in the diagnostic and 
research process. This induction to the research community alerted me yet further to the 
importance of such social interactions to the research process. In turn I was shown how these 
interactions were shaping scientific practice itself. In the environment in which I was working a 
participant could be framed simultaneously as an object of scientific scrutiny which needed to 
be contained, and as a person and subject whose particular needs researchers worked hard to 
understand and negotiate. As such it became apparent that the method of detailed ethnographic 
observations would be a valuable means of illustrating complex relations and dynamics at work. 
 
Government, industry and the market in dementia research 
 
The role of relations was further illustrated at research events where every effort was made to 
bring together different stakeholders. However, during eighteen months of fieldwork I never 
encountered an industry representative or member of the pharmaceutical industries. After the 
event, I became curious about this physical absence. As suggested in chapter one, Big Pharma is 
a principle sponsor of clinical trials and drug development. However researchers, echoing my 
experience, discussed commercial and industrial partners by their absence rather than their 
presence. For instance, the closure of R&D programmes into drug development for psychiatric 
and neurological diseases by three major pharmaceutical companies, GlaxoSmithKline, 
AstraZeneca and MSD, was a cause for great concern. This prompted the members of the British 
Pyschopharmacology Association (BPA) to write an open letter to the Minister of State for 
Universities and Science, Rt. Hon, David Willets, MP. This letter set out the biomedical, 
academic and economic impact such withdrawals would have. The representatives of the BPA 
closed their correspondence by emphasising the need for a combined political, scientific and 
medical response to prevent this trend of withdrawal from continuing (BPA 2010).  Lack of 
progress and some significant failures in phase III drug development trials had led to a loss of 
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confidence in the prospect of effective and marketable treatments. The threatened a loss of 
industry investment led scientists to lobby politicians, who in turn put pressure on industry to 
support R&D in this area. However, increasing government pressure to develop academic - 
industrial relations to support research also presented scientists with a concern that they would 
lose control of the direction of pure research to a market-driven agenda. As they saw it, pushing 
research in non-scientific directions, and increasing the potential for earlier role out of minimally 
effective treatments would not be in patients’ best interests. Thus, whilst not a principle focuses 
of this thesis, industry was an important presence in the developing research agenda. The curious 
role and narrative of industries ‘absence’ presented in this fieldwork could prompt an interesting 
direction for future investigation. 
Negotiating access to NHS dementia research: capitulating to the hydra 
 
By observing the lay-out of the NMR Centre I was observing how local, regional, national and 
international relations were experienced for researchers based at the centre. This left me excited 
about the potential of site specific project which could illustrate these relations across different 
scales. Now I had one final hurdle to cross, NHS research approval. NMR Centre researchers 
would be involved on projects recruiting through the NHS, and many of the staff involved would 
be NHS employees. As a result, I was required to apply for an NHS Research Passport, my project 
needed to go through the NHS R&D process and I needed approval from an NHS research 
ethics committee (REC). Having anticipated this I had already begun work to understand the 
research governance process. However, trying to apply this process to my project would prove a 
mammoth task, and one which I came to as a naive outsider. In spite of the encouragement of 
the head of the NMR Centre, plans which seemed so well set out soon unravelled. 
 
As I started to complete the initial forms using the Integrated Research Assessment System 
(IRAS)20 in November 2010 it became apparent that I would need to restructure my project to 
fit the terms of clinical research. I was baptised into a field of clinical research concepts based on 
radically different interpretations to those of qualitative research. In this context, participant 
observation or an interview needed to be redefined as an ‘intervention’ in the same sense as a 
                                                 
20 IRAS is the online portal for the completion and submission of applications to NHS REC and R&D. Within 
the IRAS system all project documents such as the projects hypothesis, background, design, protocol, inclusion, 
exclusion criteria and consent documentation must be uploaded and demonstrated to meet the NHS framework 
for best practice. 
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project proposing the administration of a drug, clinical procedure or questionnaire. I would need 
to define when, where and how often the intervention would occur, how long it would last, how 
many people would be involved, and the cumulative amounts of time this would take. 
Conducting participant observation is a curious practice in even the most skilled hands. It 
involves an eye for detailed observation which might lead to ‘thick description’ (Geertz 2000). 
Such observation requires the detailed recording of events, settings and performances, over an 
extended period of time. In the terms of the R&D language of the ‘intervention’, I would have 
one period of participant observation. It would last approximately three hundred and sixty-five 
days, or a cumulative four thousand, three hundred and eighty hours (based on a twelve hour 
day). Following a grounded approach I would seek to engage with as wide a range of those 
involved in the research process as possible. The shape and size of that sample, would therefore 
only be determined over the course of the project.  
 
To reconcile these ways of structuring research required me to reframe the study. Not only the 
language but my perception of the project had to adapt. I began thinking in terms of a limited 
range of interviews with discrete and defined pockets of observation. To develop an appropriate 
research protocol I needed to outline the recruitment of a ‘population’, ‘inclusion’ and 
‘exclusion’ criteria, ‘sampling’ approach and allowance for ‘bias’. As a result I would need to 
know who specifically would be prepared to let me observe their practices. I had the tacit consent 
and approval of the NMR Centre where researchers conducted their imaging work. However, 
each dementia research project was controlled by a research team which functioned 
independently from the NMR unit. I would therefore need agreement from the principle 
investigators on any project in order to configure my study within the format of the REC and 
R&D system. At this point three months had passed, and like fighting the mythical hydra, the 
number of organisations and the chain of individual gatekeepers I was in contact with were 
rapidly multiplying.  
 
Whilst my research questions is focused on researchers and the relations involved in negotiating 
of the research process, I always had to acknowledge that research participants were an integral 
part of that process. Through the NHS and my departmental ethics approval process, I had to 
reflect that whilst working with scientists on projects which addressed dementia, to some extent 
I may encounter, observe and interact with people with dementia. Such patients due to the long-
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term cognitive implications of their diagnosis would be defined as vulnerable. Although my 
primary intention remained to focus quite specifically on researchers and their collaborations, 
during the actual process of participant observation I would inevitably observe researchers 
observing patients – how could I do otherwise? A case in point was illustrated during my initial 
meeting at the NMRC, in which the director and I discussed observing technicians in the 
imaging booth during scans, conducting interviews with research nurses on the consent process, 
or with researchers about their analysis of participant data. In all these examples of observing the 
research process in action, members of the public recruited via the NHS would either be 
physically present or present in the form of their data. I therefore made a point of recognising 
the needs of these participants in the ethical documents I was producing. This would ensure that 
I would have clearance to engage with participants as part of the research process I was observing. 
A routine part of achieving clearance to work on NHS projects where there may be patient 
contact is a full criminal records check. By choosing an enhanced check I would have approval 
for any work which might include adults considered by to be vulnerable. 
 
In addressing the potential presence of the public in research encounters, and its ethical 
implications for choosing the correct clearance, I found myself re-evaluating to what extent my 
presence could impact upon participant experience. Anthropologically it was important to 
recognise the impact my observations of scientists may have upon this group. From the 
experience that I had already had in the scanning suite, I had become aware that researchers were 
going to great efforts to imagine and engage research participants. Therefore, it was clear that a 
qualitative study of clinical research with human participants would benefit from a holistic 
approach which included the role of participants. Even if not interviewed directly, or the main 
focus of the study, participants were integral actors in the research process, and therefore 
inevitably would be ‘present’ in my data.  
 
To recognise participants formally and engage with them directly, brought new levels of 
complexity to the clearance and access process. I explored how information sheets could be used 
to inform people of my presence and the aims and objectives of my project. Informed consent 
forms would signal agreement and awareness that scanning sessions would be observed and data 
generated from their involvement discussed. All this documentation was prepared in 
anticipation of going forward to a full ethics review panel. When I raised these issue with the 
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NMR Centre, I was advised against any attempt to actively include or inform research 
participants of my project. For me this was ethically highly problematic, as research participants 
would have no opportunity to actively engage with or dissent from being observed. Social science 
research ethics emphasise awareness and management of unequal power relations in research, 
particularly in the medical field (Leatherman & Goodman 2011). This supports the case for, at 
minimum, participants to be informed of the details and aims of the study I was undertaking. 
Paradoxically, the most recent version of the IRAS guidance recommends that potential public 
participants should be consulted in the research design and included where ever possible [IRAS 
2009, INVOLVE 2012].  Yet, it seemed to be impossible for me to do just this. Sadly, the 
increasing complexity developing this project to fit the regulatory framework of the NHS, in 
conflict with how I understood the project, was beginning to render a laboratory study unfeasible 
in the time that I had to negotiate such challenges.  
 
However, as a novice in the field, such knowledge was not available to me without trying to fulfil 
the research process requirements. In emergency discussion with my supervisor about the future 
of the project, I became aware that whilst I had totally failed to get access to my original field site 
I had spent the last eight months in an intensive study of the research process and reflexive 
discussion with neuroscience researchers about the process of ethical review. Indeed, this was an 
aspect of my original research design for which I had been given ethical approval for. Although 
I had not achieved my original goal of including laboratory observation, I had made contacts 
with, and achieved an insight into, the many organisations and structures involved in the process 
developing dementia research. Working around from the outside of this community had actually 
given me access to a perspective on research which I found would be echoed in many of my 
subsequent research encounters. 
 
I gained a significant insight into a common challenge for researchers working with patients with 
dementia, and particularly those wishing to undertake qualitative work. This work also made it 
apparent that there are relatively few qualitative studies of participation in dementia research. 
Those studies which have been conducted are highly critical of the lack of balance between 
protecting potential participants and ensuring that those who want to and are able to take 
participate in clinical research have a forum to do so (Nuffield Council on Bioethics 2008). This 
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raises the question: to what extent is the goal of the ethical governance of research to ensure the 
protection of the participant, or the organisational integrity of research?  
 
Dementia studies, in particular, have criticised the exclusory impact of rigid interpretations of 
cognitive capacity. The biomedical definition of capacity developed in the 2005 Mental Capacity 
Act has been challenged for lacking the flexibility to assess capacity for a person experiencing a 
fluctuating cognitive condition. A person in the early stages of dementia can experience discrete 
episodes of lost lucidity, disorientation and problems with word retrieval or word equivalence, 
which can undermine their perceived capacity. However, it has been suggested that reflexive and 
responsible engagement, with the support of a dedicated carer can enable a person in the early 
stages of dementia to communicate decisions about participation in a research study (Warner et 
al 2008). Crucially Warner et al (2008) describe how the patients they talked to, not only 
demonstrated capacity in this sense, they expressed an unequivocal desire to take part in and 
benefit from the process of research participation. 
 
In making the decision to capitulate to the hydra of NHS approval and to refocus my study away 
from the laboratory, I found my experience was met with empathy from both clinical and social 
researchers. Many of those I subsequently met had gone through similarly drawn out processes 
with uncertain outcomes, and often multiple submissions and amendments to their projects. 
Interestingly, one researcher when hearing of my tribulations said that the more information 
they supplied to the RECs to pre-empt their queries, the more problems they seemed to create 
for themselves. As a result he recommended that in future I should never attempt REC approval 
alone but only as part of team that included NHS staff. 
The collection and analysis of information which took place over course of my research into 
ethics was doubly instructive, it embedded me in the field, and reflected the nature and structure 
of NHS ethical processes themselves. Researchers, both clinical and care based, often described 
to me a feeling of their work being disconnected from the process of project approval. This was 
a theme frequently raised at research meetings, where the process was described as ‘overly 
complex’, ‘prohibitive’ without in actuality improving ‘protection’ for the participant. The 
traditional Randomised Control Trial (RCT) profile was not appropriate for the successful 
recruitment of people for dementia trials. This was particularly true for work in the less common 
dementias such as DLB, where limiting the population sample made the possibility of successful 
80 
 
recruitment levels almost unachievable. Some researchers suggested the prescriptive exclusion 
criteria of the RCT structure were entirely inappropriate for people over the age of 65 years, the 
most common age group for recruitment to dementia trials. In this age group not only was there 
a high likelihood of co-morbid disorders, but as a result, contra-indicated drug treatments which 
led to high exclusion rates and challenges to recruitment (Ferrucci et al 2004, McMurdo 2005, 
Ridda et al 2008).  
DeNDRoN as a gatekeeping institution  
 
The struggles that researchers experienced in designing trials demonstrated to me the 
fundamental importance of an organisation like DeNDRoN. At the national level DeNDRoN 
was responsible for the administration of a dementia disease register, which was seen as 
increasingly essential for the effective recruitment of participants to clinical studies. At the 
regional level DeNDRoN were key facilitators of NHS research approval processes with regional 
REC and R&D bodies. In particular, this organisation liaised between institutions and trust 
hospitals to address the problems arising in research design. Such work inevitably required 
operation across different regulatory regimes at different levels (local, regional and national). 
Through discussions with DeNDRoN staff about how dementia research worked, and how my 
study was to proceed, it became apparent that the DeNDRoN staff had become, in effect, the 
gatekeepers of dementia research in the UK. This gatekeeping role extended to include my own 
research.  For my study, DeNDRoN enabled access not only to neuroscientists working on 
dementia, but also to public-patient involvement groups in the field. Through involvement with 
these organisations I also gained access to meetings and regional conferences where clinicians 
and researchers presented and debated the value, effectiveness and future directions of their 
research. Through these events I was able to conduct multiple sessions of participant observation 
which included: meeting, observing and talking with researchers from a variety of clinical 
disciplines, including: psychiatry, geriatrics, neuroscience, nursing, psychology, health and social 
care. In these encounters scientists and clinicians discussed how they viewed dementia research 
and how they defined the pressures and challenges they faced. The key senior clinicians, who 
were so integral to the development of the dementia research agenda and whose names appeared 
frequently on research articles and policy documents, became familiar faces at such events. 
Meeting early-career researchers presenting their work became an opportunity to arrange follow 
up interviews, and discuss what they thought was changing in the field at the laboratory level. 
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Throughout the course of my research three members of the DeNDRoN research team became 
key informants. These informants were involved in managing the research network, organising 
research events, and directly helping researchers operationalise their projects. It was in this 
process of looking outside of the laboratory, at the relations and collaborations formed around 
and between researchers and research units, that I identified my ‘field site’. These scientific 
relations became my focus for over the course of the study. 
Unexpected connections: the role of ‘para-scientific’ relations 
 
The approach that I adopted generated a number of methodological challenges. I was not 
working with a discrete or stable locus such as a laboratory. Rather I had to travel between 
research settings and follow participants. Often, one research meeting or event would lead to an 
invite to another. It was through this snowballing process that the social and political 
connections which constitute the dementia research community began to emerge. Adopting this 
grounded approach allowed space for these connections, relations and events to happen and to 
inform my understanding of neurodegenerative disease for those who work and participate in 
clinical research. The strength of this methodology is that it traces practice, action, and relations 
as they are enacted (Traweek 1998, Wouters et al 2008). This methodological structure allowed 
me to observe the important organisational connections, such as those made with patient 
advocacy groups like Alzheimer’s Society and ARUK, which researchers used in their efforts to 
engage beyond the laboratory. As I go on to argue, such relations might be thought of as activity 
that falls in the realm of the ‘para-scientific’, that is they run along-side science, facilitating 
political and scientific relations and interactions (Epstein 1996).  
 
One consequence of this grounded approach was to demonstrate high degree of entanglement 
between dementia charities and the researchers and clinicians involved in developing a dementia 
research agenda. Whilst I had been aware of the importance of such organisations, I was 
unprepared for the very active overlap in the roles and goals of participants in these networks. 
By attending research meetings, conferences and public engagement events held by organisations 
such as Alzheimer’s Society and ARUK I was able to observe at first-hand how scientists viewed 
the process of public-engagement and how this reflected their understanding of the role of the 
public in research. By looking at these organisations I was also able to talk to the organisers of 
patient groups and members of the public, including those directly experiencing the impact of 
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dementia. In these conversations I was able to get a sense of how lay participants’ perceived 
clinical research and how they understood their role in the research process. In particular, I 
examine these perspectives when I explore how participant and researcher narratives of science 
can be seen to conflict and compete in chapter seven. 
 
It became evident from my observation of Alzheimer’s Society and ARUK, not only that they 
played an important role in representing the public in the public engagement of science. These 
organisations were key to the political manoeuvring taking place at the level of science policy. It 
is highly significant that leading researchers and clinicians who had high profile roles in public 
health policy often held key roles within these groups. Interviews with members of the 
Alzheimer’s Society and participant observation at their meetings gave me access to the range of 
ways in which this interface actually worked. From raising public awareness of the different 
dementias, disseminating research information, raising funds, and encouraging research 
participation and the public patient involvement (PPI) movement, medical charities were 
powerful drivers of the research process. For instance, the idea of PPI has now become an 
enshrined tenant of research participation and is championed and made possible by such third 
sector organisations (INVOLVE 2012).  
 
As I demonstrate in the next chapter, relationships between research, the third-sector, and 
government were commonplace, highly strategic and far from unproblematic. Rather, such 
relations were sites of constant negotiation, which could mobilise what Epstein describes as ‘para-
political power’, being spaces which could both support and challenge biomedical authority 
(Epstein 1996). Third sector organisations such as patient advocacy groups are increasingly 
globally connected. Such organisations therefore become yet another example of how local 
practices are interlinked with non-local relations through the transnational exchange of research 
information, patient involvement practices and political agendas. 
The virtual and visual in dementia research 
 
To capture and reflect dispersed relations in my research approach I paid particular attention to 
how medical charities and research organisations use virtual space and visual imagery to 
communicate and build the relations which shape the dementia research process. Over the 
course of my research, it became apparent that websites were an important means of connecting 
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the dispersed and diverse range of people involved in research. For example, during the period 
of my fieldwork the websites of the NMRC, DeNDRoN, MRC, DH, ARUK, and Alzheimer’s 
Society continually evolved to take advantage of existing and emergent types of virtual 
communication. The construction of virtual spaces and the use of hypermedia applications 
(‘apps’), had the potential to increase the volume, speed and spread of research information 
disseminated to the public domain. As a result, analysis of hypermedia is, by necessity a key 
element of my research methodology, data and analysis. Observing the way virtual spaces are 
used within the dementia research community also throws light upon the ways in which 
researchers are trying to form relations with one another, and with public, political and 
commercial organisations. Such connections, therefore become an important means of 
understanding what Knorr-Cetina (1999) would describe as the ‘epistemic culture’ accessed 
through the ‘material and symbolic’ processes by which dementia science is being actively made 
(Wouters & Beaulieu 2006: 52). 
 
In particular, I demonstrate how increasingly creative use of audio-visual content is key to 
understanding how connections which cross the boundaries between science and society are 
being constructed. Understanding how those connections are enacted in turn sheds light on the 
how the communities involve imagine both their selves and others involved in the research 
process. One example, which I examine in chapter six, considers the pervasive use of visual cell 
and brain imagery to make connections and appeal across boundaries, and between groups 
invested in the research process. For instance, images such as those in figure eight below, feature 
prominently on research organisation home-pages as a compelling and captivating gateway to the 
websites content. Carefully designed, produced and informed by media and marketing 
techniques, such content demonstrates an effort to bring dementia and dementia research to a 
wider audience with greater impact and immediacy. 
 
 




Describing how researchers and research organisations use images in virtual space, I trace the 
evolving relations between nationally dispersed groups of scientists and publics. The prolific use 
of virtual spaces both facilitates and construct the interface of science and society. Such spaces 
create virtual networks between ‘real world’ processes of research, diagnosis, participation and 
disease experience. The effort to ethnographically narrate this dispersed field of relations draws 
on the multi-sited approach described by Marcus (1995).  However, what is of interest in this 
project is not the anthropological method of multi-sitedness per se, but how my informants 
operate within and across their own notions of multi-sitedness (Fischer 1995). 
 
In the development of a dementia research identity I explore the use of visual imagery not only 
in virtual space; but also in conventional media such as leaflets, national television campaigns 
and promotional material produced by research and research interest groups. This material 
culture provides a further source of data to observe the social-scientific interface at work. In 
particular, the use of images demonstrates the importance of marketing and design logic in the 
development of research and patient organisations. For instance in the case of the Alzheimer’s 
Society, marketing firms such as the Conran Design Group, were employed specifically to 
develop logos, interactive tools and media content of the Society. This work has developed a 
distinctive ‘visual identity’ and ‘brand’ for dementia research and advocacy (Gorman 2007). The 
importance of such strategies reflects both the increasingly visual nature of popular culture 
(Stafford 1994) and the importance of the marketization of identities in social-scientific relations 
(Burri & Dumit 2008: 297).  In chapter five I explore the rhetorically persuasive role played by 
virtual and material culture to frame and reframe the nature of dementias as a topic of scientific, 
social, political and economic urgency. 
 
Conclusion: on the thickness and thinness of ethnographic data 
 
It is clear from the narrative I have given in this chapter that my project took a radically different 
approach to the one I had anticipated. Rather than a largely laboratory-based study which would 
trace collaboration from inside the clinical research project outwards; my study worked from the 
outside inward, looking at the dense research networks and support infrastructures in which 
individual researchers were located. This approach, in part, was a necessary result of being unable 
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to negotiate NHS access. However, it also facilitated a valuable grounded methodology which 
revealed important networks and relations in the research process (Clarke 2003). As a result, this 
thesis is based on a detailed analysis of the interaction, language and imagery which connects 
scientists, publics and the larger research and political infrastructure in which dementia research 
sits. This approach results in a classically ‘thick’ description and facilitated what Foskett (2004) 
describes as a ‘thick analysis’. That is an analysis which draws on a wide range of data visual, 
linguistic and ethnographic, to pay specific attention to the contingencies, porous networks and 
changing relations as they emerge (Clarke 2003). Exploring this ‘thickness’ enables me to capture 
a snapshot of the complex scientific, social, political and economic relations at work in the 
contemporary field of dementia neuroscience as it is enacted. 
 
In contrast to this ‘thickness’ there was also a sense of ‘thinness’ which had to be managed (cf 
Clifford & Marcus 1986, Marcus 1998). As a result, my case study reflects the kinds of distributed 
social networks explored by Nowotny, Scott and Gibbons (2001). The nature of the interactions 
I had with researchers and the meetings I took part in were inevitably partial and fragmented. 
My relationships, like the dispersed groups of researchers around me, were formed on the basis 
of professional rather than personal identities. Often these relations did not extend beyond the 
context of the dementia research agenda. As Lock, drawing on Strathern suggests, this constitutes 
an ethnography comprised of multiple ‘partial connection’ (Lock 2013: 19-21, Strathern 1991). 





Chapter 4 The burden of dementia - a ‘problem’ for 
science and society? 
 
‘There is nothing good about dementia’ 
Comment made by a dementia Research Officer. 
 
In the previous chapters I outlined the history and evolution of dementia as a shifting and 
contested disease concept, situated within multidisciplinary neuroscience and emergent 
biotechnologies. I then illustrated how these changes in dementia science relate to the apparatus 
of national and regional UK research regulations and internationally evolving research standards. 
In describing this as a dementia research community, I stressed the interaction between health, 
economics and national scientific strategy in shaping the state of dementia research. I then 
described how I identified dementia science as a site of research, developing a methodological 
approach based on grounded theory, which could access the social entanglements which 
characterise this field.  
 
In this chapter, as the opening quotation illustrates, I consider why clinicians and researchers 
portray dementia as an especially problematic field for science and how they articulate their 
concerns. A usage that was particularly prominent in research discussions was that of burden to 
describe the total impact of dementia on science and society.21 I suggest that the term burden has 
become an important metaphor, used by scientists to understand and work in the dementia field 
and moreover to gain rhetorical purchase in the wider society.  
 
Rhetoric and rhetorical analysis in anthropology and science studies 
 
Carrithers argues that rhetoric is of fundamental interest to anthropologists (2009). The art of 
persuasive communication, he argues, is evident in most human encounters; providing evidence 
                                                 
21 Throughout the thesis I have treated certain concepts as native categories, that is, ones which are in common 
currency but which have specific uses, meanings and applications not entirely encompassed by technical and 
scientific definitions. In recognition of this I have italicised these terms. 
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of ‘every-day micro-politics’ at work (Carrithers 2005: 578). By incorporating rhetorical action 
into ethnographic analysis Carrithers suggests we are able to gain greater insight into culture as 
a dynamic process rather than a static blueprint. In my analysis, I suggest the rhetorical discourse 
surrounding dementia demonstrates the beliefs and ideas embedded in the disease concept as it 
is used by scientists.  
 
Ethnographic approaches in science studies have often used language analysis to explore the co-
production of biological science and social perceptions of illness or disease (Epstein 1996, Fee & 
Krieger 1993; Landesman, Ginzburg, & Weiss 1985; Singer 1994). In particular, a useful site for 
research has developed from paying attention to how scientists have communicated to audiences 
beyond specialist disciplinary field. As Martin (1991 & 1992) and Traweek (1988) have 
demonstrated, looking at science communication provides a valuable opportunity for observing 
the ways in which beliefs and assumptions are reinforced beyond the ‘citadel’ of science (Martin 
1998). In the case of HIV, Martin demonstrates how the language used in public health 
campaigns and educational resources insight into social relations. She demonstrates that such 
relations are both shaped by and incorporated into accepted structures of scientific and medical 
knowledge (Martin 1994). Martin analyses the linguistic framework used to describe the cell 
structures and activity of human ova and sperm in American high school science text books. She 
argues that the framework used naturalises a culturally specific and gendered reading of 
reproductive processes (Martin 1991). In this argument the linguistic framing of the physical 
matter of human biology illustrates the pervasive power of science in the construction and 
maintenance of social relations and power inequalities in unexpected and insidious ways. 
Similarly, Sontag’s comparison of the clinical and scientific language used to describe HIV and 
cancer, demonstrate how different disease processes are socially categorised, and acutely reflect 
local social beliefs (Sontag 1978 & 2002).  
 
In the communication of disciplinary specific knowledge outside of their specialism or to wider 
non-scientific audiences, I found that dementia researchers use a shared language of burden. This 
is a term which used to communicate, translate and encapsulate the complex scientific and social 
issues which make dementia such a challenge for researchers. By demonstrating the flexible, 
shifting use of the notion of burden as rhetorically important, I illustrate how scientists locate 
these problems in the overlapping relations between science, government and society. 
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The language of burden in dementia research. 
 
The first use of burden I look at is in the biological language of the physical pathology involved in 
dementias as found in neuroscientific articles. The articles used here were selected as they are co-
authored by scientists who played a prominent role in research discussions I observed during my 
fieldwork in Newcastle, London and Birmingham. Often these authors were research leaders 
involved directly in the development of the dementia research agenda as it was become part of 
UK health policy. 
 
In the first article I considered, the following claim was made: 
 
Progress is being made in the development of specific biomarkers for the diagnosis, and 
even prediction, of AD including PET imaging and CSF tests for amyloid burden. However, 
AD is still diagnosed after other dementing illnesses or other conditions associated with 
memory impairment have been excluded.  
((My emphasis) Holmes 2012: 628) 
 
Here burden refers to the volumetric measurement, or ‘weight’ of abnormal, insoluble amyloid 
protein present in the brain tissue of a person with AD. This material is measured in research 
and diagnostic tests using imaging technology (PET) and cerebro-spinal fluid tests where 
abnormal proteins are measure in the fluid extracted by needle from around the patient’s lumber 
spine. The burden of dementia here is a physical and biological one, referring explicitly to the 
disease process whereby build-ups of abnormal or ‘misfolded’ proteins impede communication 
between neurons. Dementia researchers commonly identify the evolving amyloid burden as the 
first stage in the process that eventually leads to localised areas of neuronal death which 
cumulatively alter the patient’s cognitive function. This image of pathology as a burden and as an 
impediment to communications is developed further in this example: 
 
A major feature of Alzheimer’s disease is the accumulation in the brain of an amyloid-β 
peptide (Aβ), which aggregates to form oligomers, plaques, and cerebrovascular deposits. 
The putative key role of Aβ in the pathogenesis of Alzheimer’s disease led to 
immunotherapeutic strategies that aimed to reduce levels of Aβ in the brain. Active 
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immunisation of mice genetically modified to develop Aβ plaques as they age with full-
length Aβ (Aβ42) resulted in a reduction of plaque burden and improved cognitive function. 
 
((My emphasis) Holmes et al. 2008 :216) 
  
A particular interest for the dementia researchers I was working with was the potential in recent 
developments in ‘immunotherapuetic strategies’. This approach focuses on what is currently 
recognised as the key pathological process of AD, the ‘amyloid cascade hypotheses’.22 In this 
treatment process, drugs modify the immune system of the recipient to break down the insoluble 
Aβ deposits, which are understood to impede the communication between neurons, beginning 
the cascade of neurodegeneration which leads to cognitive impairment. Here the burden of plaque 
is compounded, as it is seen as a substance which is disordered and accumulating. The biological 
process is communicated using geological metaphors, such as the ‘silting up’ of neuronal 
networks, which conveys a slow but weighty and intransigent process. In contrast, the immune 
system, modified by treatment, is presented as flexible, active and responsive, breaking down 
protein barriers to improve cognitive functioning. 
 
In the two former examples, it is the biological characteristics of the disease which are referred 
to as burdening the neurological system of the person with dementia. However, the linguistic 
framing of burden in scientific articles is extended to include person-oriented concerns in 
dementia research development: 
 
Biomarkers may enable more specific selection of appropriate populations, better 
targeting, identification of subjects at an earlier stage, and better assessment of treatment 
effects, but may also increase selection bias because of different perceptions of burden by 
different population groups. Similarly, innovative approaches that might reduce burden and 
                                                 
22 The amyloid plaque cascade hypothesis remains the dominant theory of the disease process, or aetiology, in 
Alzheimer’s disease. Put very crudely, research based on this approach starts from the premise that the ‘mis-folding’ 
of normal amyloid proteins initiate the disease process. These mis-folded proteins are insoluble and toxic. The 
abnormal lay down of insoluble amyloid-β peptide (Aβ) result in progressive interruption of chemical, electrical and 
vascular pathways in the brain which leads to progressive neuronal death. However, as I explore in chapter seven, 
the role played by Aβ is a highly debated topic. This was fuelled by the uncertain results of dementia ‘vaccine’ trials 
in the US. This has caused many to question at what stage Aβ becomes an active agent in the disease process. This 
fundamentally alters whether it should continue to be viewed as a primary therapeutic target (Chiti & Dobson 2006, 
Mulane & Dobson 2012). 
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minimize dropouts, such as increasing the use of internet and digital technologies, may be 
less acceptable in certain population groups and thus could also affect selection bias.  
((My emphasis) Vellas et al. 2013: 443) 
 
In this extract, the burden described is one related to the challenge of current research processes 
and practices for participants. As I have reflected in previous chapters, clinical dementia research 
involves a highly complex research infrastructure. This infrastructure must unite the staff and 
technology required, with effective, supportive and sensitive practices which meet the specific 
needs of the participants involved. As I found through my contacts at the NMRC, assembling 
the specialist imaging technology and staff required to conduct and support this sort of research 
required the resources of larger centralised hospitals or clinics. As a result, participants may be 
required to routinely travel some distance to attend research sessions. Vellas et al (2013) argue 
that perceived and actual logistical issues can make the prospect of travel a barrier to long-term 
participation in research. Such barriers are doubly apparent for the person with dementia, 
experiencing the symptoms of disorientation involved with cognitive impairment, and also for 
the family members and carers who facilitate and support them during their visit. As a result, 
‘certain population groups’ the researcher’s argue, such as those including older people and those 
with cognitive problems, are more likely to see regular travel as a negative element of participating 
in research.23 Thus, over time members of this study are more likely to ‘drop-out’ of a trial, 
creating the potential for poor retention rates, requiring higher overall recruitment. In addition, 
those who would be less negatively affected by travel, and therefore more likely to participate, are 
also likely bias the sample for secondary, not-controlled-for criteria.24 This potential for bias 
threatens the fine scale control of the trial, with the potential for factors other than those being 
tested to influence the outcome of a study. The authors suggest that new ways of doing research 
could address such factors. By adopting utilising developments in ICT, researchers can ameliorate 
the burden travel presents for participants. Thus what begins as a burden for participants is 
                                                 
23Here population groups refer to the designation a group defined by a specific set of characteristics who are targeted 
by a specific research project: for example people with fronto-temporal dementia, over 65 years of age. This is the 
group within the wider population for whom the findings of the research design will be extrapolated to (Vellas et al 
2013). 
24What these secondary biasing characteristics might be, are not identified by the authors in this case. However, the 
implication is that as socio-economic background will impact factors such as carer support and access to private 
transport which might facilitate participation. To manage the potential for bias, it is standard practice to reimburse 
travel costs. However, limited access to familial or professional care and support is less easy to address, and remains 
a barrier to research participation for many people with dementia.  
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translated into a pressure on scientists and the practice of research. Research designs must be 
conscious of the changing ways research participation might create burden, and how this might 
be perceived by different categories of participants. Thus the burden is shifted, first to the 
participant and then back onto science. Researchers designing studies must anticipate, calculate 
and accommodate a varied and ever growing range of information which affect the populations 
they study. 
 
This example demonstrates the wide-ranging potentially burden-some aspects of undertaking 
research: the regulatory structures, changing assessments of what constitutes ethical research, the 
practical realities for patient involvement in research participation, understanding the attitudes 
and behaviours of specific socio-economic groups, and how different aspects of the research 
process may be perceived by a variety of people. Researchers may attempt to calculate, model, or 
otherwise capture such variables to reduce their impact. Essentially, however, they are trying to 
imagine and represent the potential research participant. Indeed, they are even tasked to imagine 
how new technologies, such as increasingly accessible forms of virtual and tele-data collection, 
could be developed and creatively deployed to ameliorate perceived burdens in the research 
structure and thereby relieve the burden of dementia. 
 
The burdens and barriers of dementias are not restricted to the disease pathology or the research 
process; they are also described by researchers in terms of their impact on the everyday lives of 
people with dementias and those that care for them. 
 
The impact of caring for a person with dementia arises from a complex interplay of factors 
and is related to the risk of institutionalisation. Factors in carers that increase "the burden of care" 
are usually secondary to the caring role and include stress, vulnerability, deterioration in social 
networking, and economic issues.  
((My emphasis) Eccles et al. 1998: 806) 
 
This extract reflects a set of fundamental concern for those involved in designing and 
operationalizing research projects involving people with dementia. Scientists and those working 
with them in the research design infrastructure have to imagine, research and consider how wider 
social and economic factors are impacted upon by a dementia condition. Critically, the dementia 
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research process relies on the support and involvement of a dedicated carers. Consequently, 
researchers must also consider how dementias affect the people involved in every-day social 
networks of support and care. By quoting ‘the burden of care’, the authors demonstrate how the 
concept of burden is also grounded in the social research literature on care. Thus, the burdens of 
dementia, and the dementia research process are fundamentally located in a relationship between 
researchers and research participants. In turn this relationship extends outwards to encompass 
the networks and needs of family, friends and professional carers who are implicated in the 
research process. Thus, like the cascading imagery used to describe AD pathology, the range of 
burdens created by dementias cascade outward. From the representation of changes in the 
localised neuronal activity of one person’s brain into issues of social relations implicated in 
accounts of biomedical research design and development, the burdens of dementia spread and 
multiply. 
 
The image of AD pathology, as something progressively building up, impeding and finally 
blocking neuronal connections, is mirrored by the description of the progressive degenerative 
impact on the social world of the person with the condition and their surrounding support 
network. Just as the individuals access to the social connections which locate them in the world 
become altered by the disease, so the disease affects their wider personal, social and economic 
ties, and in turn those of their carers. The burden of dementia is thus characterised as one of 
barriers and broken connections.  
 
Patients, families, and general practitioners may all be reluctant to diagnose dementia 
because it is such a serious and largely unmodifiable disease that still carries a huge burden of 
stigma. Physicians may unconsciously hesitate to label a patient as such, and family members may 
gradually take over social roles from the patient, protecting him or her from difficulties in daily 
life, but also delaying the conscious recognition.  
((My emphasis) Burns & Iliffe: 405) 
 
This quote reflects the disconnections which are linked to the social and cultural stigma with 
which dementia is described in both the social and scientific literature (Batsch & Mittelman 
2012, Burn & Illife 2009, Herskovits 1995, Holmes 2012, Van Gorp & Vercruysse 2012). Just 
as the disease process is characterised as depositing unwanted, toxic, intransigent material in the 
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neuronal network, so a diagnosis of dementia threatens to deposit harmful labels and social 
barriers from which clinicians and family members may seek to protect the person with dementia. 
In particular, the very real, but also perceived associations of a dementia diagnosis are described 
as barriers to a person’s independent social functioning.  
 
This stigma is seen as inhibiting a person’s capacity to recognise and accept their symptoms, 
diagnosis and wider impact of a dementia condition. Researchers recognise this challenge as 
understandable but unhelpful, leading to an unwillingness amongst UK GPs to give a diagnosis 
of dementia, or for a patient to receive it. This avoidance is widely characterised in scientific 
policy and literature as a major problem for dementia clinicians and researchers (Renshaw et al 
2001, Turner 2004). For them, the burden of being diagnosed with a dementia becomes part of 
yet another cascading narrative of the barriers to effective research.  
 
Clinicians and scientists described this diagnostic stigma as a two-fold burden. Firstly, due to the 
reluctance both amongst patients and GPs to a diagnosis, diagnosis often occurs later in the 
progression of the disease. As a consequence, patients who have the diagnosis required to be 
eligible for research inclusion, are less likely to meet all the inclusion controls, requirements of 
informed consent and the practical demands of participation.25 Secondly, there is a concern that 
people further on in their disease progression are less likely to benefit from new therapies and 
treatments as their cognitive decline is too far advanced for them to retain a meaningful benefit 
in terms of cognitive function. By affecting the capacity for research into the earliest stages of 
disease aetiology, stigma is therefore understood to restrict efforts to develop diagnostic tools and 
drug and therapy targets. As a result, the social and medical stigma of dementia is seen to directly  
limit the potential for science to gain effective purchase on the impact of dementia, that is, to 
develop treatments which result in the recipient maintaining as much cognitive function as 
possible, for as long as possible.  
 
                                                 
25 In the majority of trials on the UKCRN portfolio, during this study, a diagnosis of mild to moderate dementia, 
with a mini-mental-state score above 14 is required for a person to be included in a trial. As cognitive impairment 
increases over time, those who are diagnosed later in their disease process are less likely to meet this minimum 
requirement, being considered both unable to legally consent and less likely to reasonably tolerate the procedures 
they would undergo. However, Fisk and Wigley (2000) have argued for a more holistic approach to the definition 
of mental capacity should be considered. They argue that people respond differently to the progression of their 
dementia, and whilst they may possess a significant global cognitive deficit retain both the understanding, lucidity 
and willingness to engage with research if sensitively handled. 
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Researchers empathised with the fear, stigma and ground-shifting uncertainty, associated with 
receiving a dementia diagnosis. They recognised that people receiving early diagnoses and 
participating in research at this point in its development would be unlikely to benefit directly 
from its results. However, in viewing the disease as the primary target and prioritising future 
benefit over current uncertainty, diagnostic stigma was seen as a burden that must be overcome. 
Thus, the fear and uncertainty of diagnosis starts to be framed in research as a rejection by the 
patient of self-awareness and ‘conscious recognition’. Failure to receive a diagnosis is described 
as negatively impacting upon a person’s capacity to come to terms with, and receive support for, 
the changes in their health. Thus the decision ‘not to know’ is presented as a barrier when it 
comes to the patient planning their future life and care. It is described as delaying referral to 
specialist services which may be able to provide access to the existing and experimental 
pharmaceutical and cognitive therapies available, and which may maximise their changing 
cognitive capacity, and improve their overall quality of life.  
 
This collection of extracts from dementia research papers represents a small, but pertinent, 
sample of the neuroscientific articles I read in the course of this study. Inevitably, given the 
diversity of the field in which I was working, this also represents a tiny amount of the work 
undertaken and published by researchers based in the UK. However, the regularity and diversity 
of the application of the concept of burden in describing neurodegenerative conditions is both 
striking and significant. Below is an analysis which illustrates the scale of the use of the concept 
of burden in dementia research papers.26 This analysis is based on three high ranking journals 
on dementia and neuroscience research; Alzheimer’s & Dementia, NeuroImage and 
Neuroscience, processed using the Science Direct database. These are the journals which the 
researchers I worked with frequently consulted and published in, and which I routinely consulted 
for research updates. In these journals, between 2000 and 2013, it is clear, even in this superficial 
analysis, that there has been a stark rise, not only in the volume of articles published on the 
theme of dementias, but significantly in the proportion of those articles where the terms 
dementia and burden coincide. 
 
                                                 
26A systematic examination of the ways in which ‘burden’ is used in these articles is beyond the scope of the project 
conducted here. However, the importance of rhetoric discussed here, would argue for further research to track such 













articles using the 
term ‘burden’ 
2000 733 88 12.01 
2001 666 86 12.91 
2002 791 120 15.17 
2003 897 136 15.16 
2004 1416 261 18.43 
2005 1277 220 17.23 
2006 1346 228 16.94 
2007 1399 313 22.37 
2008 1695 341 20.12 
2009 1819 394 21.66 
2010 1793 424 23.65 
2011 1908 454 23.79 
2012 2320 585 25.22 
2013 2674 737 27.56 
 











Figure 11: Illustration of increasing use of burden in dementia publications 
 
The scale and pervasive use of the term burden in research articles suggests that the term has great 
utility, that is, it is useful to researchers when talking about dementia. It is a concept constantly 
moving between researchers’ accounts of the social and scientific problem of dementia. Burden is 
used to activate different aspects of dementia: the pathology, the cognitive changes experienced 
by the person with dementia, the cost and demands placed on care givers, the stigma associated 
with the disease, the challenges posed to researchers and the wider social and economic costs 
attributed to changing rates of dementia diagnoses. In a single paper, burden might slide back and 
forth between the barriers dementia creates in the cognitive networks of the person, the social 
network in which the person resides, and in ethical, practical, organisational and scientific 
networks in which the researcher and their work exist. 
 
Tracing the etymology of burden 
 
Etymologically, burden originates from Indo-European roots, meaning child or something to be 
borne. This locates it within social, and particularly familial, connections. Middle-English birde 
or burde meant 'descent' or 'race’. This meaning is also retained in the contemporary use of the 
word bairn, meaning child, in several dialects in northern England, Ireland and Scotland. Later, 




































Percentage of articles using the term 
burden 2000 - 2013
Percentage of articles




concepts of a ‘load’ or ‘weight’. This was further developed in Old English toward meanings of 
a charge, duty or responsibility. As Warnes’ discusses extensively, the rhetorical and metaphorical 
power and versatility of the term burden, is more than two millennia in the making (Warnes 1993: 
301-302). Burden, later took on a legal definition, as in ‘the burden of proof’, often applied to 
cases involving property where the ‘actor’ in a case took responsibility for proving their case (ibid: 
303). These compound meanings resonate with the weight of problems and challenges which 
dementia scientists associated with working in this field.  
 
Thinking about the language of burden in this way, also reflects how social value has become 
related to the concepts of labour, productivity and functionality in how scientists situate 
dementias in their work: 
 
Echoing the concerns of Standard and Poors, based on simple demographics, the costs 
of dementia are set to increase by 85% by 2030, with developing countries bearing an 
increasing share of the economic burden. 
 
… the complexity and cost of trials in dementia, along with some high profile late phase 
3 trial failures, means that there is a withdrawal [of pharmaceutical investment] from the 
field in many countries, with a wait for new basic insights to emerge. 
 
(Banerjee, S. 2012: 708) 
 
In neuroscientific articles, burden often appeared alongside terms such as loss, absence, failure and 
cost. Again, such terms are attributed not only to the experience of the disease, but to the research 
infrastructure and pragmatic issues involved in developing scientific research in the field of 
dementia. The language adopted by scientists reflects wider political and economic concerns, 
which shape the environment in which research happens. In particular, the language of ‘cost’, 
featured notably in research talk. For example, the dementia burden is linked in research 
narratives to cost across a range of levels: the personal cost of dementia for those experiencing its 
effects, the financial and social cost to the UK, and the costs associated with the national and 
international health industry. The concepts of cost and value reflect the increasing 
neoliberalisation of the regulations and relationships which underpin the practice of biomedical 
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and biotechnological research. As Lave, Mirowski, and Randalls (2010) describe, the process of 
neoliberalisation has been enacted through a number of key changes in scientific practice: 
 
(T)he narrowing of research agendas to focus on the needs of commercial actors; an 
increasing reliance on market take-up to adjudicate intellectual disputes; and the intense 
fortification of intellectual property in an attempt to commercialize knowledge, impeding 
the production and dissemination of science. Taken together, these shifts suggest that the 
impact of neoliberal science policy and management extends far beyond the patent system 
into the methods, organization, and content of science.  
(Lave et al 2010: 659) 
 
Indeed, the operationalization of health research, tied to pharmaceutical and bio-technological 
industry interests, are shown to have transformed how ‘valid’ objects of scientific knowledge and 
investigation are made and recognised (Abraham & Ballinger 2012). The neoliberal turn is 
characterised by increased emphasis on competition, growth, efficiency, speed, productivity and 
distribution, particularly as they relate to the field of drug development of and processing 
(Abraham & Ballinger 2012: 447-448). The rise of neoliberalism in the UK has been located in 
a political-economic shift of the 1980s. Abraham and Ballinger suggest: ‘prior to this period there 
was a governmental and legislative expectation that the basic goal, and indeed the raison d’etre of 
pharmaceutical regulation was to protect public health over and above the commercial interests 
of pharmaceutical firms’ (2012: 427).  Subsequently, the certainty of this relationship was to 
come into question. 
 
The tangled relationship between function, productivity and value in biomedical research can be 
seen in the way in which the burdens and ‘costs’ of dementia move between the practice of science 
and the description of pathology, to the social and personal experience of dementias described 
by clinicians and researchers. The loss of social ties is linked to a person’s decreasing cognitive 
function, which in turn is related to their productive capacity – an inability to relate to the social 
world becomes tantamount to an inability to perform in it. As Rose (2007) argues, in the last 
fifty years we have moved from a society which relies on the productivity of physical bodies to a 
‘brain-economy’ in which cognitive and intellectual capital play a significant role in sustaining 




Part of the ‘neoliberal’ regulatory framework which reflects this relationship between function, 
productivity and value can be identified in the development of secondary measures to assess 
efficacy. Such measures are required to quantify and give objective value to new biomedical 
interventions. This assessment of value exists in the context of the competition for limited 
national resources and a stake in the global market of biomedical research. For example, in 
epidemiology and health economics since the late 1980s, the term burden has been linked to 
quantified measures of disabling disease in the form of Disability Adjusted Life Years (DALY). 
The DALY measure aims to capture the impact of a disease by combining a measure of ‘time 
lived with a disability’ weighted by the degree to which it causes a person to loose ‘functional 
capacity’. This calculation is combined with ‘value choices’ which adjust for expected changes in 
quality of life over the life-course, taking into account the expectations for time periods during 
which the disease is experienced, and ‘years lost due to premature mortality’ (Murray, 1994: 441, 
Lopez et al. 2006, Annand & Hanson 1996). This is a highly complex measure that aims to 
quantify the holistic impact of disease upon a person. 
 
The DALY calculation of the burden of disease is highly influential in UK and international 
health policy. Thus, biomedical interventions aim to act upon the burden of disease by adding 
life years of a better quality or of higher value. This is constructed in the cost-benefit analysis of 
the QALY. Put bluntly, disease is the ‘weight’ or ‘burden’ which is alleviated by scientific 
intervention. Whereas science is value ‘adding’, disease is value ‘losing’. 
 
However, as many of the researchers I met pointed out there was concern that the burden of 
dementia could not be fully captured by these measures. This is borne out in the work of health 
economists, who suggest that conditions with high morbidity, such as cancers, cardiovascular 
disease and stroke, receive a disproportionate amount of funding in comparison to the burden 
calculated for neurological and mental health disorders, such as dementia. Based on WHO data, 
neurological and mental health conditions have the greatest, long term, disabling impact. Yet, 
neurological conditions receive comparatively less R&D funding, and the technologies 




As Annand and Hanson (1996) demonstrate, there is significant disagreement about how the 
highly complex assessment of disease burden should be calculated, and they are critical of current 
practices. For social theorists, the main issue is not only the uncertainty of these powerful 
measures of disease impact, but the very system of thought and belief which has led to the 
numerical capture and control over the value of ‘life itself’ (Agamben 1998, Rose 2007). Foucault 
(1973) identifies this turn as stemming from the birth of the concept of political economy in the 
eighteenth and nineteenth century writing of Adam Smith and David Ricardo (Cooper 2008: 
5). The reshaping of value as ‘a function of trade, exchange, and circulation’ (Cooper 2008: 6) 
led to the person being conflated w(ith their labour and productivity. This shift in thought was 
interwoven with the changing structure and control of the nation state, and the post-
enlightenment rise of science. In this context of power and control, the person, and the body 
were further separated. This separation enables the body, and the brain to become objects of 
scientific research and experimentation (Sharp 2000). As a result, the changing ‘value’ of the 
person over their life course became subject to the quantification of their biological, and 
increasingly, cognitive functionality (Rose 2007).  
 
The association between human value and the biology of aging, returns us to the etymology of 
burden. Age and aging are a critical part of how the concept has developed and its current usage 
in everyday language, government policy and health economics and biomedical research. Warnes 
(1993) identifies five ways in which burden is used when talking about age and aging:  
 
… the subjective or reflexive application of burden to being old; referents to an old person 
as well as an infant; its collective adjectival application to all old people in a society; the 
shift of the agent bearing the load from an individual or a single family to a collectivity; 
and the transfer of the weight of the load from an individual's emotions collectivity; and 
the transfer of the weight of the load from an individual's emotions, psychology and 
physical effort to monetary and fiscal charges. 
(Warnes 1993: 305) 
 
Understanding the implicit link between physical and cognitive functionality, personal value and 
national economy sheds light on the disconnection described in the literature on the impact of 
receiving a diagnosis of a chronic, disabling condition (c.f. Beard & Fox 2008, Caddell & Clare 
101 
 
2011, Kleinman 1988, Lock 2004, Maynard 2006). This supports the need to understand the 
interconnection between the evolution of the life sciences and the social, political and economic 
context (Foucault 1973). Through this analysis of the fluid connections made using the term 
burden, I have illustrated how dementia science is continually embedded in social, political and 
economic context. The concept of burden connects the bodily substance of Aβ, economic 
standardising measure such as the DALY, the real world emotional and pragmatic impact of 
receiving a dementia diagnosis, and how this is understood by scientists to affect participation in 
the dementia research process. These facets combine to demonstrate how the concept of 
dementia burden is located not within scientific context, but within a dynamic social, historical 
and scientific framework. Unpicking the association of burden embeds the disease pathology in 
the cultural beliefs and perceptions that have evolved locally around aging, later life, changing 
perceptions of personal value, the aging demographic, and the neo-liberal political-economy.  
 
Furthermore, the neuropathology of Aβ is not only a burden to brain function to be borne by the 
individual, and addressed by an abstract and uninvolved group of scientists. Rather the burden of 
dementia is represented as spreading and unfolding out from the individual, to the impact upon 
wider social relations in the shape of familial, community and professional carers who help 
support those living with the disease. Thus, the process of developing a dementia condition, 
continually intersects with personal relations and national health and social care practices, which 
locate the person in the wider political and economic dynamics at work in UK biomedicine. So, 
the language of a protein, visible only under a microscope, can be thought of as cascading 
outwards and somewhat chaotically to envelop the individual, the family and the community, all 
the way up to national and transnational levels of political economy. What I hope to have 
demonstrated here is how the language of dementia science itself, and the way science frames 
dementia are an area of study which requires a focus on relations and relationality between 
scientists and the community in which they practice and are located. I return later to the 
emerging criticisms of the use of burden as an appropriate discourse for narrating dementia, but 
now I turn to ethnographic examples which explore how the rhetorical burden of dementia are 
unpacked by researchers in their narration of the problems of dementia science. 
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Perceived problems in dementia science: barking up some wrong 
trees 
 
At the end of two days of research meetings, the attendees of the Alzheimer’s Society Research 
Network Meeting in 2011 came together for a final discussion. I sat at a table of women, who 
like me, were registered as ‘friends of research’, a group created by the Alzheimer’s Society. Part 
of the Society’s Research Network this group enables interested members of the public to attend 
national conferences alongside researchers and clinicians, who meet to present their work. A 
member of the audience, a retired neurologist and supporter of the Society was invited by the 
Chair of the meeting to start the discussion by raising a question. With dogged determination 
he began: 
 
 Well I was concerned after I read in the Economist about the billions of dollars which 
had been spent on dementia trials in America [pause].I was concerned that the shortfall 
in performance of the research work ought to be taken more seriously than it seemed to 
be. It wasn’t talked about. I am here discussing this in our own work, and it’s making me 
wonder, moreover, whether, perhaps we’ve been barking up some wrong trees, with 
overemphasis on the amyloid cascade and so on. But I must say that [name of researcher]’s 
talk which I went to this afternoon did persuade me that the connections between the 
genes and the operation of amyloid in the brain, did seem to fill this gap. But anyway I 
thought it was a good thing to have something, some discussion about the way research 
is going now and how exactly it is performing… 
Question asked by retired researcher 
 
The speaker was reflexive and questioning in his approach. He expressed concern that the 
‘shortfall’ in research was not addressed as seriously as it should be, that the problem should and 
must be recognised within dementia science policy and practice. The object of anxiety is described 
as the ‘performance’ of research, but what this implies is a failure to create products of research, 
that is, to have reached a stage in an outcome-based science which had proved the efficacy of 
medical and biotechnological interventions. His concern was framed by anxiety about how global 
investment in research was being (mis-)directed. There are several themes emerging here. 
Dementia research is placed in the cost-benefit framework of biotechnological development 
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within the structure of NHS and pharmaceutical industry collaborations. The speaker questions 
this system of relations. Is the mechanism of collaboration and investment pushing research in 
the best scientific directions? Has this relationship taken research down the wrong path? This 
anxiety around practice and process is framed in the context of changing scientific knowledge. 
As new techniques, combining new technologies, such as genetics and imaging, change our 
understanding of dementia disease pathologies, the shape of existing theories are being radically 
and persuasively redefined. This process echoes the history of dementia science as a contested 
and evolving field of research described in chapter two. Dementias continue to be reshaped as 
knowledge, organisational structures and public patient involvement practices are co-produced. 
Thus, the speaker raises the question: does the collaborative market relationship between 
academic and commercial research, have the necessary reflexivity to change direction as new 
knowledge takes shape? Do the public-commercial relationships fundamental to contemporary 
research present challenges which become a potential block or burden to be managed by academic 
dementia researchers? 
 
The panel I was attending consisted of two senior researchers and a senior clinical researcher. 
Each was a leader in their respective fields of epidemiology, metabolic research and neuroimaging 
for dementias. They were joined by the Society’s media co-ordinator, standing in at the last 
minute for a researcher who was unable to attend. The neuroimaging specialist responded to the 
opening statement, and tentatively they each reached towards a critical understanding of the 
problems faced by dementia research: 
 
I think that is a very good context and I think that, you know, the reason we’re here is 
that there haven’t been any disease modifying drugs which have successfully come 
through clinical trials. Is that because there just aren’t enough trials, and we need more 
investment in trials? Is it because the science hypotheses are wrong? Is it because we’re 
designing the trials badly? Is it because we’re doing the trials in the wrong groups of 
people? And I think those are all possible things that have been used a lot [to explain this 
failure]. 
 





During this debate the language of researchers continually moved back and forth between 
scientific practices and organisational structures. The hesitancy of the speaker conveys the 
uncertainty described by many research leaders. There was no one clearly identifiable cause for 
why dementia research was not as productive as desired, particularly in the area of disease 
modifying drugs (DMDs). The speaker suggests there are some useful targets in the research 
community which may be acted upon. For this speaker the prime target is the clinical trial. 
Addressing the clinical trial, the speaker emphasises the role of investment, the shape of the 
science being tested and the participant groups involved. By trying to recruiting the most suitable 
bodies and brains upon which research can act, science is engaged in actively defining the patient 
and research participant. This process illustrates how scientists view the problems within the 
scientific domain to be deeply interconnected with ideas about a public that somehow needs to 
be brought into the scientific citadel (Martin 1998). 
 
The burdens of dementia research were a consistent theme in the talk of scientists and clinicians 
at research meetings such as the one described above. This was evidenced by research into the 
comparatively low levels of funding for neurodegenerative disease research, in comparison to 
other high impacting disease such as cancer. Over the course of the study it would become 
apparent that the sense of failure in dementia research to capture research initiatives and 
resources was historically embedded in the narratives of dementia neuroscience. Indeed, in 1983 
Fox, writing about the evolution of a dementia research movement in the US, echoes many of 
the concerns UK researchers and clinicians were expressing at meetings some thirty years later. 
Combining extracts from policy documents produced between 2008 and 2012, with extracts 
from research meetings, I suggest, scientists are locating the burdens of dementia research in four 
broad fields: 
 
 The complexity of dementias and the science which addresses them 
 The impact of stigmas of dementia and the practice of dementia science 
 Perceptions of progress and productivity in science.  
 The implications of the collaborative relationships which dementia science requires 




These themes are expressed in the Medical Research Council’s ‘Strategic review of 
Neurodegeneration’ (MRC 2008). This document was produced following a meeting in February 
2008, of academic and industry scientists and clinicians from across the field of neuroscience 
and neurodegenerative disease. This meeting was chaired by Professor Christopher Kennard, 
Professor of Clinical Neurology, who in 2010 became head of the Nuffield Department of 
Clinical Neurosciences. The meeting was designed to inform the MRC’s Neurosciences and 
Mental Health Board policy for funding research and training to meet ‘the human, societal and 
economic burden of neurodegenerative diseases’ (2008: 4, my emphasis). The conditions addressed 
included ‘Alzheimer’s disease and other dementias, Parkinson’s disease, Huntingdon’s disease, 
multiple sclerosis, motor neuron disease and prion disease’ (ibid:4). However, the document 
makes specific reference to the clinical needs of the aging population, which of all the 
neurodegenerative conditions, places particular emphasis on dementias.27 By combining extracts 
from this document, with comments made by researchers at meetings attended during the period 
of my study, I show how particular ‘weaknesses’ in the dementia research process have been 
identified, and how policy is trying to act upon them.  
 
What follows is separated into two main analytical areas. The first section deals with efforts to 
change or redefine dementias as an object of research. This involves a changing understanding 
of the different dementias as a group of diseases, and resituating the diagnostic process involved 
in its identification. The second section addresses the relations in science, and how they may be 
acted upon to facilitate the flow of knowledge, people, resources and funding which are defined 
as a key feature of successful science. 
 
Addressing the challenge of dementias and their diagnosis 
 
Effective intervention can only be achieved at early stage in at-risk populations, since after 
the point of diagnosis it may be too late. Without better pre-symptomatic markers it will 
remain challenging to perform clinical trials. Investment in this area is needed now, even 
if unlikely to pay off for many years. 
                                                 
27 There is an underlying irony in that the dementia most often singled out as the catalyst for a focus on the 
impact of the aging population on health, Alzheimer’s disease, is in fact, the most likely to occur in the younger 
old, that is, to be identified as ‘early onset’, below 65 years. This again reflects the not altogether straightforward 




Section 5.1 Key conclusions and recommendations.  
MRC Strategic Review of Neurodegeneration(2008: 15) 
 
… [M]aybe it’s all been too little, too late; that the process, the AD process has a 
self-fuelling, self-maintaining momentum. Now that, that’s a worrying concept... 
giving treatments in the way that has been done for a decade or more, waiting for 
people to fulfil criteria. Add to that the recognition that the Alzheimer’s process 
is detectable now with some imaging with some CSF markers, perhaps ten to 
fifteen years earlier than diagnosis.  
 
So, if you perhaps take those two things together that there is this long prodromal 
period with this anxiety that the disease process is self-fuelling, you then see that 
by the time we are intervening the disease has a 10 to 15 year head start on us.  
 
We wouldn’t dream of putting effective therapies in for cancer say when people 
are at the palliative care, death bed stage. It’s too late.  
 
So, if the process has been going that long, then that means early intervention. 
So, I think that’s a really interesting thought.  
 
Comment from Professor of Neurology 
Alzheimer’s Society Research Network Meeting (2011) 
 
 
The conditions which cause dementia start long before outward signs of cognitive disturbance 
are experienced or observable in a person. This lag was identified by neurologists as a key issue 
in the apparent failure of existing treatment, and a significant barrier to effective research. 
Because the disease activity of dementias is active a decade or more before a person’s cognitive 
changes are apparent, it is hard to diagnose in its earliest pre-symptomatic stages. Thus, there was 
potentially a whole range of disease activity researchers simply never had the opportunity to 
observe. As a result, scientists saw themselves, in contrast to researchers on cancers, only able to 
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join the battle once the war had already been lost. This required a way of seeing disease activity 
at the very start. However, as yet the precise nature of that start remains unknown. This has led 
to a focus on the development of the analytical techniques focused on proteins implicated in the 
earliest stages of the disease process. By identifying these in blood and CSF, researchers have the 
potential to develop a system of ‘pre-symptomatic markers’. In the future, this may enable them 
to identify the disease in its early stages with a high degree of certainty. Moreover, it would enable 
clinicians to identify specific types of dementia. By intervening at this stage, with a treatment 
targeted at a specific disease processes, the recipient would have the best chance of retaining 
maximal cognitive function. 
 
The narrative which was emerging in neurodegenerative disease research policy is one of potential 
prodromal diagnosis, that is, one taking place prior to significant neural damage. Furthermore, 
this was based on the development of biomarkers. This narrative potentially alters the shape and 
the conceptualisation of dementias. Rather than an intransigent burdensome tangle, or an elusive, 
undefined barrier, resistant to scientific intervention, dementia becomes a well-defined and 
identifiable target. In other words, dementia is made into an ideal site for the development and 
trial of a disease modifying, or even preventative and restorative treatments. As I go on to 
elaborate in chapters six and seven, research is often framed by the language of future potential. 
This future-orientation is reflected in the shape of the MRC strategy, which categorises its aims 
as medium term (one-five years) and long term (five-ten years). The benefits of these developments 
are aims and probabilities rather than concrete certainties, and are viewed as beneficial not only 
medically, but in the interests of entwined scientific and economic advantage. 
 
Further stratification of neurodegenerative disease syndromes and sub-phenotypic 
identification would benefit whole genome association strategies and enable future 
human trials to be undertaken more efficiently and cost effectively. 
 
Section 5.1 Key conclusions and recommendations.  
MRC Strategic Review of Neurodegeneration (2008: 15) 
 
Whilst in policy discourse researchers describe working towards a clearly defined and targetable 
disease ‘object’, in scientific discussion dementia researchers retained the idea of dementia as a 
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more tangled and troublesome category. In reality, advances in research continually add to rather 
than subtract complexity to understanding these diseases. In the 2009 Report from the 
Ministerial Summit on Dementia Research, dementia was likened to obesity, as a ‘wicked issue’, 
‘difficult to define, have complex causes and solutions and consequently complex strategies for 
research’ (Brayne quoted in the Report from the Ministerial Summit on Dementia Research 
2009: 13). The causes of dementia are convoluted. As our understanding of genetics and bio-
molecular biology have evolved, researchers have become aware that the interaction between 
biology and environment is far more complex than previously understood. Concrete ‘upstream’ 
risks interact with the less easily defined ‘downstream’ risks associated with environmental and 
behavioural factors which are entangled with socio-economic dynamics (Brayne quoted in the 
Report from the Ministerial Summit on Dementia Research 2009: 13-14).  
 
As a result, a number of the projects I encountered at research meetings were focused on 
behavioural interventions. At the ARUK research meeting in May 2011, projects presented 
included the impact of lifestyle factors, framed by the title ‘living well’. Such studies addressed 
issues such as diet, exercise, the role of social life, and the benefits of the supportive social 
infrastructure. Other projects at this event addressed the interaction of dementia with other 
chronic underlying heath conditions. This approach was echoed the 2009 Ministerial Report 
which identified the impact of co-morbid conditions such as diabetes, high cholesterol and 
hypertension in increasing dementia risk and the speed of disease progression (Report from the 
Ministerial Summit on Dementia Research 2009: 23). In addition research dissemination and 
public education policy placed increasing emphasis on the importance of diet, exercise and 
maintaining social relations in later life. This was demonstrated at a ARUK public engagement 
meeting in Newcastle, where presentations were based on the theme of ‘Living Well’. 
 
An important influence on this life-style based strategy was the increased understanding of the 
role of cerebrovascular elements in dementia subtypes, particularly Vascular Dementia (VaD), in 
which the accumulation of multiple microscopic infarcts is related to progressive cognitive 
decline. Clinicians and researchers also increasingly believed that single pathology dementias 
were unusual. It was more common for patients to have evidence of multiple, interacting 
dementia pathologies. At the Ministerial Summit, speaking on lay awareness of dementia, 




Another common misinterpretation is that dementia is always caused by Alzheimer’s 
disease whereas in fact there are many different causes, including vascular dementia, 
dementia with Lewy bodies, fronto-temporal dementia, Parkinson’s disease dementia, 
Huntingdon’s disease and many rarer causes. Mixed dementia (i.e. due to more than one 
disease process) is very often the true diagnosis. 28 
 
(Ian Mckeith quoted in the Report from the Ministerial Summit on Dementia Research 
2009: 13)  
 
Researchers suggested, therefore, that the disease pathways which lead to dementia are not always 
as clearly defined, or distinctive as is first implied in the enthusiasm for the categorising potential 
of biomarkers. This complexity was true for dementias both as an object of science, and one 
suspended within the deeply social practices of diagnosis and recruitment. This suspension 
between scientific goals and social and ethical factors is reflected by the senior neurologist quoted 
earlier on the importance of early diagnosis. He completed his comments as follows: 
 
[I]t’s very challenging, ethically, scientifically, logistically to intervene early, perhaps at the 
stage where people have the signs of the Alzheimer’s process in the brain but are perfectly 
well with conventional tests.  
 
How do you track if a person has got better when they are already well? So there are things 
like that. So I think that’s it really, that we have failed because we have got there too late. 
That is one thought… 
 
Comment from a Professor of Neurology 
 Alzheimer’s Society Research Conference 2011 
                                                 
28 In spite of the recognition of mixed pathologies, the research meetings I attended tended to emphasise AD over 
other pathologies. This emphasis was perpetuated in media emphasis and the AD framework adopted by Alzheimer’s 
Society and ARUK. As a result, it is unsurprising that AD continues to dominant the dementia research narrative. 
This was particularly of concern for those researchers who were trying to carve out a niche for emphasis on research 
into FTD, DLB and VaD. 
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The MRC Strategy Review (2008) emphasizes that early intervention is part of a longitudinal 
strategy which requires long term investment in both translational and basic science. The nature 
of the scientific process means that early diagnosis would have to precede effective treatment 
development. Thus, underlying the policy strategy, the prospect of early diagnosis comes with 
some highly problematic ethical and practical caveats. For the participants, early diagnosis with a 
deeply stigmatised and feared disease, without the prospect of treatment in one’s lifetime, 
presents yet another aspect of what is to experience the burden of dementia.  
 
 
Figure 12: Cycle and proliferation of complexity. 
 
The potential burden of early diagnoses for patients was of serious concern for scientific and 
clinical researchers. However, as in the Strategic Review discussed above suggests such burdens are 
presented as barriers to be overcome, rather than absolute blockages. Amongst some clinical and 
epidemiological researchers there was a sense that the response-led approach of research funding 
and policy based on the principles of progress, advancement and intervention might accelerate 
diagnostic and screening practices before the basic scientific understanding was fully in place. 
One concern was that this could lead to large numbers of people being diagnosed early but with 
relatively little support, or high numbers of false positive diagnoses leading to over treatment. On 
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balance, such researchers considered that such an approach would not be in patients’ long-term 
interests and would be extremely challenging to manage in the existing NHS infrastructure.  
 
Ashford et al. (2007) describe the tension between the proposition and the realisation of pre-
symptomatic screening for dementias. On the one hand, early screening for dementia allows 
other common treatable conditions to be ruled out or addressed. For those found to be 
developing a condition which causes dementia, a diagnosis enables a person to make decisions 
about their personal and clinical care whilst they are able to access available treatments (Ashford 
et al 2007, Brayne 2007, UKNSC 2007). On the other hand, the knowledge required for effective 
and ethical screening is simply not yet developed; ‘[S]creening tests must be “cost-worthy”, with 
the benefits of true-positive test results justifying the costs of testing and resolving false-positive 
cases, with due consideration for proper diagnostic evaluation and potential harms (Ashford et 
al 2007: 47). Brayne, Fox and Boustani (2007) point out that whilst some current cognitive tests 
are highly sensitive, and have good specificity in identifying subtypes of dementia pathologies, 
they are unable to effectively predict outcomes. In 2007 on the promise of new biotechnologies 
for identifying biomarkers they wrote: 
 
Despite the suggestion that biomarkers may be the promise for the future, no satisfactory 
biomarker is yet available for diagnosis, severity, progression, or prediction of response 
in dementia. Similarly, imaging has been suggested as a possible technique to localize and 
identify brain changes either globally or in specific regions. Neuroimaging improves the 
diagnostic accuracy of predicting cognitive decline. However, these tests are not 
appropriate for repeated screening and are costly and time consuming, limiting their 
applicability to primary care settings. Testing for genetic risk has the same problem as 
other biological or imaging measurement— an insufficiently close relationship to 
outcome. 
(Brayne, Fox & Boustani 2007: 2410) 
 
At a European Neuroscience and Society Network meeting in 2012, Professor Brayne was one 
of the main voices advising caution in the implementation of early diagnostic screening for 
dementias. She cited the wide spread overtreatment resulting from the introduction of prostate 
screening in the US, as an illustration of the potential harm of implementing a screening process 
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prematurely (Brayne 2012). Brayne, Fox & Boustani writing about dementia screening in the US 
observe that any programme would need to be, ‘clinically, socially, and ethically acceptable to 
health professionals and the public’ (2007: 2410). One of the social issues surrounding the 
success of early diagnosis and screening is that concerns amongst the public around insurance 
disclosure would lead to a high refusal rate (Boustani et al 2006).29 The UK National Screening 
Committee (UKNSC) in their 2009 review of screening for dementia, continues to reject the 
idea of systematic screening in primary health care (UKNSC 2009: 15). However, the general 
premise that early diagnosis should be encouraged was, and remains, a high profile part of the 
national dementia strategy (MRC 2008). Early diagnosis is presented as a strategic tool for 
research development, a utilitarian tool for the state to minimise the burden of disease for the 
individual and the nation, and a pragmatic tool for the patient to maximise their benefit from 
treatment and support. However, Brayne, Fox & Boustani carefully qualify this with the 
observation, that: ‘the right to know is predicated on the assumption that better outcomes occur 
as a result of better informed choice’ (2007: 2409). As I have demonstrated GP’s reluctance to 
diagnose early would suggest that this is not an assumption which extends across UK health care 
research and practise. 
 
The prospect of early diagnosis creates a pragmatic problem for clinical research. The problem of 
diagnosis is presented as a multi-scale issue: people choose not to engage early in the diagnostic 
process, they tend not to self-refer when early changes in cognition occur, GPs are reluctant to 
diagnose at an early stage, and clinicians are reluctant to put patients forward to clinical trials. 
Thus, early diagnosis was a concern of researchers who acknowledged the limitations of existing 
therapies, where even ‘(t)herapies in development do not offer strong prospects for effective cures’ 
(MRC 2008: 4). The researchers I worked with, felt that to a degree patients, the public and 
clinicians had lost confidence and trust in the potential of clinical research. One research officer 
described in particular how clinicians had become ‘research shy’: 
 
Me: What do you mean by research shy? 
                                                 
29 Whilst this would differ the UK context where the health service is free at the point of need, the increasing role 
of private health care could lead to a similar response here. In addition, if people are diagnosed earlier and living 
longer, an early diagnosis has the potential to negatively impact on a persons’ working life, mortgage agreements, 
critically illness and travel insurance. 
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Research Officer: Research shy? Just that they’re [long sigh], that for whatever reason 
they haven’t been involved in much research. You know, we have certain hotspots where 
people are really good. Here in [large city] you know, consultants are really good, really 
helpful. You present them with a project and chances are they’ll say fine, yeah, no 
problem. You go elsewhere, and you can meet more, more difficult people. You know 
people who are just not as helpful, who have queries, maybe valid queries, maybe they 
don’t like the study. In, like, a treatment study they might say ‘no, I don’t like the study, 
I don’t like the protocol or the project. I’m not going to commit to it’. It may be they feel 
that their service at the present time is overburdened, that they have too many other 
things happening. You know, the nursing staff, the admin staff, they just wouldn’t go for 
it, and you [pause], you just get a barrier. Yeah, you could have issues around consent 
and Caldecott approvals, or [pause]. You know, certain areas are very cautious about you 
looking at notes and things like that. Certain consultants are very, very frightened of you 
doing that, and so you have to make sure you have all sorts of permissions in place so 
that you can ease their minds, but yeah. Some places it’s better than others 
Me: Where do you think fear comes from? 
Research Officer: I don’t know I’ve never really [pause]. I think a lot of it is a concern 
that [pause]. I’m going to say protectiveness, but a certain [pause], just wanting to make 
sure that their patients are looked after. You know there patients are not all [pause], you 
know, that their patients are dealt with fairly, you know, there aren’t any breaches in 
things like data protection , things like that. I mean, valid concerns, absolutely valid. But 
it maybe [pause]. I don’t know whether it [pause] I don’t know whether it goes back to 
medical school for some people. I mean I don’t know [long pause]. 
Me: Some sort of reluctance in their training? 
Research Officer: Yeah, I mean where it comes from [pause] I mean, difficult [long 
pause]. Could be the environments that they’ve been in, and maybe they’ve had negative 
experiences themselves. Maybe their opportunities to take part in research previously 
have resulted in …. I mean, you know, it’s very difficult, it is hard work, and it can 
sometimes get a bit messy, and I mean maybe they’re just not keen for that reason. I 
mean, I personally I find it, I mean particularly for old age psychiatrists, because they 
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have so little in their armoury, just so little that they can offer you know when you’re dealing 
with dementia patients, that I just, I. My mind boggles a bit to think that somebody 
wouldn’t want to, to try and increase their armoury by being involved in research and 
moving that process along. 
Me: When resources are so limited? 
Research Officer: I mean you’ve got nothing, and the only way you are going to be able to 
build on it is to do the randomised control trials, or otherwise you just can’t, you are just 
going to keep prescribing the same things. The same people are just going to keep 
gradually declining, and end up in the nursing homes, and you, you’re helpless. But where 
that shyness comes from, you’ll have to ask them 
 
Extract from an interview with a dementia research officer (2011) 
 
In spite of having been involved in helping to develop many research trials, this participant found 
it very difficult to pinpoint any single issue responsible for the barrier to professional 
participation in the research process. Several ideas are tangled together. We see the idea of 
protecting the patient, from an uncertain and potentially harmful process. Repeatedly the 
interviewee cites the idea of the process being, hard, difficult and again burdensome. Yet, on the 
other hand, the limitations of existing treatments and the need for better scientific interventions, 
better products of science, very clearly, for this participant outweigh the complexity and anxiety 
which are understood to be part of the process. 
 
Research involving cognitive impairment, aging and chronic disease  
 
Part of this anxiety is tied up with the issue of research participation and informed consent for 
those experiencing progressive cognitive impairment. In 2005 the Mental Capacity Act had come 





It was not yet clear what ramifications enforcement of the Act would have on the 
feasibility to conduct research with those whose mental competence was in rapid decline, 
or already severely disabled, due to neurodegenerative disease. 
 
Section 4.3.5: New technologies, tools and infrastructure  
MRC Strategic Review of Neurodegeneration (2008: 13) 
 
 
The regulation of clinical trials involving participants with progressive cognitive impairment is 
seen, again in the vernacular, as highly burdensome within the research community. As I outlined 
in my methodology, researchers described the regulatory paperwork involved in dementia science 
as highly complex, challenging to negotiate and time consuming. The clinical governance for 
research with human cell lines and tissues was also described as unacceptably burdensome. For 
researchers working with living subjects, there was a huge responsibility to protect potentially 
vulnerable patients. The need to protect and to demonstrate the transparency of the research 
process was seen to have resulted in a bureaucratic load. This was framed as impeding the 
involvement of a public who actively wanted to take part in research, and causing delays to and 
preventing the process of recruitment to research studies. 
 
The tension between research protection and research discrimination was addressed by the 2008 
Nuffield Council on Bioethics Working Party on ethical issues related to neurodegenerative 
conditions. The consultation paper produced from this meeting emphasises informed consent 
within the terms of the Mental Capacity Act, 2005, which required the support and formal 
consent of a ‘carer’. Here ‘carer’ is defined as an ‘unpaid person interested in the welfare of the 
person with dementia’ (Nuffield Council on Bioethics 2008: 37). On the whole, within 
DeNDRoN, the participant-carer-clinician model of consent was seen as supportive, rather than 
detracting from the research process. The carer was always an integral part of the practical and 
emotional support system required for research participation to be successful. However, 
combined consent created a new set of burdens to be managed. Research teams had to be aware 
of minimising any additional pressure involvement might place on carers, who were already 
perceived as highly burdened. It also excluded from research, anyone who did not have a carer in 




The Nuffield consultation paper cautioned that the ability of a person with a degenerative 
cognitive condition to make their own decision about research participation ‘should not be 
underestimated’ (Nuffield Council on Bioethics 2008: 35). At two research meetings I attended, 
a vocal sub-group of researchers and public participants raised the issue of the lack of trials in 
development for people with Down syndrome and dementia. Overly cautious and rigid 
approaches to consent and capacity were seen to be excluding people from research. This was in 
spite of a specific need for work in this area, as people with Down’s are at particularly high risk 
of developing early onset dementias (Report from the Ministerial Summit on Dementia Research 
2008: 17). Researchers and advocates at meetings suggested that work in this area was impeded 
by the inflexibility of this approach to capacity. This lack of flexibility did not take into account 
the case-by-case ability of people with complex degenerative cognitive conditions to understand 
and actively choose to participate in research. This created a further tangle for researchers who, 
on the one hand had to protect potentially vulnerable people from inappropriate or unethical 
research involvement, and on the other hand, wanted to ensure that all people had the 
opportunity to access the benefits of research.  
 
As such, researchers described the need to to be familiar with the variability of dementia. Like 
other neurodegenerative diseases, patients could have ‘good days and bad days’. DeNDRoN staff 
explained to me that being prepared to adapt to this variability was essential. This might involve 
in depth at-home discussions with the participant and their carer, finding out what time of day 
works best for them and being able to reschedule appointments at short notice. This 
understanding and flexibility was essential for successful relationships with participants, which 
meant better experiences of research, better retention rates and better data collection. Working 
with people with dementias in this way, researchers argued, required a much lengthier and 
negotiated approach to consent and involvement. This was in many ways, a more intricate and 
difficult process to achieve than rigid inclusion or exclusion of people based on a one off battery 
of cognitive tests.30 Making research engagement available to all people with a dementia diagnosis 
required ‘a skilled research workforce embedded in NHS clinical services’ (Mckeith quoted in 
                                                 
30 It should be noted, however, that research exclusion criteria did always have a cut off measure for cognitive capacity 
to consent, usually based on a minimum MMSE score of 14. However, conducting cognitive assessments on ‘good 
days’ rather than ‘bad days’, and taking a more sensitive and holistic approach to a person’s cognitive capacity, 
enabled those who might simply have been rejected to make their choice to participate in research known. 
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the Report from the Ministerial Summit on Dementia Research 2008: 14). However, as the above 
extract from my interview with a research officer illustrates, for clinicians, there remained a ‘fear’ 
of facilitating research amongst such potentially vulnerable participants. A policy move to address 
this fear was to encourage research training early on in clinicians’ careers, embedding research 
into the ‘the culture and practices of the NHS’ (Report from the Ministerial Summit on 
Dementia Research 2008: 24).  
 
However, the culture and practice of the NHS in older patient services was described as already 
particularly over-burdened. The expanding population of people over 65 years of age, at increased 
risk of dementia along with, and often accompanied by, a range of chronic and complex health 
conditions were often described as a particular concern for clinical researchers. Combined with 
the challenges of regulation and the wider culture of ‘fear’ around research, clinicians, the 
gatekeepers to research recruitment, continued to feel actively ‘dis-incentivised’ from 
participating in research. This was an ongoing concern raised at the 2011 DeNDRoN North-East 
conference, where concern was raised about the lack of new clinicians coming forward to act as 
Principle Investigators (PI’s) to lead in research. 
 
The disincentives to engage with dementia research were not limited to practical, medical and 
regulatory concerns. The problems of dementia science were also located by research leaders in 
the historical and social legacy of the disease. Researchers suggested that working in the field of 
old age, had long failed to inspire the interest of the general public, the government and 
researchers themselves. One phrase used to describe this was that it was not a ‘sexy’ field of 
science. When asked to expand on this, researchers described the lack of discovery and 
innovation in the field. This was linked to a lack of resources and overall investment. Regulations 
were high, the patient population was medically and ethically complex, pharmaceutical 
companies were downgrading investment in the field. This was evidentially not an environment 
inspiring new researchers and clinicians to specialise in dementia science. In what would become 
a familiar comparison with cancer research, dementia researcher failure was compared 
unfavourably to the ‘breakthrough’ science and investment in oncological research. In short, 
work on dementia was not currently curative or disease modifying. It was therefore very much in 
the field of chronic disease with the emphasis on developing effective ways to managing 
symptoms. Along with the need for more basic science, this was viewed as having less imminent 
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opportunity for translatable success. This contrasted very much with the increasingly high profile 
discourse of a ‘cure’ for dementia which was embedded in the rhetoric of future prospects, and 
the radical changing infrastructure of the dementia research community 
 
 
Challenges in research organisation and infrastructure 
 
The strategies developed to address challenges to successful practice in dementia science and the 
talk of researchers, repeatedly returned to a cycle of complexity and stigma which needed to be 
met by collaboration to facilitate progress. However, increasing collaboration multiplies the 
potential complexity which has to be managed. I suggest that in trying to manage this cycle, the 
dementia research agenda increasingly stressed an evolving relationship between scientists, 
publics and patients. This demonstrates a fundamental theme in my research, that is, how the 
relationship between science and the social are becoming increasingly entangled. As the 
discussion below illustrates, enrolling differently positioned actors in the research process is part 
of an internal strategy of dementia science. 
We don’t link well enough, and this is not me saying that, this is industry. We don’t 
harness academia well enough. Academia just gets on with its own business and trials, 
the businesses of running trials is being left to the pharmaceutical industry, and that may 
be a mistake for many reasons. And partly that is because trials, and the process goes from 
a concept, to a proof of concept, to phase II where you see whether your drug is not only 
safe but that it has some effect. Then you go into this hugely expensive Phase III, where 
you have thousands of people on current phase III trials, sometimes 4000 across 
sometimes 60 countries, and you need to have more effective, more efficient studies, 
because you can’t do anything without big trials. So we need to make our trials more 
effective, go earlier, and we have to have the courage to see when something is not 
working either. We invest a lot in trials, and then we don’t want to believe our own 
results. So the results show this is not working, but we’ve got too much invested so we 
have to carry on 
Comment from Clinical Neurologist 




This comment, again displays a mixed set of feelings about the idea of developing the research 
community. Coming from a professor of clinical neurology this comment reflects the necessity 
and value of creating links across academia and industry and across nations to address the 
perceived weaknesses in current UK research. The language of efficiency and effect are very much 
the language of neoliberal economic foundations. However, this comment also reflects caution 
and unease. The economic nature of this necessary relationship means that ‘harnessing’ academia 
could lead it to be driven in directions which are not necessarily considered by academic and 
clinical research to be of scientific or patient benefit. This suggests academia needs to have the 
‘courage’ to put on the brakes when data shows that something is not working, and not pushing 
it forward because ‘investment’ is too far down the line. This reflects the ambivalence as well as 
the enthusiasm for forging new types of links in the research community. On the one hand, they 
are necessary, on the other, they do not come without ties and obligations which need to be 
reflexively understood and considered.  
 
Concerns about academic and industrial connections, were just one aspect of a more general 
concern about the nature and structure of relations in the dementia research community. A core 
concern of senior scientists was the lack of appropriate researchers and research skills. Research 
leaders perceived that there were too few new scientists with the complex collaborative and 
multidisciplinary skills required by dementia science. As I demonstrated in chapter two, cutting 
edge research into dementias increasingly required people who were able to work across skill 
boundaries in computing, medical physics, genetics, biochemistry and clinical domains. Those 
who possessed the range of skills required were at the top of their scientific fields. But the legacy 
of a lack of career opportunity and investment into dementias meant that these researchers were 
lost to other ‘more developed’ areas of science. Thus, another cycle occurs, in which lack of 
progress is related to a failure to accumulate people and skills, which in turn limits progress. The 
failure to attract researchers to dementia science was described in MRC Strategic Review a lack 
of ‘human capacity’ (2008: 11). 
 
The lack of ‘human capacity’ in dementia science, researchers argued, led to research groups 
being simply too small, and project funding periods too short, for groups to successfully 
coordinate the ‘critical mass’ of skills with the necessary continuity to make an ‘impact on the 
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complex disease pathways implicated in neurodegeneration’ (MRC 2008: 11-12). However, 
achieving a coherent and successful interdisciplinary research team was described at the NMR 
Centre as a fickle and challenging endeavour. As I discussed in chapter two, this required not 
only selecting people with the right combination of technical skills, but ensuring recruitment 
took into account the right personalities, and a common group identity in order to forge a 
successful team. This idea featured again in the MRC Review, ‘simply putting people together in 
the same building would not, in itself create the most productive environment, and the most 
successful examples of interdisciplinary working were led by individuals with the drive to create 
this environment’ (2008: 12). This relied upon what the director of the NMR Centre described 
to me as ‘research leaders’. These were senior clinicians and researchers who had the skills, the 
understanding and the contacts to engineer, facilitate and coordinate, ‘world class research’. This 
was both a technical, political and social role which enabled leaders to have influence across 
multiple disciplinary and social boundaries. This suggests an element of tacit knowledge and 
experience, beyond technical, scientific or clinical skill (c.f. Polanyi 1967). ‘Research leaders’ must 
have both the formal and informal understanding of relationships in the science infrastructure. 
A combination of people management skills as well as scientific reputation allows ‘research 
leaders’ to cross domains, in a way that would be unimaginable for a less experienced researcher. 
MRC Strategic Review described this as a need for ‘[H]igh quality group leaders’, who would 
‘naturally attract further talent into their departments to maintain research momentum’ (MRC 
2008: 11). This principle was succinctly described by a politician at the NIHR meeting in London 
in 2011, ‘quality attracts quality’.  
 
The challenges or barriers to successful research which these leaders must overcome, were 
identified at every level in the research process. From the scientists in the shared building, to 
national and international research structures. Infrastructural weaknesses at the national level, 
between researchers and NHS institutions were of particular concern. DeNDRoN was presented 
by the MRC as a critical boundary organisation which could coordinate and mediate between 
sites and between different levels in the community. This was part of a wider process of 
embedding research in both the clinical domain and at the clinical/public interface and key to 
addressing the burden of dementia research (MRC 2008: 14). To effect this requires training, 
education and awareness in the dementia field, not only for lay participants and the public, but 
for clinicians and basic researchers alike. If ‘research leaders’ were required to create the pathway, 
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research scientists and clinicians on the ground had be exposed to the concept of 
transdisciplinary collaboration early on, to develop the trust, confidence and awareness to move 
across boundaries with greater ease.  
 
Building the relationships of science meant not just improving the flow of actors across 
boundaries; it also required the flow of resources such as technology and data. This was 
particularly important for the most expensive areas of contemporary dementia science, such as 
the use of Positron Emission Tomography (PET) and stem cell work. To build a successful and 
robust research community it was essential to attract the financial and technological resources 
which could make this work possible (MRC 2009: 12). These ‘big science’ techniques again 
required a constructive relationship between industry and academia. Another ‘resource’ which 
needed to flow was data. Gathering cohorts for phase III trials required many participants. 
Facilitating and ‘harmonising’ multi-site, international collaborations was necessary to meet the 
data needs of complex late stage pharmaceutical and technological developments. Integration at 
the transnational level across academic and industrial sites, and the national level, across the 
NHS, would ensure the development of science which could translate from ‘bench to bedside’ 
(Report from the Ministerial Summit on Dementia Research 2009: 13). Thus DeNDRoN at the 
national level and INTERDEM at the European level, were key facilitators of flow of technical 
resources and methodological knowledge (Ibid: 18-19). The primary means of addressing barrier 
and burdens in research were by creating connectivity and flows. 
 
The burdens of dementia research 
 
In the extracts from policy reports and research meetings reported above there is a pervasive sense 
that dementia research is seen by researchers as a major problem area of science. As I have shown, 
there are many facets to this problem, which exist both as part of the construction of dementias 
as objects of research, and perceived ‘weaknesses’ in the existing structure and processes of UK 
neurodegenerative disease science. The efforts by researchers to understand these weaknesses 
show them to be acting in often overlapping capacities as scientists, clinicians, advocates and 
policy maker. Such efforts have led to a focus on two critical areas in this field of science: 
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redefining the disease as an object of research and developing the research community to act 
upon it.  
 
In the rhetoric underpinning dementia research, science is often portrayed as acting through 
flows: flows of people, knowledge, technology, funding, public and political support, participants 
and data. The narratives which develop suggest that these flows are impeded by barriers such as 
the stigma and complexity of the disease, the circumstances of the participants involved in 
research, and the organisational weaknesses that fail to make research possible. Such complexities 
demonstrate the entanglement of social and scientific challenges faced by researchers. Rather 
than being separate issues, researchers talk about the burdens of dementia in ways that capture 
the connectivity and complexity of these themes. For example, a lack of researchers working in 
the field would inevitably impact on the capacity to produce novel and successful 
experimentation, which would, in turn, affect research investment, confidence and the success 
of patient recruitment into trials.  
 
The idea of research failure or weakness implicit in these concerns was recurrent throughout my 
fieldwork. For example, in the Ministerial Summit on Dementias Research, the question: ‘What 
are the barriers to effective research on cure?’ was answered by a round table group, who in 
clustering their concerns identified both stigmatised perception and regulation as principle areas 
for action: 
 
 Public and professional attitudes 
A significant barrier was considered to be the attitudes and stigma attached to 
dementia, not only in relation to the wider public, but critically among many 
individuals in the health and social care environment. 
 Regulatory Delays 
The research environment in the UK was seen to be ‘regulatory heavy’, potentially 
stifling research development and innovation’. 
 




The language used here characterise the barriers to progress in dementia research as systemic 
rather than isolated flaws. Like the language of Alzheimer’s pathology, the burdens and tangled 
relationships of dementia dominated research talk. Here, burden is used to capture an inhibiting 
effect on the flow of knowledge, materials and investment around the research community. The 
content and rhetoric of scientific talk make an implicit connection between the social, scientific 
and biological problems of conditions which cause dementia. In particular, the biological themes 
of disease complexity, diagnostic limitation, cognitive degeneration, aging and chronic disease, 
are closely associated with the intractability of the social and organisational issues present for 
researchers. Thus, where research teams were ‘fragmented’, dementia diseases were ‘sporadic’ 
(MRC 2008). This demonstrates how the language of dementia and dementia science in policy 
constantly echo one another and draw attention to entanglement between cultural, social, 
biological and scientific ways of making sense of this group of conditions. 
 
When scientists describe dementia as a burden, I suggest, it is both part of the reality of dementia 
research as it is perceived, and at the same time part of a rhetorical process which serves to identify 
dementia research as a critical, imminent and uniquely problematic issue within biomedicine. In 
the process of prioritising dementia as a problem for research, it is made into a distinctly political 
and social problem, particularly relating to funding and participant recruitment. The language 
of dementia research also reflects Rabinow’s notion of biosociality, by demonstrating how the 
scientific framing of a condition is enmeshed in evolving forms of social interaction and 
identification (Rabinow 1996). Key in this regard are the way in which social attitudes to a disease 
associated with age and aging are embedded in and reproduce the social and economic structures 
which dominate UK society. The language which structures scientific knowledge and 
infrastructure in dementia research also reflects the challenging characteristics of long-term, 
chronic conditions which are less easily subject to scientific intervention. As such the burdens of 
dementia research illustrate issues in the social conceptualisation of physical and mental change 
over the life course and how science might intervene most appropriately and effectively around 
the co-produced category of dementia (Jasanoff 2004). The analysis in this chapter of the way 
burden is used has also illustrated the mutuality of government, public and scientist.  
 
In the next chapter, I turn from the language of burden to the imagery of risk. Risk imagery, I 
suggest, is being used to capture, externalise and address the problems described by dementia 
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scientists reported in this chapter. Specifically, I show how the scale and shape of the dementia 
risk are being developed to communicate research concerns to a wider audience. I pay particular 
attention to the way scientists, clinicians and advocates use language and imagery to create 
powerful rhetorics to convey both the scale of the ‘crisis’, and also suggest a sense of the proximity 
of the risk. This chapter will set the scene for the responses developed by scientists in their appeal 





Chapter 5 The rhetoric of risk: the construction of a 
persuasive crisis.  
 
Following the Ministerial Dementia Summit in 2009, a cross-parliamentary group, the 
Ministerial Action Group on Dementia Research was formed (MAGDR). The group’s aims were 
‘to increase the volume, quality and impact of dementia research’ (Great Britain, Department of 
Health, Ministerial Advisory Group on Dementia Research 2011). In order to achieve these goals 
MAGDR formed five sub-groups, chaired by leading clinicians who also held key organisational 
roles in government, academic and third sector organisations. The five sub groups were asked to 
focus on: the identification of priority topics for the research into care, cause, cure and 
prevention of dementia; guiding and securing funding; facilitating research; translating research 
into treatment and, finally, communication. The communication sub-group was designed 
specifically to identify: 
 
…ways of raising public awareness of, and support for, dementia research and 
increasing public engagement in dementia research, via recruitment to trials and 
other studies. 
 
(Great Britain, Department of Health, Ministerial Advisory Group on Dementia Research 
2009) 
 
This sub-group was chaired by members of the UK’s two main dementia charities: Rebecca Wood 
Chief Executive of ARUK, a specialist in charity management and strategy in the non-
governmental (NGO) sector, and Clive Ballard Director of Research for the Alzheimer’s Society 
and Professor of Old Age Psychiatry.31 In the Department of Health’s Dementia Information 
Portal, the implementation of a ‘dementia strategy’ is described as ‘Improving public and 
professional awareness and understanding of dementia’: 
 
Public and professional awareness and understanding of dementia needs to be 
improved and the stigma associated with it addressed. This objective should 
                                                 
31 Clive Ballard would step down from this role in early 2014, to focus on the development of a research group at 
UCL dedicated to the study of conditions related to age. 
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inform people of the benefits of timely diagnosis and care, promote the 
prevention of dementia and reduce social exclusion and discrimination. It should 
encourage behaviour change in terms of individuals seeking help and in the way 
professionals deliver services. 
(Great Britain, Department of Health, Dementia news information and 
conversations, 2011) 
 
What these strategies describe is a process in which public engagement is placed at the heart of 
an evolving dementia research community. As in other areas of biomedical advance, public 
engagement and communication are expected to play prominent roles across UK science policy. 
This is reflected in the MRC’s Strategic Plan 2009-2014 entitled ‘Research Changes Lives’ (MRC 
2009). This document identifies as one of its four strategic priorities the need for enhanced 
communication between ‘scientists, the public and policy makers’ in order to address public 
uncertainty and demonstrate accessibility, accountability and transparency (MRC 2009: 29). In 
identifying the future direction of research communication, the document pinpoints the 
importance of evidence-based research in the wider realm of decision-making: 
 
The challenge is to show the public that the funding we receive is well spent. We 
aim to make the MRC’s work more accessible to the public and policy-makers, 
demonstrating the value of our research and highlighting our achievements both 
nationally and internationally.  
 
• We will encourage and support more transparency in MRC decision-making.  
• We will improve MRC accountability by maintaining and enhancing the 
mechanisms we use for public involvement.  
• We aim to improve understanding of and stimulate support for medical research 
among the parliamentary and policy-making communities.  
• We will support the continuing need for evidence-based policy and decision-making.  
 
((my emphasis) MRC 2009: 29) 
 
The primary motivation for this approach to public engagement is one of fiscal accountability to 
the tax payer. However, underlying this fiscal accountability are more complex issues of creating 
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and maintaining trust, reputation and defining ‘good’ knowledge within both national and 
transnational contexts. The importance of scientific knowledge is presented not only as it impacts 
upon political decision-making on science, but on how evidence-based scientific knowledge 
should inform political decision-making more broadly. Thus, as the above quote illustrates, 
scientific accountability involves more than a simple economic connection between social, 
governmental and scientific organisations. The process of developing science depends on 
maintaining and strengthening relationships with public bodies, and the publics which they are 
influenced by. This requires scientists to translate and disseminate not only pure science but an 
understanding of the role and importance of research outside of the citadel. Without this activity 
it is unlikely that dementia science would become a national priority. 
 
In this chapter, I look at how scientists communicate the risks posed by dementia, and how this 
becomes part of the process of creating connections and relations with the public. This dialogue, 
beyond the scientific domain, in turn, shapes public and professional understandings of 
dementia conditions, and the changing nature of dementia science.  
‘The impending storm’: dementia & the language of urgency and 
emergency 
 
In the Headline Report eighteen months into the MAGDR project, the chair of the advisory 
group, Paul Burstow wrote: 
 
Dementia costs UK plc £23 billion a year. And this is just the economic cost; 
the real social cost, for the 820,000 people living with the condition and the 
many others whose lives it touches, is incalculable 
 
Dementia continues to pose many challenges - to scientists, policy-makers, 
and above all to those living with the condition and their carers. Left 
unaddressed, these costs will continue to grow. Leading scientists are already 
warning that the NHS will struggle to cope if the prevalence of dementia continues to 




((My emphasis) Burstow quoted in Great Britain, Department of Health, 
Ministerial Advisory Group on Dementia Research, 2011) 
 
Such policy and media reports illustrate an increasingly familiar epidemiological prediction of a 
growing number of people living with some form of dementia. Lock reflects upon how such 
powerful predictions, originating in the complex and long term calculations conducted in 
research become rapidly dislocated from the original statistical science which produced them 
(Lock 2013). Such calculations and numerical representations are reductive in that they take on 
a meme like quality, in order that they can be continually condensed. As such they become 
eminently reproducible slogans. This is reflected in the 2013 ‘1 in 3’ campaign in the UK. Here, 
complex calculations are translated into the punchy and powerful slogan which predicts that by 
2020 one in three people in the UK will be living with some form of dementia. Such formulations 
are intended to capture a sense of urgency and crisis.  
 
Bakhtin suggests that the language used to articulate our experience of the world not only 
represents but creates our reality (Cresswell & Baerveldt 2011). By taking a realist approach 
conversation and dialogue become a primary focus for analysis. So when listening to clinicians 
and researchers discuss the future of UK’s dementia research agenda at the joint NIHR and 
MAGDR meeting, it was notable that they talked of ‘reactive approaches to public health’, and 
described the dementia research field as ‘blowing up’. The delegate’s choice of expression was not 
merely indicative of, but actually part of the evolving shape of UK dementia research. They 
characterised the sense of enthusiasm and urgency, the explosive groundswell of public, scientific, 
commercial, academic and governmental attention driving an agenda committed to the 
diagnosis, treatment and care of people with dementia in the UK. Yet at the same time these 
phrases capture and communicate a tangible anxiety which underpin clinical research into 
neurodegenerative conditions. 
 
During January 2012, a spate of articles and media reports described the threat of dementia using 
the language of environmental disaster, likening the dementia risk to a ‘tidal wave’ approaching 
an aging population and threatening to overwhelm national resilience. In the face of such a 
catastrophe, scientific solutions are presented as the best hope of stemming the ‘tide’. Repeatedly, 
researchers at meetings would described the disparity between research funding in dementia 
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science in comparison with other illnesses which dominated public health expenditure. Again 
this is reflected by Paul Burstow who writes: 
 
Dementia costs the UK twice as much as cancer, three times as much as 
heart disease and four times as much as stroke - yet dementia research 
funding has not gone as far as these. 
(Burstow in DH, 2011) 
 
The risk and costs of dementia are a fundamental part of how these conditions are discussed. By 
looking at trends in the language and imagery chosen by researchers and research organisations 
to convey dementia risk, I demonstrate how they create a sense of scale and crisis at a national 
level. The framing used to describe the risks associated with dementia relate to the condition’s 
characteristics as chronic, progressive and, as yet, a poorly controlled group of diseases associated 
with aging. I consider how this dementia imagery compares with that used in two other key health 
research awareness campaigns: cancer and AIDS/HIV. I show how this comparison sheds further 
light on the particular way dementias are perceived. Cancer and AIDS/HIV research are 
examples where researcher advocacy has been used to create powerful health research campaigns, 
and strong disease and hence, biosocial identities. I show how the dementia research advocacy 
movement shares many similar characteristics, yet has developed its own distinctive use of 
metaphors in order to capture the disease entity. I then go on to show the different ways in which 
the scales dementia risk are being created. These scalar representations are used to construct the 
threat of dementia both as a large scale risk, and an immediate and personal crisis. This 
movement between scales demonstrates how the rhetoric of dementia research awareness is 
attempting to act on an ‘imagined’ public in increasingly sophisticated ways. 
Dementia as flood 
 
The ‘Later Life’ conference was organised for researchers and practitioners working in the field 
of gerontology. Opening the conference, Clive Ballard, Professor of Old Age Psychiatry and 
former head of research for the Alzheimer’s Society, described the growth in the prevalence of 
dementia disorders in the UK. He referred to fellow scientists and clinicians who had likened 
increasing dementia rates to an impending wave; a ‘grey tsunami’, threatening to overwhelm the 




He then qualified his use of the term ‘tsunami’, considering it in poor taste and depersonalising, 
an unsuitable way of describing the experience of people with dementia. But, he referenced it 
none-the-less, as he felt it fitted closely with the picture of personal, economic and social crisis he 
had derived from his experience as a clinician. Ballard reflected on the capacity of current health 
and social care services to treat and support older people with complex health needs, especially 
the long and severe cognitive decline associated with dementia conditions. He effectively 
combined personal stories with epidemiological forecasts of dementia diagnosis rates in the UK 
over the next decade. Appropriate or not, the imagery lingered; a great wave was heading 
destructively and inexorably in the UK’s direction. 
 
Ballard’s reference to the ‘grey tsunami’ refers to a relatively small but significant move amongst 
researchers internationally.  
Rising tide of late-life dementia is both a triumph of public health and an opportunity 
 
(Larsen & Langen 2008: 431)  
 
The Impending Storm: Addressing the Health Needs of Aging Populations 
 
The perfect storm is brewing. The proportion of the world’s population age 60 and older is 
projected to grow from 11% to 22% between the years 2000 and 2050, an absolute increase 
from 605 million to 2 billion people. Health systems across the globe are ill prepared to meet 
the needs of aging populations. The challenges are many. Underinvestment in prevention 




Will healthcare be drowned by the grey tsunami or sunk by the demographic iceberg? 
 
The devastating impact of population aging in the decades to come is becoming like the proverbial 
weather: everyone is talking about it but no one is doing anything about it. Predicted increases in demand 
for health and social care from 2010 to 2030 for people aged 65 and over in England and Wales 
include:  
 people with diabetes: up by over 45% 
 people with arthritis, coronary heart disease, stroke: each up by over 50% 
 people with dementia (moderate or severe cognitive impairment): up by over 80% to 1.96 
million 
 people with moderate or severe need for social care: up by 90% 
(Mander 2014: 8-10) 
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Articles with titles such as those above, were part of a significant move which introduced the 
language of tides, storms, waves, and tsunami’s to discussions of the risk posed by growing rates 
of dementias. Such language often relate dementia to its potential to overwhelm individual, 
familial, and community resilience and threatening the very foundations of the national health 
and social care infrastructure. As I discussed in chapter four, this threat relates to the 
identification in health economics of dementias as one of the most debilitating chronic 
conditions prevalent in the United Kingdom. Like heart disease, stroke, cancer and diabetes, 
dementia risk has been associated with age and lifestyle, and treatments currently involve long-
term management, rather than curative intervention. Combined with the personalisation of 
health and social care (HSC), which marks a strategic reassessment of the role and structure of 
state involvement in the funding and organisation of long term care, the threat of dementia is 
characterised as a ‘perfect storm’ threatening UK society. Writing in the British Medical Journal 
(BMJ) Chief Executive of the Carers Federation is quoted as raising concerns about the 
restructuring of funding in HSC: 
 
“Things are almost developing to the point of a ‘perfect storm’ for retraction of 
voluntary sector monies,” she said. “Across the country, funding of voluntary 
sector organisations had fallen by 40%” 
(White 2011: 342) 
These examples give the risk of dementia watery characteristics, and imply force of nature outside 
of human control. Interestingly, Ballard criticises the use of natural disaster imagery that he 
himself is using. Later in this chapter I examine criticism of the rhetorical shifts in researchers’ 
language when describing dementia. In this section, however, I focus on these emotive metaphors 
of tide and flood, and how they are used to characterise the challenge of dementia as a particular 
type of crisis. By using the language of watery natural disaster, dementias are located in a 
particular role in society. In the face of some impending storm, society and science may attempt 
to predict and prepare for the dementia deluge. It cannot, however, be prevented but must be 
‘weathered’ by means of a complex and coordinated scientific, social and political response. 
 
By rhetorically linking dementia with the destructive force of nature and natural disaster, research 
leaders such as Ballard affirm and construct the importance and scale of the dementia issue. A 
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risk of this magnitude would surely require a powerful coordinated response, and scientific and 
clinical research quickly rushes to fill the void that opens before the impending ‘tsunami’. The 
description of the scale of the dementia as a natural disaster can be linked to a process which has 
been taking place over the last decade in which significant chronic public health issues such as 
cancer and heart disease have increasingly adopted the language of the epidemic (Weiss 1997, 
Mandell & Green 2011, Zeilig 2013). The ‘perfect storm’, reflects the implications of this 
language. Like a storm, the epidemic is an unstoppable and uncontrollable force of nature, during 
which a ‘natural’ contagion rages out of control, challenging the best efforts of biomedicine in a 
heroic struggle. 
 
The language of the epidemic captures a sense of urgency and uncontrolled crisis. Whilst chronic 
conditions such as dementias, cancers, or heart disease do not involve contagious agents, 
increasingly in both science policy and media, the language and rhetoric of the epidemic is 
pervasive (Lock 2013). This rhetorical move conveys the considerable health challenge of chronic 
disease, that is, to convey the sheer numbers of people affected and the cost of the long-term 
treatment and care.  
 
Root metaphors of disease play a key role in the social study of biology and biomedicine (Gaines 
& Davis-Floyd 2004: 100). Analysis of discourse and rhetoric in the biomedical encounter has 
become increasingly important in the shift from mechanisation of the body and the patient-as-
object, towards the more humanistic conversation-oriented practitioner-patient relationship 
(Floyd & St John 1998, Kleinman 1988). With increasing emphasis on ‘Mode II’ science in 
science policy, the idea of relationality in biomedicine can be seen to extend to the research 
practice and policy and the shaping of disease construction and perception. Social research into 
disease experience and scientific discourse around the conditions HIV/AIDS and cancer have 
informed my interpretation of the scientific and public discourse emerging around dementia 
conditions (cf Sontag 1978, Martin 1994, Landesman, Ginzburg &Weiss 1985). In an analysis 
of the metaphors used in the description of cancers, for example, Sontag observes how both 
patients and clinicians describe the disease activity and process as ‘animalistic’. In her account, 
she notes that the word cancer is linked to the Greek karkinos and Latin cancer, meaning crab. 
Sontag also describes how cancer cells are referred to as ‘spreading’, ‘invading’, ‘attacking’, and 
‘eating’ (Sontag 1978: 10). In contrast, in the case of AIDS/HIV, researchers have identified how 
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scientific and lay descriptions tend to represent the condition as systemic and fluid, and capable 
of boundary crossing. Such language, as used by clinicians, patients and reflected in medical 
policy, convey connotations of pollution, deviance and decay, reflecting an implicit connection 
between the infectious agent and the social stigma associated with sexual and drug-taking 
practices implicated in the spread of HIV (Martin 1994, Sontag 1978, Epstein 1995, 1996, 2008). 
Such linguistic practices, which cross the boundary between public and scientific discourse 
reproduce underlying social attitudes and values in powerful ways. 
 
What then of the representations of dementia? The use of the watery images of tides and storms 
to represent dementia demonstrates two very different rhetorical modes. On the one hand, the 
storm, flood and tsunami present nature out of control, violent and threatening, crossing 
boundaries with destructive potential. On the other hand, the movement of the tides suggests a 
more rhythmic or cyclical process driven by nature, a process which is predictable, yet inexorable. 
These competing metaphors reflect a tension which exists in the scientific representation of 
dementias which I explore here in more detail.  
 
The storms of dementia are spoken of in research on a number of levels: in the pathology of 
dementia conditions, progressive neural death overwhelms the capacity of the cognitive function 
of the brain. As I explored in the previous chapter, scientists’ and clinicians’ are also acutely 
aware of the complex and destructive burden dementia places upon a person’s ability to function 
neurologically and consequently the impact of their condition on their personal and social 
worlds. Likewise, the activity of the storm or flood of dementia resonates with the expanding, 
invasive burdens which flow out from the pathology of the disease to engulf families, 
communities and nations, personally, socially and economically. Biomedical research is thus, in 
this metaphor set up to compete against the violence of a natural force. Framed as mobilising 
resistance to the encroaching effects of the disease processes, science is responsive to the threat 
of the storm, protecting society from and attempting to ameliorate the damage it inevitably leaves 
in its wake. The imagery of dementia is portrayed as a space of violence or conflict and the role 
of research is one of active protector. This is reflected in the description of pharmaceutical, 




Whilst the rhetoric of the tide shares some of the stormy connotations, it suggests a slightly 
different relationship between the nature of the disease and the role of science. Part of this 
rhetorical shift towards tides suggests the connection between dementia and ageing, and wider 
themes surrounding progressive, chronic, neurodegenerative conditions. On the one hand, age 
continues to be identified as the principle risk factor in the main dementia conditions, AD, VaD, 
DLB, and FTD. These affect approximately 5% of people over 65. This rate increases to 20% for 
those over 80 years of age (O’Brien 2005 &2006).32 Such epidemiological estimates, like the tides 
are expected to rise. In this metaphorical context, the disease process of dementia is associated 
with the unstoppable fact of aging. The research process has had to, in many ways, learn to adapt 
to and accommodate the realities of living with dementia. ‘Defeating dementia’ has required a 
research process which reflects greater understanding that participants are subject to a process of 
ebb and flow, good days and bad days, and a slow but inevitable disease progression. The 
responsive role of researcher in this context has a different orientation from that of heroic 
protector described above. The response is adaptive, reflexive in its preparation of long-term 
defences. This is reflected in the continuing emphasis amongst researchers on the gradual process 
of scientific discovery, and the continuing need for basic and observational research to 
understand the nature and processes involved in different dementia pathologies. This is not 
nature under scientific control, but science preparing long-term means of defending the 
boundaries of society against the more unforgiving and unrelenting processes of nature. Thus, 
the tide imagery also suggests an underlying anxiety for dementia research. If age is the primary 
risk factor in the most common dementia conditions, to what extent can science successfully act 
upon them? 
 
The processes of aging, however, are increasingly not beyond scientific attention and 
intervention. Research into cellular aging is a rapidly evolving field of science and a core focus 
in the MRC strategy (MRC 2008). As a result, whilst researchers may appear to be working with 
the current ‘tide’, research has already demonstrated its potential to intervene in the aging 
processes and perhaps reverse its natural course. This is recognised in the achievement of 
extended life expectancy itself (Kitwood quoted in AlumNews 2010). However, as the MAGDR 
                                                 
32 It is important to emphasise that whilst age is a primary risk factor, it is not an isolated one. Like many chronic 
conditions, in dementia increasing age is understood to part of a complex picture of multiple interacting risk factors 
including genetic and bio-psycho-social factors which vary between people. However, under emphasis on the factor 




report states, ‘the tide is turning’ (Great Britain, Department of Health, Ministerial Advisory 
Group on Dementia Research 2009: 1). Advances in fields such as metabolic aging, cellular 
degeneration, and stem cell research are seen to have novel potential to inform future 
intervention in degenerative conditions such as age related dementias. This ‘war on aging’, allows 
research to maintain its heroic and mobilising role in the construction of a fight against 
dementia, even in the face of the tide of an aging demographic and an intractable disease (Lock 
2013, Moreira & Bond 2008, Vincent, Bond & Tulle 2007). 
 
There are similarities in the representations of dementia and cancer as battlegrounds and 
conflicts in which the researcher joins the patient and the public in a common fight. However, 
there are interesting differences in the lines along which these battle lines are drawn, and how 
the combatants are represented. Whilst people living in remission with cancer, or HIV controlled 
by medication, may be described as ‘survivors’ who are ‘beating’ their conditions, in dementias 
there are no survivors. Prior to my period of research, representations of the image of the person 
diagnosed with dementia in science policy, engagement and advocacy tended to be highly passive. 
The person themselves was indeed often absent from the discourse taking place. It was extremely 
uncommon for the voice of a person with dementia to be heard directly. This was reflected in 
the dementia awareness campaigns at that time, which often presented the dementia through the 
voice of a proxy: a family member, a professional carer or a practitioner. This portrayal of 
dementia patients, as I return to later, has undergone a rapid shift since 2010. This decade has 
promoted the direct voice of the person with dementia more than ever before, albeit 
accompanied by family members in the background. However, up until this point, the person 
with dementia had been represented in a distinctly passive position relative to both the disease 
and the science involved.  
 
In spite of these attempts to remodel dementia engagement to emphasise an active relationship 
between patient-practitioner and patient-researcher, metaphors of ‘greying’, fading and dissolving 
continue to dominate dementia engagement practices. The Department of Health early dementia 
diagnosis leaflet and television campaign, created in association with the Alzheimer Society 
reflects the persistence of these associations. Narrated by a woman describing her father’s 
changing conditions, she describes her awareness that something was not ‘quite right’. With his 
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changing cognition, the image of the father slowly dissolves from the screen becoming washed 
out, grey and translucent: 
 
   
   
“This is my dad.” “He’d started to forget things. It 
couldn’t just have been old age.” 
“I tried to ignore the signs 
but it was getting worse.” 
 
Figure 13: National television campaign "This is my Dad" - Fading 
Great Britain, Department of Health. (2012) 
http://www.nhs.uk/dementia/Pages/dementia.aspx?WT.mc_id=91103 
 
As the daughter encourages her father to seek help from his GP, eventually receiving a diagnosis 
of early dementia and treatment for his condition, his image eventually gradually returns to full 
potency and their relationship is sustained (figure 14). This representation of dementia as 
blocking or breaking connections, becoming a barrier to social relations and functionality, 
resonates with the discussion of the language of the disease, and the problems identified in 
research practice discussed in the previous chapter. The accumulation of abnormal disease 
pathology blocking neuronal connections, leading to a progressive loss of cognitive function is 
mirrored in both the language and imagery used in the narrative of this advert. Again what 
dementia unmakes, the social ties which fade away, are, albeit temporarily, remade through the 
biomedical engagement. 
 
The risk of the untreated progression of dementia leading to the untimely dissolution of the 
person and their social ties, is linked to the rhetoric of loss and social death which tended to 
dominate dementia narratives in the twentieth century (Hughes 2011, Leibling & Cohen 2006). 
The concept of fading is linked to the discourse of the ‘greying’ of society. Using the image of 
the loss of hair pigmentation in later life, ‘greying’ has become extended to convey the changing 
demographic balance of age, and often carries connotations of a loss of social value and potency 
in later life (Kitwood 1997, Mclean 2007). In response, attempts have been made to remobilise 
the ‘grey’ concept as a political and economic identity (Hazan 1994, Higgs 1995). 
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“He was diagnosed with the 
early stages of dementia” 
“Spotting the signs early 
meant we could get the right 
treatment and support.” 
“And I’d have the Dad I know 
and love for a little longer.” 
 
Figure 14: National television campaign "This is my Dad" - Returning 
(Great Britain, Department of Health, 2012) 
http://www.nhs.uk/dementia/Pages/dementia.aspx?WT.mc_id=91103 
 
In spite of the active inference of the ‘grey’ movement as a political or economic force, defining 
older people as an underrepresented group, emphasises the sense of social disempowerment 
associated with later life. This narrative came under intense scrutiny in the eighties and nineties, 
as researchers began to address the contribution of disease rhetoric to the overall stigmatisation 
of conditions such as dementias (c.f. Bond, Coleman & Peace 1993, Kitwood 1997, Mclean 
2007). In dementia narratives, the image of the ‘quiet death’ or the ‘death of the self’, although 
challenged vociferously remains stubbornly persistent, continuing to appear in both social and 
scientific representation (Sweeting & Gilhooly 1997). At the Alzheimer’s disease International 
Conference, for example, a number of presentations focused on how internationally, the 
depiction of dementia in the media, fiction and reproduce rather than address the disease stigma 
(ADI 2012). Such stigma, it is suggested, has an ongoing impact, not only on the public but also 
on practitioner perceptions of dementia, which continue to affect willingness to engage with 
screening and early diagnosis of a dementia condition (Cartz Piver et al 2013).  
 
As I discussed at the start of this section, Clive Ballard simultaneous uses, yet criticises the 
concept of the dementia ‘tsunami’ to illustrate the struggle taking place to capture and enter into 
a discourse about dementia. This dual reading of the metaphors reveals dementia science as a 
site of continually emerging and socially reflexive questioning which is rapidly reshaping its 
practices. Science policy and engagement must capture interest across science, government and 
the general public. Thus researchers and advocates continually try to find ways to communicate 
their needs and concerns, in areas such as achieving funding, making an early diagnosis, or 
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successful recruitment to randomised control trials. Key to these endeavours is the process of 
imagining the character and interests of the ‘public’ and how the priorities of science might be 
made persuasive to them.  
 
However, as Sontag reflects upon in Illness as Metaphor (1978), whilst rhetorics are eminently 
powerful at communicating and disseminating social and biomedical characteristics of a disease, 
they also engage people in inadvertent and unwanted ways. People diagnosed with a condition 
such as dementia, can find themselves subject to labelling which they find unhelpful or damaging 
to their sense of self and identity. With the increasing power of patient advocacy groups, the 
rhetorics quickly become open to public critique. I experienced this at an Alzheimer’s Society 
research event where the use and connotations of words such as ‘carer’ and ‘challenge’ commonly 
used by practitioners, were debated by family members of those who had the condition. Some 
participants felt empowered and recognised for the hard work involved in ‘caring’, and their 
contribution as a ‘carer’. Others, disagreed, they felt the title diminished the personal and familial 
content of their relationship as ‘husband’ and ‘wife’, which could and should never be reduced 
to that of ‘carer’ which, for them, carried an entirely different set of expectations and 
responsibilities. For them, all kin should care but not all ‘carers’ are kin. This tension reflects an 
ongoing debate about the recognition – moral, economic and practical – of family members who 
are also carers for a relative with a chronic and long-term condition. It also illustrates the way 
that the language emerging at the interface of biomedical and pubic engagement with chronic 
conditions such as dementia, can carry conflicting implications. For example, one woman at the 
Alzheimer’s Society meeting in Birmingham in September of 2011, in a state of some distress, 
spoke of how being labelled as a ‘carer’ fundamentally threatened and undermined what she 
understood as the very nature of her relationship with her husband. 
 
In spite of these attempts to change how the problems of dementia are captured, metaphors of 
water and disconnection continue to dominate discourse used in science policy, engagement and 
advocacy. As I have discussed in the previous chapters, the precise causes and disease processes 
involved in dementia pathologies are highly complex and the understanding of their aetiologies 
is evolving rapidly. Thus, the mobile and fluid imagery of water acts as a useful means of engaging 
with a disease which is seen to be of imminent risk, and yet in a state of perpetual emergence. 
Having described the imagery used to convey the urgency of the threat of dementia, in the second 
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part of this chapter, I turn to the different techniques used by the main dementia research 
charities to capture and communicate the scale of risk to the public. 
Scales of risk 
 
Raising the public profile of dementia was seen as a fundamental means of mobilising and 
maintaining political and economic will to support a dedicated dementia research agenda. This 
agenda would enable solutions to be found to the problems posed by dementias and the need to 
develop more effective research-led solutions. In a society where multiple health concerns 
compete for public attention and are typically presented in terms of crisis and risk, how can 
dementia research enrol the public to its cause? In this section I reflect on the creative use of 
scalar imagery in public awareness campaigns to help raise funds and encourage early diagnosis 
and participation in research. The scales created appeal on the one hand to large-scale risk and 
use epidemiological-type data and predictions. On the other hand, great effort is made to also 
make that risk intimate and personal. The strategic movement between the global and the 
personal were central to efforts to enrol the public in the dementia research movement. Here I 
use extracts from documents, research meetings and health promotion materials to explore how 
these scales were created and used by those involved in constructing the dementia research 
agenda. In particular I use extracts from an ARUK animation which powerfully visualises these 
scales. 
 
One approach used to capture the urgency of dementia was to set the condition in relation to 
other key health crises. Comparisons of relative prevalence, cost, funding and research into other 
conditions, in particular cancer, became a familiar part of the rhetoric taking place at research 
meetings, in policy documents and public engagement materials. Drawing on epidemiological 
and health economists’ calculations of the ‘cost’ of disease, this clip from the ARUK animation, 
captures a financial and visual comparison between dementia, cancer and heart disease (figure 
16). Where cancer is a tower block, dementia is a skyscraper. Cancer and heart disease play a 
particularly prominent role in the public awareness of health. Diseases such as cancers are highly 
recognised and understood to seriously impact upon the person diagnosed with the condition. 
They also have a history of highly successful public engagement, awareness and fundraising 






Figure 15: -Statistics of scale for dementia 
Alzheimer's Research UK 
http://www.youtube.com/watch?v=PrVooMwg0LU&feature=youtu.be 
 
By setting up this comparison ARUK creates a scale of relative risk, suggesting that dementia 
should share this profile in the public imagination and that these conditions have a ‘cost’ which 
must be recognised. This ‘cost’ is then related to the relative funding of research in these areas, 
linking back to research scientists’ descriptions of a legacy of underfunding for their field of 
research. Like the image of people with dementia discussed earlier, dementia was seen to have 
been faded out into the background in terms of investment and interest. As shown in chapter 
two, scientists in this field have long felt that theirs is a ‘cinderella subject’ which never quite gets 
to go to the research ball. 
 
During the animation, different scales of text are used to highlight the comparative underfunding 
of dementia relative to its counterparts. This is in spite of the towering cost of dementia care 
demonstrated in the previous slides. Whilst the solitary dementia scientist shrinks into the 
background, the grey-coloured cancer scientists are present in number, dominating the screen 
and, by inference, national research funding. The simplicity of the animation captures a sense of 
the competition for resources between conditions. By highlighting the risks and costs of 
dementia to the UK economy, the resource emphasises the importance of directing a greater 
proportion of resources to meet the relatively cost of tackling dementia. The comparison between 
dementia and cancer research was a familiar one at the research events I attended. At a meeting 
organised by ARUK to encourage public engagement, four senior clinical researchers working 















Figure 16: Comparing scales of funding and resources 




David: So unlike cancer for example where we know possibly what the problem 
is, the uncontrolled division of cells, and we understand a lot more about the 
mechanisms that drive it. We still have a much poorer understanding of what 
drives those pathologies that are associated with AD which can be clearly more 
complex. I don’t know whether any of our other [pause] Roger [pause] do you 
want to say something? I had you filed away under good news but um (laughter).   
Roger: If we just think back to the early 1960s, those of you who were alive in the 
1960s, it was a time of great optimism. It was the time that we went to space and 
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it looked as if science could do almost anything. And at that time the US 
president set a target to beat cancer by 1970, we all thought wonderful we’ll have 
done it by 1970. And actually it didn’t happen, and this brings us to Jim’s point, 
it took 50 years of really hard work to understand the biology of cancers, and now 
we’re getting developments coming thick and fast. But we had that time of decade 
after decade of investment and research before we could do it. 
David: Ok so that’s one thing, 50 years and 12 times the budget to, you know, 
required to produce the affects that we need. So I’m also going to articulate a 
question that has already been asked by someone else this afternoon which is all 
the emphasis that we have heard today, as this is the theme of the meeting on 
prevention, on treatment of the disease, on understanding, we have heard, about 
seven years on the research of care. And yet for people on the front line, and I’m 
including professional carers as well as family carers, there are real, real issues. 
Why is it that research into care for people with dementia seems to be such a 
Cinderella subject in relation to all this hot stuff around molecular biology and 
so on? 
Extract from a ARUK Meeting 2012 
 
The comparison here between dementia and cancer research raises several interrelated themes: 
complexity, time, funding and success. The inference is that the growing effectiveness of cancer 
treatments are due to better understanding of the basic underlying biology involved. This is in 
contrast with dementia, where it is suggested the biology of the disease is more complex and less 
clearly understood. This lack of clarity is not only due to the complexity of the disease but the 
legacy of underfunding. The ‘successes’ of cancer research are due to an intensive long-term 
programme of research investment which has been lacking in dementia science. There is also the 
implication that the type of science is related to the measures of ‘success’. The first researcher 
asks why ‘hot’ bio-molecular science is prioritised over research into care? Care research, whilst 
addressing the ‘real’ needs of people and care-givers living everyday with dementia, is perceived 
to be left out in the cold when it comes to public and political attention. This raises an interesting 
issue about how researchers see themselves as viewed by the public when it comes to their 
attempts to counter risk. Biotechnological interventions are understood to have greater social 
and scientific value or ‘impact’, when compared to research on lifestyle and caring practices which 
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manage rather than resolve the problems of dementia. This bias is further reproduced in the 
ARUK animation in which the underfunding of research is represented by a white-coated figure 
gazing into a microscope, an image which suggests that dementia research success will lie in the 
realm of the laboratory. This also reflects dementia researchers’ own concerns about competing 
in the national health research market and begins to illustrate their anxieties about success and 
progress. Is research better represented as striving for a heroic response to the storm, or should 
it be a builder of more long-term tidal defences? 
 
Having established dementia on a level with competing risk between conditions, research 
engagement goes on to create a sense of scale. Clearly, every health concern must have its rhetoric 
of catastrophe in order to claim a place in the public’s attention and on the national funding 
agenda. In dementia, the catastrophe is often communicated in numbers, the figure most often 
repeated being that currently 820, 000 people are living with a form of dementia. Although 
numbers can be a powerful means of representing scale, research engagement and its use of 
media is going a step further in illustrating how abstract numbers relate to more tangible and 
familiar concepts. One method used to achieve this is relating numbers to images of space and 
place. Thus, the ARUK uses its animation to illustrate that this number of people is more than 
the population of some of the UK’s major cities, including the capitals of Wales and Northern 
Ireland (figure 17). Perception of the scale of dementia is shifted to a new realm with the 
suggestion that the number of people in the UK with dementia would be equivalent to the 
nation’s third largest city. All the while a contemplative rhythmic sound track plays in the 
background of the animation. This sound track, at once sorrowful yet rising in tone, intimates 
hope and possibility and is similar to a Cancer Research UK (CRUK) advertisement released in 
the same year. This advert makes a similar appeal for support and awareness. However, there the 
similarities end, and it becomes clear the ARUK and CRUK have adopted very different ‘brand 
identities’. The CRUK edits together the images of an invading black stain, which retreats with 
images of research and a description of success in research – once again a white-coated scientist 
peers down the microscope, representing the archetype of clinical research. This narrative sits in 
direct contrast to ARUK’s animation which explicitly focuses on the relative scale, impact, and 




Constructing the image of the risks and costs of dementia, could simply be read as realising the 
very real epidemiological gravity of the situation. However, this doesn’t pay attention to the level 








Figure 17: Relating scale of dementia to space and place 
Alzheimer's Research UK 
http://www.youtube.com/watch?v=PrVooMwg0LU&feature=youtu.be 
 
This is reflected in the ARUK’s most recent campaign to coincide with the 2014 World Cup. 
Described as raising awareness of the scale of dementia as a global problem, the organisation used 
its daily Facebook feed to post the flags of the matches taking place. Each nation is given its 
World Cup statistics and ranking, followed by the number of people estimated to be living with 
dementia. Using such a high-profile and popular sporting event which has been shown to cross 
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many social divides in term of public interest, is yet another example of a dementia research 
organisation working hard to find creative and timely ways to locate the disease at the very heart 




Figure 18: The dementia World Cup 




Time is another reoccurring feature of the attempt to convey the scale of the dementia problem 
and the urgency of the crisis. In one advert, the rhythm of music accompanies an image of a 
ticking clock, followed by the caption: ‘Every 3.2 minutes in the UK someone develops 
dementia’. How this has been calculated is unclear, but it creates a very real sense of the 
immediacy of the threat posed by the disease. The reference to an abstract ‘someone’ suggests 
                                                 
33In the comments a writer notes that the numbers of people with dementia seen in blue in the first slide aren’t very 
easy to read for her husband due the impact dementia on visual processing. ARUK immediately responds, thanking 
the commentator, and true to their word, the following day the offending colour has been made higher contrast 
and more visible. 
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that anyone might find themselves dealing with the impact of dementia diagnosis at any time. 







Figure 19: Relating risk of dementia to the passage of time 
Alzheimer's Research UK - Dementia Statistics 
http://www.youtube.com/watch?v=PrVooMwg0LU&feature=youtu.be 
 
Sharing the burden in a community of risk 
The use of the techniques such as the World Cup and the comparison of dementia rates to the 
populations of different cities, appeals to culturally embedded senses of space, place and identity. 
The threat of dementia is not remote, it is within one’s local town, it is ‘here’. Thus, research 
and disease engagement takes the ‘inchoate’ and intangible ‘public’, and constructs a defined 
notion of locality and community (Fernandez 1986, Carrithers 2008, 2009). Dementia, its risk 
and its threat, are then located within these communities, the disease is given place and identity 
within society. This is part of a distinct process in research engagement which makes dementias 
not only a range of conditions which threaten society on a grand scale, but a threat of the most 
local, personal and intimate kind. This is reflected in the changing dementia rhetoric which 
moves dementia research from using the register of national and social responsibility to using 
that of representations which appeal to the idea of the risk to the person, the individual and in 
particular, the family. This is reflected in the Department of Health national television campaign 
who’s images I referred to earlier. I now look at the script in more details:  
 
This is my dad.  
He'd started to forget things. It couldn't just have been old age. I tried to ignore 
the signs but it was getting worse. I was afraid I was losing him. I was worried 
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about bringing it up. But he agreed to see the doctor. He was diagnosed with the 
early stages of dementia.  
Spotting the signs early meant we could get the right treatment and support. And 
I'd have the dad I know and love for a little longer.  
If you're worried about someone's memory, talk to them about visiting their 
doctor. 
Transcript of ‘this is my dad’, National television campaign  
(Great Britain, Department of Health, 2012) 
http://www.nhs.uk/dementia/Pages/dementia.aspx?WT.mc_id=91103 
 
The simplicity of the emphasis ‘this is my dad’, takes dementia from the national scale of risk, to 
the intimacy of the bond of a primary kin relationships. The language of ‘forgetting’, ‘loss’ and 
‘worry’ are combined with the fading image of the father, to suggest how dementia presents a 
threat to that relationship. The final line ‘I'd have the dad I know and love for a little longer’ 
appeals to emotive cultural values associated with primary kin relations in the UK (Strathern 
1992a). Again the narrative emphasises that biomedicine holds the potential to sustain these 
valuable social ties, which the onset of dementia threatens to disrupt and dissolve. 
 
The personalisation of the risk of dementia, and the need for research and awareness was evident 
at research meetings. One neurologist opened a meeting by commenting that because of his age, 
he was now in a higher risk group for developing one of the dementias. This was said in part 
jokingly, but at the same time he conveyed that his interest in achieving effective treatment had 
taken on a new dimension and urgency. Researchers also referred to their own experience as 
carers as well as practitioners. This long quote from a gerontologist reflects the emotive role of 
kinship in experiencing dementia. She also questions why dementia advocacy, in comparison to 
other disease movements such as autism awareness, seems less able to engage with those 
diagnosed with the condition and their families and carers.34 
 
Well actually I was at [pause] yesterday I was attending an international meeting 
on autism which is quite irrelevant to what I am doing today, and I was surprised 
                                                 
34 The gerontologist is a non-native speaker. As a result there are a number of non-standard phrases. I have 
transcribed the discussion verbatim, because her comment showed her struggling emotionally and intellectually with 
the difficulties faced by both scientists and members of the public in the face of conditions which cause dementia. 
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at who was attending the meeting, it was attended by service users, by families 
and professionals, and these service users, autism and Asperger’s, were obviously 
there, but also these families brought their children who were very vocal, and I 
was quite impressed actually with the strength of their interest, and in all fairness 
when I was thinking about these people and the cases that were raised in the 
1960s, that with all the advances, with all the services which had been developed, 
and people were still unhappy about the services that were available and the 
service providers ….  If only 1% of what you’ve got in dementia, and I think we’ve 
just got to keep pushing for, and I don’t think there are many service users here 
in this room, yes? We are all professionals, or we have somebody who we care for, 
or we are worried as well about our own memories. But I think that we need to 
engage with the service users, and there is a lot of what we could hear, what we 
can learn from them. 
First of all I would like to stress that people with dementia know exactly what is 
happening to them, there is personality, there is wishes which have to be heard. 
The Mental Capacity Act (2005) actually allows for their wishes to be heard even 
when they are declared mentally incapable. But even people with severe dementia 
know what they are saying, they have got lucid moments. When my mother –in-
law smiles at me and says ‘you’re a lovely girl’, I know she really means what she 
says, when she says to her son ‘I love you’ I know how touched he is. So I can 
understand, you know, why people disengage because we know that people with 
dementia seem to disappear, but they are not, they know exactly what is 
happening to them, and we need to get the community to know that, to know 
exactly what people in the field of mental health learn, how to listen to their 
needs. So I think you know there are some fields like cancer, but there are some 
other fields where not a lot of investment has been put, but great achievements 
have been made. 
 
Amongst researchers narration of their involvement in, and concern for, a more effective 
dementia research agenda, there was a great willingness to share personal experiences caring for 
and kinship ties with people experiencing dementia. During public presentations or when I 
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discussed perceptions of the issues in dementia research with professional researchers, clinicians 
and advocates, it was not uncommon for them to express their concerns in terms of their kin 
relations. They were expressing an understanding of not just the politics or the science of 
dementia, but a personal understanding of the impact of the disease. Even in talking about 
dementia research, the condition could be made to cross the boundaries of the scientific, the 
social and the personal. Contrasting with the pathology of dementia which is seen as breaking 
connections, there was a conscious effort within the research community to make connections. 
Great effort was put into making dementia escape purely biomedical accounts and cross 
metaphorical boundaries.  
 
The stigma of dementia was constructed as the prime barrier to the effective connection of 
publics and scientists with dementia research. As discussed in previous chapters, the intensity of 
this stigma is located in complex beliefs including: the inevitability of age-linked 
neurodegenerative conditions, the personal and social devastation of these syndromes and the 
lack of treatments currently available. This stigma is seen as one reason dementia discussion into 
the background. This has been reflected in the early phases of dementia awareness campaigns in 
which the voice of people with dementia were often represented by those involved in their care 
or treatment. The reluctance to include people with dementia in campaigns has been linked to 
concerns about protecting vulnerable people from a kind of instrumentalisation. The reluctance 
was particularly apparent given that up to the 2000s people tended to be diagnosed later in the 
progress of their condition, when their capacity to give independent informed consent had 
already severely deteriorated. Advocacy inclusion was made even more sensitive in the context of 
marketing campaigns where the boundaries between social, medical and commercial interests 
are blurred. The movement towards first person representations of dementia is therefore located 
in the more recent shift interrelated biomedical and social ideas about dementia. Increased rates 
of early diagnosis have combined with refined understanding of capacity to consent, signalled by 
a shift from a paternalistic and protective NHS to a relational patient-centred discourse. Changes 
in disability politics which pushed for improved understanding and inclusion practices also 
impacted this shift (Barnes, Mercer & Shakespeare 1999, Shakespeare 2006). These factors are 
in turn related to the increasing availability, permeation and normalisation of media, and 
particularly social media, as a tool of personal and social identity making. As such, social media 
become a core tool in crossing political-biomedical-commercial boundaries. Thus, whilst the 
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representations of carers and practitioners remain intensely valuable in the dementia movement, 
a critical part of de-stigmatising and bringing dementia out of the shadows has been the growing 
inclusion of people with dementia themselves. In recent campaigns we see the image and hear 
the voice of people diagnosed with dementia in highly polished marketing campaigns which 
maximise the scale and impact of dementia awareness campaigns. These factors are illustrated by 
in the ‘Mind Over Matter’ exhibition. In this event people who wanted to donate their brain to 
dementia research, after their death were asked volunteer to be photographed and to describe 
their motivations for participating in dementia research. This included people who remained 




Figure 20: Mind Over Matter 
‘Memory, Forgetting, Brain Donation and the Search for Cures for Dementia’ (Parry & Dabrowska 2011). 
http://www.mindovermatterproject.co.uk/donors.html 
 
Sponsored by the Wellcome Trust, this event aimed to challenge the boundaries surrounding 
both dementia and the protective anonymity of organ donation in the UK. The simple and 
elegant portraits of participants in the ‘Brains for dementia’ scheme are accompanied by 
biographies of the participant’s lives. These biographies describe the participant’s individual 
motivations for becoming involved in dementia research through brain donation.  
 
During the same period, in 2011, the Alzheimer’s Society launched a series of films and adverts, 
in collaboration with the NHS and the organisation ‘Social Care’. These adverts are linked to 
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the Alzheimer’s Society website, and through key social media websites to the Alzheimer’s 
Society’s dedicated channel on the ‘YouTube’ website. The Society has a dedicated You Tube 
channel, which acts as a repository for an array of audio-visual content developed and 
disseminated by the Society. In the ‘I have dementia’ campaign, the scene begins with the camera 
drawing in close to focus on the face of a woman. Standing alone, at the centre of the frame the 
woman introduces herself and says “I have dementia”. Focusing on her voice, the woman gives 
a first-person description of dementia. This stands in marked contrast to the more familiar 
collective representations of person and carer used in dementia advocacy media. The camera 
slowly moves away from the figure, who is shown standing isolated on a grey background, 










It’s caused by Alzheimer’s 





and sometimes I repeat myself. 
It can happen to anybody and I 




But be patient with me and 






If everyone understands the 
condition more, and helps out 
I can still do many of the 








Figure 21: “I have dementia I also have a life” Campaign,  
Alzheimer’s Society (2013) 
http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=2092 
 
Gently the camera tracks back to the face of the woman who says, ‘I have dementia, but I also 
have a life’. After watching this advert, the website provides an immediate link to an 




Ira: The only thing you focus on in this commercial is the person. 
Jackie: It gets across the message that people generally back off because they don’t 
understand dementia so we wanted to just mimic that with the camera move. 
Ira: You maybe start by shying away from them but you end up as you understand 
the condition more and then more move back in and appreciate it more. I think. 
Jackie: By stripping everything around them away you become less judgmental, 
so you don’t judge so much who they are by their environment 
 




The distancing motion of the camera is used to illustrate the perceived stigma, lack of 
understanding and fear which leads to social withdrawal from open discussion and recognition 
of dementia. The visual rhetoric attempts to persuasively re-engage the audience with the 
personal identity and life of the participant, albeit accompanied by the moving shadow of 
dementia. This reflects the personhood and person-centred-care approach which has gained 
increasing prominence in gerontological studies since the late 1990s (Kitwood 1997, Dewing 
2008). 
 
The growing visibility of UK organisations focusing on disease advocacy and research 
engagement is part of a wider global trend (Epstein 2008). Hypermedia, that is, forms of media 
which utilise multiple, interconnected modes of virtual and ‘real world’ communication 
technologies, play an increasingly sophisticated role in locating and connecting disease awareness 
in the public domain (Diebert 2013, c.f. Wellman & Haythornthwaite 2008). It is debatable to 
what extent these are precisely ‘new’ forms of communication (Wilson & Peterson 2002). Here, 
the aspect of hypermedia I wish to highlight is its role in creating connections between the public 
and clinical trials. Hypermedia provides novel means of bridging the domains of science, 
government and public. For instance, through the ARUK website, I can connect directly with 
people experiencing dementia from my living room; take a virtual tour of a laboratory; see which 
research studies are now recruiting; view step by step the discussions taking place about dementia 
research at the G8 Summit and so forth. Hypermedia provides a constantly developing tool in 
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the process of making campaigns for dementia awareness and research engagement. Such 
techniques enable dementia research to permeate the social, scientific and political landscape in 
new and unexpected ways.  
 
Along with these powerful communication technologies, a central technique has been the use of 
high profile political, media and arts figures to spread awareness and develop the profile of 
dementia research. One prominent figure in this move is the author Sir Terry Pratchett, who has 
been diagnosed with posterior-cortical atrophy. He described his thoughts on dementia and 
dementia research in a blog for the ARUK website: 
 
If there is indeed an emerging sense – finally – that we’ve stopped pussy footing 
around dementia and can now bear to utter its name, we nevertheless find a cloud 
of unknowing persists. People read, watch and hear more about it than ever 
before. They know it’s out there. They know it will claim more of us as we 
continue to age. They fear it.  
 
‘Sir Terry Pratchett – Dementia blog, what’s the point of it all’, ARUK (2013) 
http://www.dementiablog.org/terry-pratchett-on-dementia/ 
 
Celebrity involvement has become a key way in ensuring the public ‘know it’s [dementia] out 
there’. Singers, actors, presenters and politicians, who often describe their involvement within 
the context of familial care can caring relationships, have become an integral part of the process 
of conveying both the scale and intimacy of the dementia crisis. The celebrity voice has the power 
to reach across social boundaries, to engage through media which permeate our everyday lives. 
Their prominent role within the global economy also enables them to access and cross political 
and economic boundaries as lobbyists, fundraisers and advocates. Celebrities thus become 
powerful tools or conduits for both the dissemination and construction of dementia awareness 
on a global scale. This is a scale which the majority of scientists, carers, patients or advocates have 
neither ready nor independent access to. The celebrity aura with its grounding in fashion and 
popular culture provides a very particular kind of access to the public imagination when 
popularising dementia awareness. Their familiarity, their pervasive and recognisable presence in 
our lives and our homes, also imbues their role with a sense of proximity and intimacy. Our 
familiarity with them, and their descriptions of personal and familial experiences of are brought 
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together to reinforce the familiarity and immediacy of dementia as a political cause. Such 
narratives play an important role in locating dementia conditions within our sense of community.  
 
The recent Dementia Friends campaign, developed by the Alzheimer’s Society and Public Health 
England, demonstrates the massive scale and complexity of the media strategies being developed 
in dementia awareness. The Friends campaign aims to increase local awareness of the issues and 
impact of living with dementia, so that people with dementia-related conditions can receive 
greater support within their communities. Anne, a retired nurse and a person diagnosed with 
early-stage dementia, fronts the campaign. We see her speaking about her diagnosis and asking 
for support for the Friends organisation. At this point, a sequence of images are shown of singers, 
actors, authors and presenters singing the Beatles’ 1967 song, ‘A little help with my friends’. 
Televised during prime-time viewing on national channels and through YouTube, the advert has 
embedded interactive features. Using the ‘red button’ on a remote control, the film can be 
stopped at any point. Clicking on different faces opens up short clips of one of the celebrities or 
Anne herself describing their involvement in the advert, their experiences of dementia and their 






“Click here to 
become a Dementia 
Friend and find out 
how you can find 
ways of helping 
people like me” 
 
 
Figure 22: “I get by with a little help with my friend”. Public Health England (2014) 
http://www.youtube.com/watch?v=LfrnWrpPq54 
 
This advert brings together multiple techniques: the first person representation of dementia, 
media and hypermedia communication, and celebrity advocacy. This demonstrates the 
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increasingly creative efforts collaborations between government and third-sector organisations to 
bring awareness of dementia into the public arena. 
Creating research responsibility 
 
Having consider the techniques and rhetoric used to create the scale and intimacy of the 
dementia crisis in the UK, in conclusion to this chapter, I consider in what ways the idea of 
community is being used in strategic development of dementia research. The strategy of bringing 
dementia awareness and support into everyday life and creating the sense of a dementia-aware 
society are visible in the narratives created around public participation in dementia research. 
Importantly, this participation includes the public not only as supporters, advocates or 
fundraisers for dementia research, but as potential recruits into research, tissue donation and 
clinical trials. Being part of an aware community ‘at risk’ from dementia, engages the public to 
be part of the solution. Increasingly, engagement with dementia emphasises that the solution to 
this crisis lies in biomedical research and its promise for future treatments. At a research 
engagement meeting, during a discussion of research needs and aims, one neurologist 
emphasised that research requires not only funding, but people to be prepared to participate as 
research subjects. Research requires not only people who are known to have a neurodegenerative 
condition causing dementia, but also healthy participants to help researchers understand the 
processes of ‘normal’ aging, as well as dementia pathologies. The neurologist made this appeal 
to the audience of scientists and public participants: 
 
We clearly need people living with dementia to agree to donate their 
brains, but we also need people, and this is where you can help. 
 
Quote from a neurologist at the Alzheimer Society Research Network 
Meeting 2012. 
 
As a result the dementia research community is continually being extended. As the above quote 
suggests, even without a family history or experience of dementia, healthy members of the ‘public’ 
are all potential participants. UK citizens are thus framed as experiencing the social and 
economic impact of living in an aging society, and becoming increasingly tied into the dementia 
research network. Increasingly at risk from developing a dementia condition, the rhetoric implies 
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that the public are both invested in, and share responsibility for, working towards a solution. 
With the simple use of a personal pronoun, ‘publics’ are no longer an inchoate and intangible 
‘other’ somehow to be accessed or acted upon by science. The public is made into participants, 
and critically those participants are personalised. As with the portrayal of people living with 
dementia in the media, research participants are being continually made into ‘I’, ‘we’, ‘you’ and 
‘me’ (Carrithers 2008).  
 
The personalisation of dementia research participants is reflected in a DeNDRoN engagement 
poster. A young woman in a white coat bends attentively over a coloured petri dish, pipette in 
hand, microscope at the ready, surrounded by the immaculate, brightly lit white surfaces and 




“Defeating dementia - our brains would be nothing without yours” 
Figure 23: Our brains Campaign, ARUK 
Observed during a research meeting. 
 
Here the brain comes to represents more than simply its physical matter. It is made into a 
representation of the skill and potential of the scientific community. The ‘public’, as supporters, 
funders, research participants and tissue donors, are framed as essential collaborators and 
combatants in defeating dementia. The rhetoric harnesses the idea of communal responsibility 
and the critical co-dependence of science and society. The ‘labour’ of research participation 




Chapter 6 Making and breaking connections in dementia 
research. 
 
In the previous chapter I focused on strategies used to communicate the perceived crisis of 
dementia. Using examples from some of the prominent dementia research and engagement 
campaigns, I argued that rhetorical language and imagery are used to create mobile and fluid 
scales of risk in a concerted effort to place dementia and its clinical research at the centre of the 
public imagination. This is achieved by moving between the macro-scale, using population levels 
of predicted numbers of the growth in dementia diagnoses which bombard the observer by the 
sheer scale of the number of people at risk, and at the intimate scale of personal, familial and 
community experience. The intimate scale draws on familiar social signifiers such as locality, 
sport and celebrity. I ended by showing how the language and imagery of community are 
extending into the narrative of dementia research. Increasingly, engagement practices are being 
used to frame public involvement in clinical research as a relationship. This is a relationship 
which has mobilised a mutual social and scientific investment in, and responsibility to, the 
collective battle against dementia. 
 
In this chapter I look at the rhetoric of research and engagement practices which are providing 
momentum for the restructuring of social and scientific perceptions of, and relations with, 
dementia and clinical research in the UK. In the first half of this chapter I discuss how research 
is challenging connections between age and dementias. I link challenge to research which is 
attempting to reshape social perceptions of age and aging more broadly. I look at how this is 
taking place in developing the market identity of older people, constructing them as valued actors 
in the development and consumption of goods. I then look at how this model of public 
involvement has been extended to clinical research, through the development of Public, Patient 
Involvement (PPI) initiative, considering the implications for clinicians and researchers. This 
demonstrates the close strategic relationship between researchers, clinicians, advocacy groups and 
government in the UK.  
 
Whilst the storms and scales of the previous chapter are highly effective at conveying the urgency 
of the research agenda; risk can be itself a problematic strategy. Risk rhetoric has the potential to 
reinforce old stigmas and create new ones. The emergence of a new type of research community 
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has led researchers and advocates to employ a number of strategies to frame social relations with 
biomedical research. In the second half of this chapter I look at how highly sophisticated and 
creative engagement practices use a variety of social imagery to construct the public’s relationship 
with dementia research. I focus on three examples, research participation as: a gift, as an act of 
altruism and/or as a social contract. What results is a balancing act between risk and hope, fear 
and trust. The narrative of dementia research is characterise by perpetual attempts to balance one 
rhetorical push with that of another. These competing rhetorics create an interface at which the 
dementia researcher community is evolving to be resilient, flexible and responsive. However, 
these relationships are not without their limits. This chapter concludes with a discussion of the 
limits of rhetoric, introducing how a research community remains a site of anxiety and 
contradiction for scientists in the field. 
 
Breaking connections: Restructuring relations with dementia 
 
In developing public awareness and involvement in dementia, research and advocacy groups have 
become very aware of the stigmas associated with dementia. As explored in chapter two, these 
associations are long in the making and are deeply embedded in social and historical perceptions 
of what dementias are and what they do. Stigma was perceived within policy as a core barrier to 
be overcome. Attempts to understand and counteract stigma have resulted in a process whereby 
some connections have been made increasingly visible in order to break them. The two 
associations I found were most often addressed in research policy and practices are two of the 
now familiar interconnected themes in this thesis: changing perceptions of age and aging, and 
changing perceptions of dementia as a group of conditions. In this section I look in more depth 
at the research initiatives which have attempted to challenge and restructure these core themes.  
 
This is not normal aging 
 
‘Dementia affects over 750,000 people in the UK. It is not a disease in its own 
right and it is not a natural part of ageing. It is an umbrella term that describes a 






Figure 24: "What is Dementia?"  
(Alzheimer's Society 2011) 
https://www.youtube.com/watch?v=2mRbQCDeJAc 
 
Conceptualising dementia as ‘not normal aging’, is an important part of the process of 
restructuring the association between dementia and age, and reshaping how the public and non-
specialist clinicians engage with these conditions. In an Alzheimer’s Society information film 
accessible via their website and streamed through YouTube, Anne Colbert, the Society’s Acting 
Research Communications Officer, describes the key facts about dementias. She emphasises both 
that dementia is not a disease in and of its own right, and that at the same time it is not a ‘natural’ 
part of the aging process either. This is a key statement which was repeatedly emphasised in the 
public awareness material from the main dementia charities and at public engagement and 
research events. It performs a number of key functions. It embodies the disease process as an 
external invader; ‘it’ is not natural, it should not be there. Corbett emphasises that whilst 
‘dementia’ is caused by a range of different disease processes, and is not, in itself, a disease 
category, the pathologies that cause the symptoms of dementia are tangible, and can be targeted 
by scientific research and intervention. This demonstrates the shifting tension which exists 
between defining and categorising dementia as a disease concept which can be used in raising 
awareness and promoting research on the one hand and, on the other, capturing the identity of 
this group of disorders. Corbett’s description highlights the diffuse complexity which makes the 
contemporary use of the term ‘dementia’ biomedically unsatisfactory. 
 
This dissatisfaction is linked to a second function of the phrase ‘this is not normal aging’. The 
strong association between age and the most common forms of dementias is inescapable but 
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problematic. Researchers are concerned that if ‘dementia’ is seen as an inevitable consequence 
of aging, it becomes naturalised and unassailable. As has been discussed already, such an 
approach has the potential to further stigmatise these conditions, increasing reluctance to receive 
or give diagnoses, and to marginalise dementias a valid focus for research. However, the principle 
narrative of the imminent crisis is that of the increased scale of prevalence due to an aging 
population. Thus the ‘war on dementia’, can also be seen to take place at the level of a rhetorical 
struggle between the need to ‘de-naturalise’ dementias and reconstruct the disease entity, and 
simultaneously ‘normalise’ these conditions, to make them a higher profile and accepted field 
for research support and recruitment. This tension is suggested in the image work taking place 




Figure 25: "Defining Dementia" 
Alzheimer's Society http://www.alzheimers.org.uk/infographic 
In ‘defining dementia’, the text 
emphasises again that dementia 
itself is not a disease. The text is 
enclosed in and surrounded by 
unspecified cell-like structures. 
The different coloured cells 
might stand for the 
biomolecular structures involved 
in healthy brain activity, or the 
‘unnatural’ cell structures which 
mark the pathogenisis of disease, 
blocking and damaging neural 
connections. 
 
These attempts to break the negative association between age and dementias are part of a process 
of creating biomedically ‘good’ and pragmatically ‘useful’ definitions of dementia conditions. 
This is part of an intensive effort by researchers in tandem with what Epstein has described as 
para-political advocacy organisations, to ‘rewrite the story of dementia’ (Epstein 2008). These 
efforts generate a vast array of images, narratives and metaphors, which sometimes work in 
synergy and sometimes conflict. This reflects the underpinning uncertainties and contradictions 






In reconfiguring dementias as disease entities, the connection with age remains a thorny issue. 
How can research reshape this association without further stigmatising age or undermining the 
importance of it as a significant factor in the increasing prevalence of this group of conditions? 
How can age be made a positive tool in the research endeavour? This complex challenge has led 
to a particularly interesting, collective research response in the North-East. The Changing Age 
campaign launched in 2010 was developed by Newcastle University and marks a collaboration 
between local government councils across the North-East. The university committed itself, across 
disciplines and departments, to becoming a ‘world-leading centre of for aging research’ 
(University of Newcastle 2012). The Chair of the North-East Councils described their 
involvement: 
 
We are proud to support this Charter and to play our part in achieving its aims 
in every community we serve. Whilst we recognise that there will be challenges, 
there will also be opportunities to be grasped as councils take forward their 
increasingly important role in supporting everyone, regardless of age, to live 
healthy, safe, active and positive lives. 
 
Counsellor Paul Watson Chair, Association of the North-East Councils 





The Charter emphasizes the idea of community, and the importance of the relationship between 
people in the region and the work of local researchers at the university. The Institute of Health 
and Aging was a dominant partner in this collective. As the title states, the campaign is a bold 
attempt at social engineering; to change perceptions and associations with age. At the heart of 
this initiative is a challenge to the association of aging, and more specifically old age as a social 
and personal ‘burden’. This is reflected in this quote from Professor Tom Kirkwood, Director of 




Too often, public and political debate has focused on population ageing as a 
negative issue, a ‘burden’ to be managed. The campaign we are launching today 
seeks to change this, recognising the tremendously positive contributions that an 
ageing population has on society, and encouraging a profound change in attitudes 
to ageing, informed by facts and not by outdated misconceptions. 
 




The breaking of the association between aging and burdens, and the reframing of age as 
‘tremendously positive’ and full of ‘opportunities’ ties this initiative to the wider rhetoric of the 
politics of aging. As the main image used to present the Charter emphasises, an explicit attempt 
is made to draw a connection between the politics of age and the politics of race:  
Figure 26: The North East Charter for Changing Age.  
Campaign leaflet provided at the Later Life Conference, London (2013) 
The inference is that, just as the acceptance of racial diversity and tolerance are signifiers of a 
‘modern’ and ‘moral’ democratic society, so age should hold an equivalent moral and political 
status. By making this explicit, the Charter attempts to challenge the deeply embedded negative 
associations of age which are often perpetuated in everyday public and political discourse. This 







the social and political agenda. Interestingly, science is placed outside this issue, capable of acting 
upon, but not itself implicated in, the reification of social relations with age.  
 
Biomedicine and science have played an important role in increasing quality of health over the 
life-course, and thus, the extension of the human life-span. Increasing longevity is hailed as ‘one 
of humanity’s greatest achievements’ (quoted in AlumNews 2010). This creates both a positive 
perspective on age and contributes to the heroic identity of biomedical research. As the Charter 
states: ‘(I)llness and death have been postponed through centuries of scientific research, ingenuity 
and perseverance’ (2012). The emphasis is on life as valuable, and therefore more life is more 
valuable. Aging is thus framed as a cumulatively positive process, a resource to be valued, rather 
than a value stripping, degenerative ‘burden’. 
 
The economics of later life 
 
Part of the value of aging is located in its economic value and the potential created by longer 
lives. Extending the life-span is framed very clearly in the Charter in terms of the neoliberal 
economy, as an ‘economic good’: 
 
Longevity has made, and continues to make, an enormously positive contribution 
to our economy. Older people are contributors and consumers of products and 
services, adding substantially to economic growth  
 




At the Later Life Conference I attended in London in January 2013, the main emphasis of 
speakers was on research into the development of better provision and delivery of services, goods 
and infrastructural resources for older people. These services address not only the provision of 
health care, but assisted living technologies, legal and financial services, and ‘life-style’ products 
targeted at people over the age of sixty-five years. Thus, the needs of a growing older population 
are framed as having the potential to expand and grow the national economy. One presentation 
from a researcher working with the Rowntree Foundation on equity release, acknowledged the 
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need for a dramatic restructuring of the pension system. This is supported by the Charter which 
suggests that the age demographic and nature of later life has changed to such a degree that age-
based exclusory practices which restrict access to work, education and social activities need to be 
radically reformed. Exclusion is seen as wasting the mental capacity of a growing sector of society. 
 
By attempting to break the association between aging and burden, this research inspired initiative 
tries to shape later life as a positive time of national social and economic potential. This is 
demonstrated in the headline: ‘great changes=great opportunities’ (North-east Charter for 
Changing Age, 2012). This is in extreme contrast to the rhetoric of storms and tidal waves 
discussed in the previous chapter. Here research is riding the storm, turning the challenge of 
aging to the benefit of the nation. As a result, the attempt to make people over the age of sixty-
five and research priority takes place within a community which defines value in terms of and 
individual’s capacity for consumption and productivity. As extracts from the promotional 
material provided at the Later Life conference and the Changing Age for Business programme 
demonstrate (see figures 27 and 28), it is clear that a particular type of old age is being marketed, 
one which is active, healthy and prosperous.  
 
The aim of the images above are to challenge the assumption that old age means ‘passivity and 
dependence’ (Kirkwood quoted in AlumNews, 2010). However, such images may bare little 
resemblance to the lifestyle experienced by large sections of UK society across their life course, 
and the reality for many older people. For many over the age of sixty-five, subsisting on a state 
pension, living with long-term, chronic conditions such as dementia which require high levels of 
costly personal care and support, the reality of old age and its challenges cannot be ignored.35 
This may explain why the ‘burden’ of old age, remains such an intransigent image; aging can be 
hard. Indeed, on one level it is the burden experienced by older people that leads to growth in 
the market in health and social care, which is being used to construct their value. Rather than a 
shift in social attitudes to old age, this movement can be read as a revolution in which aging 
reproduces rather than alters the dominant socio-political and economic framework.  
 
                                                 
35 The basic average state pension was calculated as £118 per week in 2011-2012, rising to £124 in 2012-2013 






Figure 27: Living North (2011) 
Part of the promotional material handed out at the Later Life Conference,  





Figure 28: “Changing Age for Business” 
Later Life Conference, London, January 31 2013 
 
However, it could also be argued that the Charter is making pragmatic use of the dominant 
political economic framework in order to effect social change. Are researchers simply making 
best use of the strategic and rhetorical connections available to address a critical and urgent issues 
of social need? Furthermore, we might ask, given the entanglement of the market in society, 
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whether a market-oriented approach does not indeed present the best means of acquiring the 
momentum needed to effect social change for older people who currently experience 
marginalisation? 
 
It’s a very difficult environment at the moment. There are huge cuts taking place 
across social care, but at the same time we’re very aware of the aging population, 
it really is a perfect storm. There is minimal marketing focus aimed at the over 
fifties, and very little understanding of what the over fifties want and need. Ideally 
we would want to resist the notion of grouping, and emphasise the individual. 
But we have to work with functional definitions. Newcastle has taken on the role 
of getting aging and dementia research recognised worldwide. In 2009 we received 
the Queen’s Award, that project was really a result of more than thirty-year’s work. 
Now we want to build a societal theme around aging by pooling our research 
resources. The Campus for Aging and Vitality combines research with retail. It 
helps develop business start-ups, and provides access to research for new 
businesses. My vision for that is that this becomes the new Silicon Valley for aging. 
The engine that drives that research is the Charter for Changing Age. We aim to 
break down the barriers around age inclusion by getting companies involved in 
marketing to the changing demographic, overturning marketing prejudice. 
Newcastle University has excellent ties and access to older people’s groups. 
Particularly there is a need for research into home living and enabling people to 
maintain a positive quality of life. There is a great need for collaboration in this 
space; ensuring researchers and business are in communication. The Institute of 
Aging and Health and VOICE North [Valuing Our Intellectual Capital and 
Experience] have been very important organisations. Medicine is core to this, but 
then again the pharmaceutical companies and the life sciences organisations are 
central to this also. 
 
Extract from field notes taken during a contribution by a researcher at a 
roundtable discussion on Changing Age for Business 




As the field note above suggests, for researchers, the move to ‘change age’ should not be simply 
critiqued as a cynical or naïve exploitation of old age. Those working within the research systems 
are aware of this potential reading, and they are prepared to engage with it. As a result, during 
discussions, researchers often went to lengths to emphasize the sincerity and earnestness of their 
efforts to change how older people are involved in society and in the structure of research by 
using the prevailing political-economic framework. By breaking the connection of the ‘burden’ 
of age, new connections are forged which value the knowledge older people. By working with 
older people, researchers benefit from their knowledge and understanding to improve product 
designs. Although at times this narrative runs close to the boundary of representing older people 
as a resource for more effective marketing rather than knowledge collaborators in the process of 
design.  
  
An example of how this engagement of older people has been effective can be seen in the ‘The 
Bench’ research project. A case-study from this project was used by researchers to demonstrate 
how public participation and inclusion could effectively be integrated alongside collaborative 
connections across research, business, design and manufacturing (see figure 29). The case-study 
was cleverly chosen as it showed how a simple, common place object such as a bench, could be 
problematic for older people in unexpected ways. The involvement of members of older people 
through VOICE North, provided essential knowledge for the design of improved public seating, 
not only for older people, but as a basic design improvement for wider society. One researcher 
involved in this project described the design process, and how it informed design and 
manufacture:  
 
Participants described that some materials such as stainless steel, were cold and 
uncomfortable to sit on, particularly when joint pain and mobility were issues. 
Slick shiny surfaces, such as plastic, favoured for aesthetic, durability and cleaning 
purposes were hard to grip. This made it difficult for a person to use their arms 
to help themselves to lower and raise themselves out of seats. The height of seating 
was often low, and the proportion of seats shallow. Many seats now are designed 
without backs or arms. This required a person to sit unsupported and made 
public seating difficult to get into or out of. For those with vision or cognition 
problems the low contrast colour of commonly used materials made seating 
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difficult to see and frightening to negotiate. Seating was also not designed for 
sitting, but for keeping people moving. In order to feel comfortable and safe 
moving about public spaces participants reported they needed to be able to take 
a break, but existing seating provided little relief. There was also nowhere to safely 
place a bag of shopping or a walking aid in clear sight, and this could be a source 
of anxiety as a stick, for instance, might fall over, be difficult to retrieve from the 
ground, be forgotten or stolen. It was also common for seating to have no flat 
surfaces to lean on or place a drink. For a person using a walking aid, or requiring 
both hands to safely lower themselves into a seat, this made it practically 
impossible to engage in the simple act of sitting on a bench to have a cup of tea. 
 
The design combines ergonomic features with aesthetic design and looks little 
different from seating one can find anywhere in public spaces in the UK. However 
listening closely to the feedback of participants, the backs are higher and seats 
curved to facilitate comfort and movement. Seating spaces were clearly 
demarcated by arms, which had high contrast rubber moulded handles designed 
for high visibility and grip. These made seats more usable, provided effective 
support for sitting or standing. The handle design also allowed belongings to be 
placed securely in front of a person. This was an example of good inclusive design, 
not just for older people, but generally advantageous. 
 
Extract from my field notes at the Later Life Conference, London 31st January 2013. 
 
The researchers emphasised that the benefit of ‘The Bench’ project was not limited to those 
involved in the project who might find the seat better for them. The emphasis is on the benefits 
of this knowledge exchange for all society. In emphasising the knowledge of older people it does 
not isolate them as a special group, but acknowledges them as collaborators in the making of an 
age-friendly environment. This collaboration extends to the companies in the North East who 
became involved in a range of design-project, to benefit from insightful designs and their market 
potential. This inclusive role in research and design has been particularly successful in the field 








Figure 29: The bench case study. 
Changing Age for Business. Later Life conference, 31st January 2013 
 
Remaking connections: Imagining ‘publics’, ‘participants’ and 
‘collaborators’ 
 
When developing technologies of assistance, design can directly incorporate feedback from 
members of the public, to produce goods, services and materials which have direct benefits for 
people’s lives. This strategy appears to reinforce the response-mode of research, that is, the For 
Patient Benefit model which dominates the NIHR. However, how far is it possible for this model 
to be extended into clinical research, and how is this shaping the relationship between research 
and the public? This question was partially answered in a discussion of Public and Patient 




Research Manager:  As partners and collaborators they’ve been really effective. 
This year we’ve had the first real push with the dementia themed call. PPI has 
helped researchers; it’s helped them make successful grant applications. Having 
them involved as co-applicants or through steering groups has definitely been 
useful. 
 
Me: Why do you think that involvement has been effective? 
 
Research Manager:  How has it been effective? Well I don’t know. If you want 
proof, well we can’t really say what difference it’s actually made. At the least it’s 
not doing any harm. For researchers and scientists I think it depends. Initially I 
think there was a delay in how it was perceived. At first it was seen as another 
‘tick-box’ criteria. But I think that depends on the researcher and their 
relationship with the research network. Some totally do believe in it. One or two 
people I’ve spoken with have told me it’s really changed how they think about 
their studies. But, then, being a PPI coordinator you’re talking to the converted. 
Other researchers just really don’t think it’s very helpful. But it’s difficult for the 
researchers. They have to avoid just instrumentalising the participants, just 
getting their data so they can publish. The pressure to recruit can overwhelm you.  
 
But there has been a change in researchers, in their perspective, in their work and 
in the law. When I started running studies, patient participation wasn’t all that 
common. I was surprised by the high-level focus. I was surprised to see it time and 
time again. It’s the last bullet point of the whole executive summary. As long as 
that drive continues, PPI will be part of it. If it attracts a sufficient amount of 
business and studies [pregnant pause]. 
 
Me: You sound like you might feel a bit cynical about it? 
 
Research Manager:  I was cynical. I thought it was a political stunt. But then 
it’s been retained. It’s making a difference to research proposals and it’s making 
a difference to their success. PPI is a time consuming process. It takes up a lot of 
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resources, but I would say it’s worth it. At a local level there’s no doubt it has 
helped. It’s offering people an opportunity to be part of the processes, and lots of 
people are taking that opportunity. 
 
I mean it is a political agenda. It is a cynical way of keeping people engaged. But 
PPI, I really enjoy it and I believe volunteers believe in it. They get something out 
of it. 
  
I run training sessions on getting feedback. I’m always surprised by how many 
people come back. I think first and foremost it’s a very positive thing. At the same 
time I do see it as a sophisticated marketing approach. But that’s not really a 
problem; I mean it’s all a social good. My thought process is that at some level, 
we need to be offering something at some level. But I think some researchers are 
embarrassed by the process. I think half of people struggle with the approach. 
  
I mean, from the perspective of the volunteer, the public, they are on a mission. 
What they are going through is life-changing. They are constantly trying to make 
sense of it, to turn a negative into a positive by talking with and teaching others. 
They come out of it with something a bit more positive. It’s kind of the personal 
benefit of a tragedy that can’t be escaped. 
 
I jump at the chance to talk, to interview, to do questionnaires. People need to 
talk, to rationalise and get things off their chest.  
 
Me: Would you want to take part in a trial? 
 
Research Manager: In trials? I think it depends on the situation. Taking part 
in the trial … there’s the whole placebo effect. I guess I don’t want to think about 
it. I wouldn’t want to think about a situation of degeneration and death; I mean 
there’s such a lack of understanding about dementia and mental health. I have a 
friend, he was a clinician who developed MCI (mild cognitive impairment), his 
wife is now his carer. I was talking to him on the phone and he sounded fine. 
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You know he was high-achieving, really career-driven. But then a couple of times 
we met and he was really struggling. It was incredible, it was so real. 
 
Extract from an interview with a research manager 2011 
 
This dual view of public involvement was further evidenced in government health policy 
literature: 
 
Direct involvement of the public in research, both as research participants and 
more actively in the processes of planning and commissioning of research and in 
the effective translation of its message … Such messages should utilise new 
media/social networking and professional communications expertise and be 
carefully targeted. 
  
Ministerial Advisory Group on Dementia Research: Headline Report 
 June 2011: 9-10. 
 
The work of PPI attempts to find new ways of forging connections and relationships between 
‘publics’ and researchers. PPI is, broadly speaking, about making and sustaining the connections 
which give members of the public and patients a stake in an emerging dementia research agenda. 
As the above interview with a research manager illustrates, these connections can be viewed in a 
variety of ways. These reveal the multiple ways in which scientists imagine the ‘public’ and 
understand their role in, and relationship with, science.  
 
On the one hand, PPI marks a change in the practice of science at the legal and bureaucratic 
level of the state. As has already been discussed in the UK context, PPI has been enshrined in 
clinical research through the gatekeeping role of the NHS R&D and REC processes. The REC 
application requires researchers to substantively demonstrate how they have, or intend to, 
include public and patient participants in the planning and development of research protocols. 
Perhaps, just as importantly, if public participants were not included, a researcher may be asked 
to explain and justify why this is the case. The REC process thus becomes impossible to negotiate 
without acknowledging the role of the ‘public’. The necessity of this process fuels the greater 
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interdependence between researchers and interstitial groups such as DeNDRoN, and 
parapolitical organisations such as the Alzheimer’s Society and Alzheimer’s Research UK who 
often broker access to existing public and patient groups.  
 
PPI has also become increasingly integral to the high priority concern around the process of 
recruitment for clinical research. Engaging with PPI in project development, facilitated 
registration on the UK’s Clinical Research Network Portfolio (UKCRNP) which records every 
NHS approved clinical project. Being part of the UKCRN Portfolio facilitated access to the 
Recruitment and Feasibility Tools (RAFT) developed by DeNDRoN to identify potential 
problems in a project and address them early on (Great Britain, Department of Health, 
Ministerial Advisory Group on Dementia Research 2011). DeNDRoN could then support 
researchers negotiating access to tissue samples and aid in the process of recruitment, through 
the newly developed and growing neurodegenerative disease register. The regional groups at 
DeNDRoN were working hard to strengthen ties with local PCTs, through which clinicians were 
encouraged to ask patients to join the register early in the process of diagnosis with dementia. 
The register enabled researchers to access patient data and contact information for people with 
a specific form of dementia who had already had an opportunity to consider research 
involvement and expressed a willingness to participate. Access to the UKCRN was possible 
through the Alzheimer’s Society website. The advocacy charity thereby became a means of 
enabling an interested person to become a potential research participant, or collaborate in PPI 
in future research projects. As this description shows the combination of changes in research 
legislature with the development in the research infrastructure and collaboration with patient 
advocacy groups created a highly entangled set of strategic connections to facilitate access to 
people and data. PPI can therefore, on one level, be viewed as a tool of research, a means of 
negotiating existing research bureaucracies, achieving recruitment needs and accessing tissue and 
bodies for research. In this sense, PPI is a political and strategic act carried out in order to 
maximise the scientific-good and in which the public, although engaged, remain secondary to the 
primary goal of extending the scientific agenda around dementia. However, for some, PPI was a 
further unwelcome extension of bureaucracy into research practice. It was seen as a time- and 
resource- consuming political act which detracted from the actual process of research, conflicting 




For other researchers, the presence of lay people in decision-making panels on project funding 
and research priorities was more than a passive distraction. Their contribution had the potential 
to actively threaten the integrity of the scientific process. Following the ‘deficit model’, some 
researchers felt public participants lacked the knowledge about science to give an informed 
opinion about research design, particular in relation to basic science (cf Bucchi & Neresini 2007, 
2010). PPI groups were understood by its detractors to be primarily interested in outcome-based 
research and principally the development of treatment which would directly benefit recipients. 
In this framework, the public are perceived by researchers to be acting as ‘future users’ and 
‘consumers’ of the products of research (Lezaun & Soneryd 2007, Mohr 2011, Thorpe & 
Gregory 2011). For some researchers, this approach generated anxiety that PPI had the potential 
to drive science in directions which might not benefit the wider dementia research agenda. The 
concern is that limited scientific understanding is not simply a deficit but actually a question of 
whether publics reason in the same way as scientists. Does the reasoning of public and patient 
participants fail to embrace to the same objectives as the scientific agenda? However, constructing 
the public as consumers of clinical research aligns more closely with the response-mode science 
apparent in the Changing Age for Businesses model. Here, the involvement of patients and the 
public becomes part of the process of marketing research to the public. In short, PPI creates a 
market for science that the user can invest in.  
 
In this section I have described the tension that exists when PPI is incorporated into attempts to 
extend knowledge about dementias. Critics see PPI as driven by the commercialisation of science 
and therefore a threat to scientific integrity. Advocates do not see PPI in terms of producers and 
consumers, but as a way of enlisting collaborators or ‘co-applicants’ into clinical trials. The role 
of publics and patients is presented as making the science both more successful and more socially 
robust, thereby becoming both a scientific and social ‘good’. This presents a scientific 
understanding of public involvement which contains what Irwin describes as ‘tensions, shifts in 
emphasis and partial contradictions’ (Irwin 2006: 301).  In the next sections, I explore how the 
quest for public involvement draws on rhetorics of gift exchange and mutual interest in an 
attempt to give the public a sense of integration in the dementia research community.  In contrast 
to rhetorics around risk and adverse events described in the previous chapter, this approach to 
ageing and dementia effects a kind of normalisation of dementia. Dementia becomes a 
manageable and targetable condition one that medicine and research can act upon it - part of 
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everyday life in a re-configured version of what it is to age well in contemporary society. This is 
achieved through an engagement process which attempts to form new kinds of social contracts 
between science and society. 
 
Dementia engagement and science as a social good. 
 
In attempts to embed and normalise dementia and dementia research within UK society, what I 
observed was not simply researchers having to spend more time engaging publics and participants 
but also experimenting with different styles and media of communication in order to create new 
forms of intimacy between scientists and their publics.  In this section I describe: 1.) the pervasive 
and everyday nature of such engagement strategies, 2.) how engagement images are used to 
capture ideas of hope, potential and community and 3.) how this has become the basis for 
thinking about science as a social good in contemporary society. I then conclude by suggesting 
that, whilst rhetorics are immensely powerful and useful in this social-scientific contract, they are 
continually under tension in dementia research from the anxieties which result from this 
relationship. 




Figure 30: Alzheimer's 
Society pin 
On a Friday afternoon I went to my local bank to conduct a 
transaction. By the cashier was an Alzheimer’s Society campaign 
stand. For the donation of a pound you could be supporting 
research to help understand the ‘cause, cure, care and prevention 
of dementias’. I gave a pound and in return I received the small 
blue and silver, tear-shaped pin pictured above. Later I would visit 
the cash machine outside a Tesco store, which announced the 
organisation’s commitment to the Alzheimer’s Society, and how I 
could use my transaction to donate money to help support the 
future of dementia research.  
 
Having donated to the Society I became the recipient of regular postal updates on their research 
and their on-going campaigns. These told me not only how to support the Society, but how the 
financial donations might be used within the research process. Explicit links were continually 
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made between support for dementia awareness and support for research into conditions which 
caused dementia. In regional events such as The Alzheimer’s Roadshow, the Alzheimer’s Society 
and Tesco collaborated to bring regional researchers together with local people and ‘potential 





Figure 31: Alzheimer's Society fundraising for clinical trials 
 
As part of my ethnographic engagement with the dementia research community I also earlier that 
week, ‘liked’ the Alzheimer’s Society and ARUK on Facebook. As a result most days my ‘wall’ 
provided regular updated posts on campaigns and fundraising events, research developments, or 
the opportunity to listen to podcasts of people’s experiences of dementia. I listened to a celebrity 
ambassador describe her experience of the mood swings and personality changes which 
accompanied her mother’s development of fronto-temporal dementia. Creating such daily 
pockets of dementia awareness result in what Amit and Rapport have called, ‘mundane daily 
opportunities for consociation’ (2002: 4-5). In other words, there is a pervasive and low-level 
exposure to the national dementia strategy whose evolution I have described in the earlier parts 
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of this thesis. Encounters in one’s local bank, on public transport or in the supermarket, are part 
of a highly coordinated strategy to respond to what the Prime-Minister’s office has described as 
‘the dementia challenge’, that is, part of a programme which aims to make the UK a ‘dementia 
friendly society’ and a world leader in research. 
 
Brains are good to think with: connections of potential, hope and futurity  
 
In their efforts to bring the public into the research network by means of the everyday, 
researchers used an intriguing degree of creativity. ‘Lion’s Face’ a nationally performed opera was 
based on the experiences of researchers and people with dementia (figure 32).  
 
 
Figure 32: Promotional banner for the Lion's Face opera 
Northern Stage (May 2010). 
 
During its performance at the Northern Stage, DeNDRoN North-East helped to coordinate an 
exhibition in the café of MRI and cellular brain images (figure 33). A 2010 funds and awareness-
raising project around brain injury associated with Bristol University’s Clinical Research Imaging 
Centre, invited people to, quite literally, knit their own neurons for an exhibition.  At each of 
these events, what is clear that centre stage is the increasingly iconic and readily available image 
of human brain matter.  
 
Having talked with researchers about their use of imaging techniques in the laboratory, I was 
intrigued at how these highly complex and sometimes contested forms of imaging were being 
used to facilitate researcher-public interactions. In a crude play on Lévi-Strauss’ (1964) famous 
dictum, we might ask why are ‘brains are good to think with’? By this, I do not only mean that 
we think with our brains, but that the image of the brain functions metaphorically and 
metonymically in dementia engagement. It becomes a way of representing patient and research 
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communities, as well as enabling them to talk to and connect with one another. In short, as Joyce 
observes through an exploration of brain MRI, the brain is a powerful, fluid and pervasive symbol 







Figure 33: DeNDRoN “Brain Arcane” Exhibition.  
Northern Stage (May 2010). 
 
The use of readily recognisable images of the brain draws attention to the innovative potential 
and authority of contemporary biosciences and biomedicine. Such neuro-images signify the 
capacity of science to exteriorise that most complex of organs, the brain. This is an organ which, 
as I examined in the second chapter, has become increasingly associated with the nature of being 
human, and the makeup of the person. The image of the brain is associated with intelligence, 
personhood, and the not-yet understood potential of the brain/mind. The complexity of the 
brain is also part of the stigma and fear related to dementia conditions, which are portrayed as 
an ultimate threat to the personal, social and biological lives of those affected. Like biological 
images of the gamete or the dividing embryo, images of the brain, uncoupled from the body and 
made visible by science, carry this message (cf Franklin & Roberts 2006, Franklin & Ragone 
1998). In this case of dementia research engagement, whether such images are scientific, 
animated, stylised or even knitted, these associations connect different worlds in order to fashion 
a research community.  
 
This image-work aligns varied representations of the brain with the immense possibility of 
cutting-edge science. Indeed, such is the power and intrigue captured by these representations 
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that a successful strategy for recruiting people to trials has involved offering participants a copy 
of their brain scan to take home. The power of the image is linked back to the power of the 
appearance of objectivity which is contained by the visual in scientific communication, the idea 
that ‘seeing is believing’ (Daston & Galison 1992, Delahanty 2010). Thus, during a presentation 
to the Alzheimer’s Society’s ‘Friends of Research’, a researcher gave an account of the benefits of 
structured behavioural interventions for people with early stage dementia. She focused on the 
interventions and their effect on the quality of life and on the cognitive scores such as 
participants MMSE. At the heart of her presentation were a series of functional brain scan 
images. In the presentation the researcher paused: 
 
Well I don’t understand the science, you’d have to ask the medical physics people 
on the team, but this shows us that for a number of people brain activation 
improved following people’s participation in the trial, which shows us good 
evidence that the intervention worked. 
 
Both the researcher and the audience were required to have faith that the brain images supported 
the behavioural and patient-reported data the researcher described. The images were presented 
as confirmation that there had been an empirical and observable change in brain activity which 
confirmed what the people who took part in the trial reported and demonstrated in their 
behaviour: lower depression, higher levels of functionality, and improved scores on cognitive 
tests. She herself was not a specialist in brain imaging and therefore could not give a detailed 
interpretation of what the images showed. However, the bright blue, yellow and red shapes on 
the scans, were used to support the inferences she made from the measures she felt comfortable 
explaining. The images were not therefore, in this context data, rather they had become a means 
for the researcher to bridge the complexity of neurobiology and neural-plasticity and brain 
functionality in a talk to a non-specialist audience. The researcher did not need to explain how 
the image demonstrated changes in function, or how benefit was calculated across the group. 
What the images achieved was to reinforce and make concrete the core message: The 
intervention was validated by an objective and technological eye, and therefore had potential as 




What is pertinent here is the extent to which brain images seem to capture the imagination of 
scientists, funders and ‘publics’ alike, and become a shared totem in ‘defeating dementia’. They 
feature in photographic and brain image data exhibitions, in operatic events celebrating 
dementia research, in working with local dementia patients and regional ‘heroes’ to raise funds 
for new imaging equipment. Sometimes poignant, sometimes flamboyant, the visual element of 
brain-imaging and memory lent themselves to creative cultural representations which could 
permeate across social domains, forging relationships with the public as potential future research 
participants. 
 
Thus images of the brain, become what Star describes as a boundary object (Star 1989, 2011). 
Boundary objects do not merely denote objects which are open to plural interpretations and 
flexible associations, although these are essential traits. Rather, such images enable researchers 
and publics to co-ordinate their efforts, even though they are working with different kinds of 
knowledge interests in and understandings of dementias. The knowledge being negotiated might 
be between differently situated participants in the research process, a patient with direct and 
specific experience of the impact of dementia on their life, a researcher concerned with 
recruitment and retention rates, or a policy maker trying to define priorities for future science. 
Brain images can therefore be seen to mediate complex collaboration networks in dementia 
science. Such images have different meaning and utility for different actors at different levels and 
across different contexts.  
 
A key aspect of this capacity for multi-layered, multi-scale definitions is that it can contain the 
idea of the future potential of research. The future capacity of science is a key part of the public 
engagement rhetorics which surround dementia research. This is reflected in the Alzheimer’s 
Society material in figure 34. Here the images of blue and white pill capsules, the colours 
favoured by the society, are used as a representation of this future ‘treatment’. What that 
treatment may be, and in what manner it could be physically delivered to the patient are 
unknown. The image of the ‘pill’ here, like images of the brain, is again used to cross boundaries, 







Figure 34: Marketing a cure: the ‘pill’ as a representation of hope. 
 
The image of the pill neither asks nor requires explanation, rather it collapses multiple 
associations for the multiple stakeholders involved in research. The pill condenses patient and 
public hope for treatments along with the need for research to find economic, governmental, 
scientific and public support. Without this support it would not be possible to continue the work 
which will make the realisation and implementation of a future of treatment possible. In these 
examples we see the crucial use of tentative auxiliary verbs ‘could’ and ‘might’. Such pervasive 
hedging, and subjunctive language denies certainty whilst promising possibility. Yet, the message 
conveyed in these examples reinforces the certainty that science, like hope, will always be needed. 
Thus science strengthens itself as an inescapable and unending necessity. Like the approaches of 
Bloch (1986) and Miyazaki (2004), the method of hope here is an essential part of the rhetoric 
of scientific engagement. Hope captures potential in action whilst suspending the need to realise 
a certain outcome. The significant difference here is that hope, potentiality and community are 




These examples demonstrate how public engagement becomes part of a process of reshaping, not 
only the researcher, but also re-positioning the public in relation to clinical research. This move 
reflects a shift in governance and what constitutes a responsible science and, moreover, a 
responsible, scientifically-engaged citizen.  
 
The rhetorics of brain donation and research participation: altruism and gifting 
 
Enrolling the public in a dementia research culture is not simply a case of bombarding society 
with an indiscriminate, ever-increasing volume of images of dementia and its research. Here, I 
examine the social framing of the promotion of dementia research participation. Using the 
example of brain donation for dementia research, I reflect upon the idea of participation as an 
altruistic act of gifting, or what Simpson refers to as ‘corporeal charity’ (Simpson 2004). In the 
discourse of research participation as gifting, participation becomes an extended moral act under-
pinning a generalised exchange. This is an exchange which takes place between the participant 
and wider society, and in which the scientist is located as the caretaker or broker of the 
transaction. I argue that this framing of the research exchange locates clinical trials in a novel 
social contract between state, market and society.  
 
The framework of the gift in tissue and organ donation and human participation in research, is 
dominant in post-war European biomedical research policy (Titmuss 1997, Waldby & Mitchell 
2006). This rhetorical framing is based on the principle that research participation, like other 
kinds of tissue donation, must be free from coercion, manipulation and monetary gain. The 
individual makes a free and informed choice to donate their time and their body. In other words, 
it is a gift freely given. However, as extensive discussions of human organ and tissue donation 
have demonstrated (Waldby & Mitchell 2006, Waldby 2014), such ‘gifts’ are complex, socially 
layered artefacts and events. In Mauss’ terms these layers form the ‘spirit’ of the gift (hau), which 
evoke unspoken ties and promises of future reciprocation (Mauss 2002). In the donation of parts 
of the human body, both living and posthumously, these ties and the expectations they form 
develop within distinctive cultural traditions (Simpson 2004). As I discuss below, where the gift 
involved is from the human body, for example a human brain pledged for Alzheimer’s research, 
the layers of complexity become even deeper as concepts of biology, personhood, and identity 




In Miyazaki’s analysis of Fijian gift giving, he does not focus on the ‘spirit’ of the gift or the ties 
it creates. Rather Miyazaki is interested in the state of atemporal suspension created by the 
narrative of the gift. He uses the concept of hope to capture the anticipation but not the certainty 
of future reciprocity. Hope, Miyazaki argues, can usefully be seen as ‘a common operative in all 
knowledge formation’ (Miyazaki 2004: 9). As I discussed in relation to role of boundary objects 
in dementia science, the gift of research participation is not reciprocated by actualised results 
and treatments, but a future of hopeful possibilities. I argue, that the way in which scientific 
engagement and collaborative knowledge work in dementia research has developed relies heavily 
on this fluid and dynamic suspension. This suspension is evoked by the idea of participation as 
a gift given by the patient given to and valued by science and society. This notion of participation 
as a gift predicated on the suspension and future hope is articulated in my interview with the 
research manager (see pages 173-175), who suggests that participation in dementia research turns 
‘a negative into a positive’. Whilst there may be limited benefit for the participant themselves, 
the opportunity to contribute to potential future research and treatment development creates 
‘personal benefit of a tragedy that can’t be escaped’.  
 
The Brains for Dementia Research initiative illustrates how the posthumous donation of the 
human brain carries complex ties of gifting and suspended expectation: 
 
Why do people donate? 
Dementia can overwhelm peoples’ lives 
For many, signing up to become a brain donor can help reduce the helplessness 
they feel in the face of this condition. 
People often want to take this step as a personal and practical contribution 
towards research that will uncover new ways to treat and prevent dementias. 
 
Extract from the Brains for Dementia Research leaflet, provided at a DeNDRoN PPI Meeting 
(2012) 
 
At this point, I want to briefly return to the ‘Mind over Matter’ Exhibition in 2011, which 
worked with the Brains for Dementia Research campaign, donors and the Wellcome Trust to 
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examine and make public what it means to donate a brain. The organisers have produced a 
website, in which participants describe why they made the decision to donate their brain. These 
appear alongside the participant’s photographs, names, narratives, dates of birth and where 
appropriate the date of their death.  
 
‘As well as wanting to help to find a cure for dementia, Albert enjoys the thought of symbolic 
immortality that brain donation offers’ 
Mr Albert Webb 
 
‘Beryl and Erick decided to donate their brains to CFAS because both of her sisters suffered 
from dementia and they wanted to do something to help in finding a cure for it’ 
Mrs Beryl Foreman 
‘Conscience is the only reason she decided to become a brain donor’ 
Mrs Betty Munns 
 
‘She and her husband decided to become brain Donors simply to help “other folk’ 
Mrs Brenda Buck 
 
‘He would like his brain to be used to discover cures for diseases such as Alzheimer’s because 
he thinks, that “losing memory, not knowing where you are, not knowing who you are, is a 
terrible thing”. He would like to be remembered for trying to do his best for the human 
race’. 
Mr Eddie Holden 
 
Mind Over Matter: Memory, Forgetting, Brain Donation and the Search for Cures for 
Dementia (Parry & Dabrowska 2011). 
http://www.mindovermatterproject.co.uk/donors.html 
The participants’ explanations, and in turn the message conveyed by the project, combine the 
sense of hope and possibility with pragmatism and the suggestion of wider social responsibility. 
There is pragmatism in the idea that there is an immediate reward in the sense of an increased 
sense of personal and moral value. The idea that bad deaths can be made good is woven into 
evolving biotechnologies and has become part of a cultural cosmology in which science offers the 
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possibility of escaping the inescapable (Simpson 2001). Our classic image of being diagnosed 
with dementia has become so frightening and the grieving process so painful and prolonged that 
dementia has indeed become an archetype of the ‘bad death’. Research participation, and in this 
case brain donation is seen pragmatically as an opportunity to turn something bad, in to 
something good and to find value and usefulness in a disease which threatens to erase a person’s 
sense of social value. This need to ‘do something’, frames research participation, not only as an 
outward, focused act of altruism for a society of strangers, but also a personal and familial act of 
resistance. As the following Facebook post from the Alzheimer’s Society suggests, whilst dementia 
engagement and research involvement cannot resist the disease, it offers the ‘opportunity’ to 
suspend the devaluing nature of the condition. 
 
 
Figure 35: Social media framing research engagement as altruism. 
 
The value that is gained from participation in research is located in the potential for the benefits 
of future knowledge to improve the lives of “other folk”. The idea of the benefit to an anonymous 
unknown ‘other’ is central to the official ethos of organ and tissue donation. Brain donation is 
an act of altruistic social good. However, at the same time references to the potential that this 
act may help future friends and family, mobilises the idea of a personal, posthumous legacy. This 





example, the grandchildren they don’t yet have) to encourage engagement with the research 




Help us protect this generation from 
dementia. 
 
“Please help us make sure dementia doesn’t 
exist when they grow-up 
Help us fund research into a cure for 
tomorrow and provide the best care for 
people with dementia today 
We must protect future generations from this 
devastating condition” 
 
Figure 36: Mobilising kinship and futurity to support dementia research. 
 
If in Miyazaki’s example of Fijian gift-giving, the ritual process is oriented to evoke the ‘hope of 
God’s blessing’ (2004: 8), dementia engagement in the UK evokes the blessings of science to 
improve the quality of our later life, and future lives. These shared hopes connect UK science 
and scientists to emerging notions of civil society. As defined by Cohen and Arato civil society 
is ‘a sphere of social interaction between the economy and the state, composed above all of the 
intimate sphere (especially the family), the sphere of associations (especially voluntary 
associations), social movements and forms of public communication' (1994: ix). In the context 
of the current decentralisation of the welfare state, Powell argues that, ‘virtue and welfare’ have 
become defined by ‘individual agency and personal responsibility’ (2013:32, cf Powell 2007).  A 
logical corollary of this view is that in the interplay between state and society ‘citizens contend 
for power through society in the pursuit of civic virtue’ (Powell 2013: 6).  What I observed in 
the development of public engagement strategies were scientists and advocates contending for 
power and resources, using the language and rhetoric of civil society to enrol the public into a 
community of research 
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Viewing the rhetoric of dementia engagement through the analytical framework of hope and 
the gift, two further rhetorical themes emerge:  a state of perpetual suspension and possibility, 
and an ongoing movement between the individual and society. In this dynamic context, the 
scientist or the researcher becomes the caretaker of donated time, tissue, bodies and resources 





Figure 37: 'Our brains in their hands' campaign. 
 
A fragile, exposed human brain, is held carefully in the sterile, purple gloved hands of an 
anonymous white coated scientist. The headline ‘Our brains are in their hands’. What message 
does this convey? Science has its hands on our brains? It can cross the boundaries of the body? It 
has powerful access to our sense of self, our personhood, and our biology? The brain becomes a 
manageable artefact, a public artefact upon which science can act. The scientist is taking 
responsibility to protect this fragile object, and we are bound to them in our hope and trust. 
Extract from field notes at the DeNDRoN North East Research Network Event (2012) 
 
As the image above suggests, a central part of the relationship between researcher and participant 
is a sense of trust and belief in the role played by researchers and the messages which convey the 
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idea of science as a social good. These messages play heavily on the idea that a ‘cure’ for dementia 
must exist, even if it is locate in the future. Science merely requires the time, resources and 
ongoing public support and involvement in order for it to be found. Therefore, as part of a 
cyclical logic, clinical research participation becomes integral to both the rights and duties of the 
modern citizen. The impact of public-scientific engagement thus crosses the formal boundaries 
implicit in the idea of a public understanding of science. Dementia research both uses and has 
become permeated by novel forms of social interaction. This kind of engagement entangles 
people in shared notions of hope, responsibility and trust in dementia research: as citizen, as 
scientist and as participant.  
 
The limits of rhetoric  
 
In this chapter, I have explored some of the rhetorical strategies in dementia research, 
engagement and awareness campaigns. I have shown how such campaigns are part of the process 
of remaking negative perceptions of the association of dementia with ‘normal age’ for which 
research has a limited medical capacity to intervene. Both research and non-research contexts are 
used to consolidate a sense of collectivism and collaboration between the scientific community 
and the general public. This approach uses a range of rhetorical moves which connect research 
and research participation with the idea of civil society and uses a dynamic framework of hope, 
potential and trust. Dementia research is thus suspended in a state of continual emergence and 
possibility.  
 
To conclude, I want to reflect on the limits of rhetoric in the campaign for a socially embedded 
dementia research agenda. Far from a campaign delivered fait a compli, this process of research 
engagement is constantly changing and adapting. As the growing network of connections 
between researchers and their publics expand, there is greater potential for information to flow 
against the grain of power, that is, not from scientists to the public, but from the public 
commenting upon the work of science. It is therefore useful to think of civil society as a 
'communicative space' located between ‘competing forces’ in which each group, researcher, 
public participant, policy maker, and industry representative tries to bend ‘the other’ toward 
their particular interests (Powell 2013: 5). This encounter makes for a reflexive negotiation 
between science and society.  The ARUK advert illustrated in figure 37, suggests that we should 
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place ‘our brain in their hands’, but equally, it would seem, we should be aware of the extent 
that their hands need our brains.  
 
Drawing on Miyazaki’s development of the concept of hope I have suggested that suspension 
plays an important rhetorical role in sustaining the value of science in-spite of uncertain results 
and complex processes. However, this places the social-scientific relationship under continual 
tension. This tension runs between hope and trust in the scientific process and expectations for 
science to create tangible products. This is a tension which is not always easy for scientists to 
manage and negotiate. With the increasingly public nature of dementia science, and research 
participation championed as a ‘social good’, public responses to science cannot be wholly hidden 
and ignored. As a result, there are limits to the power of rhetoric to engineer social response and 
action in relation to science. In the chapter that follows I examine the constant process of pull 
and push, persuasion and dissuasion taking place in the relationship between dementia science 
and the UK public. I explore ethnographically examples of when these contradictions and 
anxieties bubbled to the surface. In this volatile and emerging context, I demonstrate how 
researchers use the fluidity of scientific potential to play with the image of science, allowing them 
to sustain the boundaries of their scientific authority, whilst attempting to use the notion of a 




Chapter 7 Anxieties, contradictions & expectations in 
dementia research 
 
In the previous chapter I discussed the communicative strategies developed between research and 
research advocacy groups. I argued that these strategies aimed to consolidate the relationship between 
the wider public and dementia researchers in the UK. This work formed part of a structured research 
agenda which aimed to de-stigmatise dementias, increase rates of early diagnosis, and encourage 
participation of both patients and healthy participants in research into dementia causing conditions. As 
a result of these foci, the public have become an increasingly integral part of the dementia research 
agenda, and opportunities for research engagement, education and awareness have multiplied at an 
impressive rate. I observed this at many of the meetings and events I attended and researchers described 
both the benefits and pressures this approach to science created for them. In this chapter, I use 
ethnographic examples to examine the tensions scientists’ describe in their work. These encounters I 
have described as anxious conversations. They demonstrate the degree to which experimental health 
research involves a relationship between social, political and scientific domains which is not always clear.  
 
Having described these conversations I then go on to discuss three main themes around scientific anxiety 
in dementia research: how to define good science? how to manage the issues raised by scientific 
complexity? and how to work with public expectations? I describe how scientists’ responses to these 
moments of anxiety and conflict lead to cyclical arguments which defend the boundaries of scientific 
authority but then go on to argue for their need for increased fluidity and porosity. Using the work of 
Fischer (2009) and Schechner (1998, 2002, 2011), I demonstrate how these arguments constitute a sort 
of scientific play. In this play, objects of scientific contention are created and destroyed only to be 
recreated. This leads me to recall, Barbara Woodwood Calton’s question with which I began in chapter 
one:  in dementia research between 2010 and 2015, what, if anything has changed?  
 
A ‘poison chalice’: Anxious conversations about research 
 
The hotel conference room is strikingly familiar, a large open space, deeply 
carpeted with matching cushioned chairs. It is hot and humid in June 2011, as 
more than fifty researchers, clinicians, policy makers, and lay participants meet 
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in the north-east of England to discuss the state of dementia research and hear 
presentations from current projects and research initiatives. The success of the 
regional network was praised by a senior neuroscientist: ‘You are officially the 
most active research community in the NHS in this area’. 
 
There was much enthusiastic talk from both researchers and clinicians of the 
‘collective group identity’ connecting researchers and publics, enabling trials to 
start ‘on-time and to target’ improving the ‘quality and quantity’ in research.  
 
As the meeting progressed, discussions were littered with comments which 
painted a slightly different picture of how researchers and clinicians felt about 
developments in dementia research. 
 
When describing the direction taken to develop the burgeoning national 
dementia strategy,  a direction which was to achieve a significant profile in the 
national health funding priorities and public domain, a senior clinician and 
policy maker commented: ‘well we weren’t going to get anything done unless we 
focused on something’. A simmering sense of uncertainty lies below the appearance 
and performance of collective confidence. 
 
Extract from field notes at the 
 Joint Meeting of Regional Association of Old Age Psychiatrists and DeNDRoN 
 
The development of priorities for a national dementia research agenda combined political and 
scientific priorities, as well as being driven by the pragmatic necessity to create and capture public 
interest.  Such interest provided the momentum necessary to ensure long-term investment in the 
field. At the meeting described above, the development of the dementia commissioning pack was 
a hot topic of discussion. As the UK prepared in 2013/14 to move from a primary care trust 
model to localised clinical commissioning groups, this commissioning pack was designed to help 
general practitioners decide how to prioritise dementia-based services in their area. For the first 
time, dementias had dedicated guidance, in the same way as, for instance, cardiac rehabilitation 
services. This guidance demonstrated the success of research organisations and patient groups in 
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raising the political profile of dementia so that it was recognised as a national health and research 
priority. The pack aimed to combine ‘clinical, financial and commercial’ information 
(Department of Health, July 2011) with evidence-based specifications of services, creating a ‘tool-
kit’ for commissioners. The pack aimed to deliver a clearly defined and locally specialised range 
of services whilst maintaining a nationwide patient-centred approach. At the same time, the pack 
had to reflect strict guidelines for fiscal efficiency and value for money, as the impact of the 
financial crisis of 2008 continued to be felt (Nuffield Trust 2011). A stark balance was being 
struck between the understanding, empowering and empathetic language of person-centred 
treatments and carer support, and the financial imperatives of cost-benefit analysis. This 
illustrates the difficult balance being negotiated by clinically-informed researchers, policy-makers 
and practitioners in the NHS managing the clinical, political and economic environment of the 
time. In spite of the plurality being negotiated, the period from 2010 to 2014 marked a 
significant success for dementia research. Over the course of this period, pledges of government 
funding increased dramatically, political and public support was at an unprecedented high, and 
more research was being conducted in this field than ever before. Why then, at the meetings and 
events I attended and the interviews I undertook, was the pervading atmosphere one of tension, 
uncertainty and anxiety? Why, rather than focusing on the achievements and successes of the 
commissioning pack, did a clinician comment, with a tone of resigned frustration, ‘well, at least 
it’s a start’, suggesting a degree of pessimism about the approach being taken.   
 
What this comment revealed was that there was a sense that beneath the benefits, gains and the 
positive progress achieved and acknowledged amongst clinicians and scientists there was a sense 
of caution.  It was not clear what had in fact be achieved so far, what was possible, what had been 
promised, and what precisely, were the public and politicians expectations for dementia research? 
Such comments gave the conference an air of ambivalence.  At times it felt like a performance 
in which unravelling threads revealed doubts about the seemingly optimistic project of changing 
the social, clinical and scientific attitudes toward research in the field of dementia. Achieving a 
dedicated dementia research funding stream as a national research priority had been long in the 
making, but by 2010-2011 it was beginning to be realised in terms of real funding and resource 
allocation. As a consequence, therefore, the success of dementia research was no longer a 
dreamed of impossibility, the imminent future of drug and therapeutic strategies was a growing 




“It’s like a poison chalice, we have the support, we have to do something with 
it now, or we risk putting back the course of dementia research by decades…” 
 
At the same time as I was becoming aware of researcher anxieties, I was also seeing increasing 
evidence of the frustration voiced by public attendees at research events, as recorded in my 
journal: 
 
During the day, I got to know some of the different participants sat around my 
table. One of these was a PhD researcher, Diane. With her supervisor she was 
working on an early stage project to look at the impact of new hospital discharge 
protocols. These were designed to streamline treatment and discharge rates, 
reduce the length of hospital stays in order for people with dementia to return to 
home with appropriate support as quickly as possible. This was based on the 
evidence that longer in-patient stays tended to positively correlate with the 
progression of their dementia condition. Diane was at the stage of processing the 
data they had collected and presenting their early findings which were largely 
positive. People with rapid discharge and at-home support were reported to 
experience a less rapid decline in their symptoms. This was Diane’s first 
conference presentation and her supervisor was in the audience. We shared 
stories about our nervousness, fear of exposure and uncertainty about how our 
work would be received by our peers.  
 
Her paper came after lunch, by which stage much coffee and sugar had been 
consumed to bolster the flagging group. Everything seemed to be going well, her 
results were clearly presented and tempered by the familiar researcher’s caution 
that I used myself: ‘the evidence suggested’, it ‘might be possible’, and there ‘were 
good indications’. There developed a tense atmosphere in the room, in particular 
a gentleman sat in the front row, he shifted impatiently in his seat, noticeably ill 
at ease even in such a large space.  
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When questions were invited he was quick to stand up and address Diane, “This 
would seem like a really important finding. When will it be put into practice in 
hospitals?”  
 
Diane’s response was carefully worded, “well this is an early phase of a much 
bigger study, I’ve been particularly looking at the discharge process but this has 
to be looked at more in-depth in the wider treatment process and would have to 
be tested amongst a larger group”.  
 
The questioner’s agitation grew, “you keep saying this, ‘when’, ‘if’ ‘possibly’”. 
Gesturing frantically to the lady sat next to him he said “what about people, like 
my wife, who need these changes now?”  
 
Diane was clearly anxious, the room was still, as she tried to explain again her 
work was only part of the picture and it was ‘early days’.  
 
“That’s all very well, all you researchers keep saying that, but when are you actually 
going to do something?” 
 
At this point the chair, a senior clinician and national policy advisor stepped in, 
very assertively protecting the researcher, “I think we have to keep in mind what 
we mean by basic research, research doesn’t just translate into a change in practice 
overnight, there are many, many stages that a complex trial like this will have to 
go through before we start to think about the process of implementation. Have 
we got any more questions?’ and with that this particular discussion was 
definitively closed. 
 
Extract from field notes,  
Joint Meeting of Regional Association of Old Age Psychiatrists and DeNDRoN. 
 
These two examples capture a pattern repeated at many of the research events I attended over 
eighteen months of fieldwork. These meetings were often day long, involving presentations on 
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multiple projects. Huge amounts of effort and information were put into the process of 
knowledge exchange, communication and engagement. The languages of caution and 
uncertainty continually bubbled beneath these exchanges making for rather anxious 
conversations. These conversations were punctuated by moments of acutely uncomfortable 
conflict, as the one described above, in which divergent perceptions of what constituted 
successful or ‘good’ research were brought into focus. 
 
It is thus apparent that whilst strategic, collaborative and entangled, the community which I have 
been attempting to trace is far from unified and harmonious. Yet, this is not a thesis about a 
manipulative science, separate from, and acting upon a naïve and passive public. In other words, 
it is not a simple power relationship of experts over lay-participants. Research images and public 
engagement events were designed to influence and persuade, but in drawing the public into an 
emerging research community, individual researcher’s strategies were increasingly subject to 
direct criticism. As such, research meetings often felt like rollercoasters of hope, confidence and 
potential at one moment and risks and despair at another. Such discussions about research 
between lay people and scientists, demonstrated the fundamentally different frameworks being 
used by different actors in dementia research to judge the development and success of a research 
agenda that they themselves were actively shaping. 
 
 
By necessity to have any hope of achieving the desired outcome of progress in dementia 
treatment, research and patient organisations had used the public and political domain to create 
dementia as a visible and viable object of national research and investment. A bargain had been 
struck; research had made itself and its lack of resources prominent, with the promise that 
adequate financing, infrastructure and support would enable it to deliver improved diagnostics, 
treatments and care. As such, positive and outcome-based action was expected and had to be 
seen to be being taken.  
 
Public participants, including patients and carers such as Tom and Barbara introduced in earlier 
chapters, expressed that, for them, the priority was the efficient implementation of existing 
research knowledge so that people currently living with dementia could benefit as much as 
possible. This prompted researchers involved in engagement to ask a range of questions about 
their dialogue with public and political stakeholders. Given the scale and diversity of potential 
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problems presented by clinical trials on dementia syndromes, what were the best areas to focus 
resources on? What were the limits of what was yet not known about the different dementia sub-
types and their interaction? Do the public and policy makers understand the structure of research 
science and the challenges of this particular group of conditions? These questions suggest two 
slightly different foci. Researchers are anxious about how the ‘response-led’, fPB, research 
environment, could create unrealistic pressure on them for the immediate development and 
implementation of new interventions. For them, such interventions are still suspended in the 
future, either through lack of knowledge or the convolutions inherent in the research process. 
For public participants, it is not future knowledge but an anxiety about why existing knowledge 
is so difficult to implement. How can research ‘know’ something, but be unable to effect direct 
and immediate change in health care practices? This tension between different perceptions and 
temporalities of knowledge was often the tipping point in the public-science relationship. Yet, 
how were researchers managing the anxieties that came with working with this tension? To what 
extent would their stakeholders tolerate the time required to develop treatments or technologies 
to the level of phase III clinical trial, that is, one capable of yielding usable drugs and 
interventions? 
 
In discussing these issues with scientists, I found the conversations often returned to the nature 
of the complexities of scientific research. Bureaucratic regulation, the meticulous processes 
underpinning science, the challenges of collaboration and indeed the additional pressure of 
needing to communicate effectively with the public, were all part of the ‘organized 
disorganization’ of research (Hagstrom 1964).  The strategies necessary to develop the identity, 
funding, recruitment, infrastructure and support for UK dementia research, demonstrate a 
growing entanglement between science, state and society. In short, researchers in rising to the  
‘dementia challenge’ were acutely aware of what they perceived as the fundamental gap between 
the rhetoric of hopeful potential knowledge (which made a project financially, logistically and 
organisationally viable in today’s UK health research structure) and the reality of what could be 
achieved in terms of tangible patient outcomes.   
 
In the next section of this chapter I discuss four recurrent themes illustrated by these anxious 
conversations about research and public engagement: defining good science, contesting 




Defining good knowledge, good science, and successful research 
 
As I explored in the opening chapter of this thesis, the question of what constitutes ‘good’ 
knowledge about dementia, is rooted in a long historical process and continually emerges as 
scientific methods and technologies evolve. In this process, changing social perceptions of 
cognitive degeneration and aging combine with the emergence of collaborations between clinical, 
laboratory and biotechnological approaches. The evolution of dementia research within the 
context of new techniques in neuroimaging and bio-molecular chemistry continue to reshape, 
redefine and re-categorise dementia pathologies. This processes has made dementias increasingly 
amenable to complex statistical analysis, and we have more data about these conditions than ever 
before. At the same time, the model of the clinical trial has become the pre-eminent discourse of 
objective, quantifiable success. The observable, measurable and replicable model which moves 
from basic ‘proof of concept’ to implementation creates a form of knowledge which is presented 
as tightly controlled and subject to rigorous testing.  
 
At its height, the model of clinical research has been realised in the form of the randomised 
control trial, the ‘gold standard’ of biomedicine (cf Timmermans & Berg 2010, Moreira & Wills 
2010, Simpson and Sariola 2012). In RCTs, particularly ones which deal with changes in 
cognition and behaviour, the benefits of research are demonstrated through numerical 
assessments developed in the field of health economics, such as the QALY/DALY discussed in 
chapter two. In the UK, and across the globe, these developments in science and technology have 
taken place within the context of the political economy of nation states.  These relations are in 
turn embedded in global market relations. For the researchers I worked with, ‘good knowledge’ 
was the result of ‘good science’, that is, knowledge produced by an internationally recognised, 
systematic, rigorously tested and accountable process. However, the international dimension 
introduces a further layer of complexity to the world in which researchers were working. This 
was illustrated at the NIHR meeting where the development of ‘good’ and ‘better’ dementia 
research was variously defined as robustly evidence-based, peer-reviewed, collaborative and 
efficient, fPB (for patient benefit), and ‘on target and to time’. As the discussion above illustrates, 
there is no simple correlation between ‘good science’ and success; for whom is it successful for 
and in what ways?  If we take as a starting point a definition of ‘success’ as the achievement of an 
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externally agreed and recognised objective, we might also ask, given the range of targets that 
researchers were aiming for, how did researchers themselves evaluate the ‘success’ of their science 
(Oxford English Dictionary 1991)? 
 
I have demonstrated, therefore, that the nature of successful science is often a political and 
economic question as much as it is a scientific one. Even scientifically, for the researchers I was 
working with at the time of this study, knowledge about dementia causing pathologies was, and 
continues to be, in a rapid state of flux. As researchers come to know and understand more about 
dementia, there continue to be fundamental questions and issues at the level of basic science, 
classification and scientific discovery.  As such, ‘good’ research was changing, modifying and 
adapting to new knowledge about dementias.  
 
Dementia researchers, therefore, were never working with simply defined disease objects, but as 
parts of a highly complex assemblage. Consequently, everyday discussions of success or failure 
between researchers were based on the concrete experience of specific tests or findings within a 
particular project. This was often linked to how this result would contribute to, or impact upon 
other parts of the project, and how publishable the result might be. ‘Goodness’ in basic science 
or early stages of clinical research therefore, does not map neatly on to the conceptualisations of 
‘success’ which are held, or believed to be held, by different actors in the research process. For 
those hoping to benefit from science, the ‘good’ was perceived to be located in how the finding 
or product of the process could be used to add ‘value’.  This ‘value’ might be at the personal level 
of the health of the individual, or at the national level influencing public health.  It might also 
be at the level of the global market for the saleable products of health research. Whilst researchers 
are aware of these competing definitions, ‘good science’ was located in the accumulation of 
findings (positive or negative) achieved through ‘good science’, that is, science which is robust 
and processual.   
 
To illustrate these variable readings of what it is to be successful in science, let us begin with a 
model account of successful drug development. Drug X has been identified as having the 
potential for reducing Y, a therapeutic target implicated in the early stages of the development 
of the pathologies which result in AD. Proof of concept and animal-phase testing has 
demonstrated that the drug effectively achieves the reduction of Y in brain tissue. Phase I-III 
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testing in humans confirms the safety of the drug for humans and demonstrates its efficacy, that 
is, that the drug reduces disease progression in a significant number of participants. The drug is 
approved for human use by the European Medicines Agency (EMA), and the UK NICE 
assessment suggests that the treatment has greater ‘benefit’ than ‘cost’ and is suitable for wide-
scale use. Drug X becomes the recommended first-line treatment for early stage dementia. 
Consultants and patients have confidence in the findings. People with early stage cognitive 
changes come forward for early diagnoses and are widely prescribed the treatment. As a result 
many users of the drug benefit from a slowing of the deterioration in cognition. The drug is 
successfully marketed and produces a national economic benefit. The researchers involved are 
able to publish successful results, and develop their reputation and careers. 
 
This example is a dramatic over-simplification. However, even as a hypothetical ideal of success, 
patients who are users of the drug may still evaluate success rather differently. For instance, not 
all users may respond to the drug as expected and  the benefits of that response may change over 
time. Some recipients will have negative side effects which reduce or even override their sense of 
its benefit. It may be that local health policy makes the therapy more accessible in some regions 
than others.  Specific consultants may have their own understanding or experience of the benefits 
of this or other similar therapies. These experiences may make them more, or indeed less, likely 
to make it available to their patients. In addition, those experiencing early memory changes, and 
their primary physicians, may, from prior experience, not have confidence in the diagnostic and 
treatment processes itself. As a result, of such factors the potential user may never have access to, 
or knowledge of the availability of the therapy. This brief thought experiment fashioned from 
my experience with researchers, illustrates how multiple factors beyond the laboratory  - 
individual biology, local policy, physician and patient knowledge and experience - all have the 
potential to change one perception of a research intervention as ‘successful’ into one that is a  
failure. 
 
In reality, most clinical trials will never reach this translational stage of development. Cummings 
et al (2014) in their analysis of American-based clinical trials for drug-development in Alzheimer’s 
disease, between 2002 and 2012, suggests that 99.6% of trials failed to reach the point of 
regulatory review. In addition, relatively few potential ‘agents’ are entering phase I, suggesting 
that the number of new pharmaceutical treatments remains small compared to other fields of 
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research. Where a drug does successfully proceed to ‘human-phase’ testing and wider 
implementation, the process is agonisingly slow, estimated to take around ten to fifteen years. 
Initially, the drug will be available only to the specific range of patients or carers involved in that 
trial. Implementing that treatment across everyday clinical practice is in itself a difficult process. 
It requires changing the knowledge and perceptions of a range of medical practitioners and 
indeed the general public. Thus, making science perform ‘successfully’ does not stop at the 
laboratory door. It engages with local beliefs and attitudes in clinical, political and societal 
domains.  
 
Crucially the dementia research that I was observing was not at this stage of development. The 
majority of the work being discussed by research leaders during the public engagement events 
that I observed was very clearly observational or basic science and not about interventional 
treatments. This is not to say that such treatments would not be developed but that scientists 
were trying to understand the pathologies which cause different types of dementia, and identify 
the best potential therapeutic targets for intervention. Nonetheless, this was a long way from 
providing credible treatments for the large numbers experiencing dementia.   
 
The vaccine and the cascade: contesting causation. 
 
Having established the difficulty of determining what is successful research, in this section I want to 
reflect on a specific case study of how researchers tried to develop a dementia vaccine.  Let me begin 
with an extract from my field notes:  
 
Following the main speakers at an ARUK research event we were invited to look 
around the postgraduate posters on current dementia research projects. David, an 
early career researcher was presenting a poster on his work on molecular imaging 
in dementia research. I asked him about the possibilities of a cure for dementia 
and he described to me the current work being conducted on the bapineuzumab 
dementia vaccine. In lay terms he enthusiastically laid out for me how the vaccine 
aimed to use the body’s own immune system to systematically break down the 
beta-amyloid plaques. A was a dominant target for many in the neuroscientific 
community, believed to be a principle factor in the causal sequence that leads to 
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the neuronal and cognitive degeneration associated with dementia, a process 
which had become known as the ‘amyloid plaque cascade hypothesis’. I had heard 
about the idea of the vaccine through articles and the media, but I explained I 
didn’t really understand what made it a vaccine.  He gleefully took me through 
the process, most of which I failed to follow, of how the body’s own system could 
be switched on to target the particular proteins involved, in something akin to the 
way classic vaccines use the introduction of small amounts of the disease causing 
material to stimulate the body’s immune system to recognise and build antigens 
to prevent future infection.  
 ‘So what happened?’ I asked;  
‘Well, it worked’, he answered, pausing wryly, ‘a trial in the States showed that it 
really effectively broke down the amyloid plaques, cleared them from the affected 
areas.’ 
‘There was just one problem’ he smiles. I waited for the punch line ‘It just didn’t 
halt the neuronal degeneration’ 
‘Oh’ I said confused, 
‘Yeah, the neuronal and cognitive changes kept happening. That’s the interesting 
thing, we’ve always thought the plaque preceded the degeneration, but, now, well 
there’s lots of debate, it means that potentially we’ll have to completely change 
our understanding of the disease pathway. There’s older researchers who are really 
committed to the cascade hypothesis, they’ll keep going down that route. And 
then there are people like my supervisor who thinks, hold on, if the plaques aren’t 
causal then there’s something else in the disease process which we just don’t 
understand yet.’ 
‘So the trial didn’t work then?’ I asked. 
‘Well that depends what you mean by ‘work’’ he answered. 
 
Extract from field notes on a discussion with an early career researcher 
 





We have seen a lot of, particularly as the big pharma companies are doing less, 
we’re seeing less new drugs coming through, we’re seeing less clinical trials in 
smaller biotech companies, we are much more desperate for individual drugs to 
work. And I think we have seen a few examples of failed trials where really they 
should never have moved past phase II, the evidence just wasn’t strong enough, 
but they have been so desperate to take them on that… Perhaps they need to be 
taking stronger advice at that stage. And also there are mechanisms for looking at 
data in trials, sort of part way through, and canning the trial early if it’s not 
working. Very few companies do that, but actually if it saves people participating 
unnecessarily, plus it saves money, we should be doing a lot more of that. 
 
Clive Ballard during a discussion at the Alzheimer’s Society Research Network, 
2011 
 
In the first instance, the failure is in hypotheses, whereas in the second example it is in the way 
that the market has driven the research agenda beyond what the evidence can support.  In the 
third example we can see how research failure is transformed into a potential opportunity for 
hope and future success:  
 
 
Figure 38: Re-narrating the failure of clinical trials (ARUK 2012) 
http://www.alzheimersresearchuk.org/clinical-trials-for-alzheimers-now-is-not-the-time-to-give-up-2/ 
 
The recent failure of two phase 3 clinical trials for Alzheimer’s drugs is a blow to 
the field. Like three previous drugs that also failed in trials, these two antibodies 
– bapineuzumab and solanezumab – worked by targeting a protein called 




will also provoke pharmaceutical companies to question whether they can 
continue to invest in clinical research for such a challenging disease. But now is 
not the time to give up, and these perceived failures could in fact hold the key to 
future success… 
 
With bapineuzumab, understanding why the drug failed will be crucial to 
developing treatments with a better chance of reaching their goals. For 
solanezumab, early reports suggest that there may have been some benefits for 
patients with mild Alzheimer’s disease – adding weight to an emerging theory 
that drugs targeting amyloid would need to be given early to be successful. If we 
can find a reliable and inexpensive method of identifying people on the cusp of 
amyloid build-up, but who have not yet developed symptoms, then drugs that 
target amyloid could have a good chance of bringing real benefit. Meanwhile, 
work on treatments that attack different features of the disease must also 
continue. 
Erik Karran (ARUK 2012) 
 
Here the failure is placed on the timing of drug interventions and the challenge of getting access 
to participants early enough in the disease process. The views of the head of ARUK are summed 
up in an item on their blog in 2013. A trial which fails to produce desired outcomes, may still 
point to additional knowledge which may influence future success. As a result, this questions the 
nature of failure in science itself.  
 
 





At the start of my research in 2010, the potential of disease modifying immunotherapies for 
dementia causing conditions, described popularly as a ‘dementia vaccine’, were gathering great 
momentum and hope was growing within the research community, as well as amongst patient 
advocacy groups. The image of a vaccine drew on the great public health ‘successes’ of the 
childhood vaccination campaigns of the twentieth century, which successfully controlled or, in 
some cases, eradicated some of the infectious diseases which led to high rates of infant and 
childhood morality (Rusnock 2008). However, the failure of the 2012 trials brought great anxiety 
and uncertainty.  A significant amount of industry investment had been dedicated to this research 
pathway, yet how would industry respond to such prominent and late stage failures? To what 
extent did this finding challenge the Aβ hypothesis upon which much dementia research was 
based?  
 
As both the early career researcher and the head of research for the ARUK reflected, such failure 
whilst in many ways ‘devastating’, could not, and should not, be confused with failure in the 
everyday sense of the word. In the classic Popperian manner, hypotheses can and do fail, and, for 
scientists this is part and parcel of ‘good science’ (Latour & Woolgar 1986). Failure and 
falsification prevent ineffective research from progressing, and thus create the opportunity for 
more effective approaches to emerge. In particular, for David, the early career research introduced 
above, this was an exciting time.  The failure of these trials had opened up the possibility for new 
avenues of research and new questions to be considered in a way that had been less possible when 
the Aβ cascade hypothesis had been so dominant.  Yet, if one was a scientist intellectually and 
personally committed to further research on the cascade hypothesis, the outcome of these trials 
could be seriously disturbing. For those who were sceptical of this hypothesis, the trial’s failure 
strengthened the argument for an independent research agenda rather than one driven by the 
logic of the market. Thus, for researchers, success and innovation required space for and 
acceptance of, the possibility of failure in ways that may not be fully appreciated by the public. 
Participation and expectation  
 
Given that research in the field of dementia is still, in many ways, in its early stages, researchers 
often had to engage in a delicate balancing act between the persuasive rhetoric of their potential 
success, and intimations of caution and potential failure. Researchers relied on promoting the 
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possibility of new and more effective treatments, whilst at the same time recognising, as one 
researcher put it:  
The impossibility of predicting the outcomes of the scientific developments. 
When people say “we’re relying on luck then?” I tell them “There’s a lot of luck 
in science”. 
In one breath, researchers emphasised their commitment to developing and translating new 
interventions into practice, whilst in the next, they stressed that this did not necessarily mean 
new effective treatments would be found in this decade or, indeed, in the next. Enrolling the 
public in the research agenda was, therefore, a balancing act. This balance was brought into 
particular focus in the process of recruiting participants who had dementia. I was to find this 
when I found myself in an anxious conversation with a group of nurses involved in the 
recruitment and consent process for clinical research: 
Clinical trials nurse 1: The inclusion and exclusion criteria are really strict. They 
[the research projects] have to make sure that they get the right kind of patient 
for the right trial. But we’re seeing more and more people coming forward who 
are interested in participation.  
Me: Does that mean many people won’t get on to a trial? 
Clinical trials nurse 1: No the majority won’t be suitable, especially with older 
people where lots of them might have pacemakers or be on a lot of medication 
and things like that. 
Me: How do people respond to that? 
Clinical trials nurse 1: What do you mean? 
Me: If they’re [people with dementia] being encouraged to get involved and then 
find they can’t take part in a trial. Does that cause any difficulties? 
Clinical trials nurse 2: I mean it’s a very carefully run process. We’re very careful 
to make sure people don’t have any false expectations, that we don’t give them 
any false hope. We spend a lot of time with them explaining how it works. We 
make sure they know right from the start that there is every chance they probably 
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won’t be suitable, and we make sure they’re OK with that. It’s a process we’ve 
worked really hard to get right, and there are always new trials which they might 
be able to get involved with in the future. 
At the start of the conversation the tone was enthusiastic and open, we were discussing a process 
which they experienced as positive and of mutual value. The coordinators of North-East PPI 
groups saw the genuine benefits participants described and experienced in becoming part of the 
extended research community. These benefits were presented to me as not just participation on 
a clinical trial, but also as highly socially supportive. Public research events, such as the one I was 
attending, enabled people experiencing dementia and their carers to meet, not only with 
researchers and clinicians, but also with one another. A special session was held during one event 
for PPI members to come together and discuss how the initiative was performing, and what other 
sorts of events or sessions members would like to see happen. During this session participants 
expressed that they got pleasure from their involvement, and were always interested to hear about 
the new developments in research. There was also discussion of the forthcoming visit to the 
regional Brain Bank, where participants were going to be given a tour of the facility and discuss 
the brain donation process. 
As at so many events, these conversations were positive and hopeful, and I was left in no doubt 
that the PPI members I met felt genuine benefit from their involvement. However, in my 
conversation with the research nurses, as soon as I asked my question, the atmosphere became 
decidedly frosty. I was suddenly conscious of having crossed the line from an appropriate inquiry 
to more sensitive territory. The conversation was quickly brought to a conclusion as the nurses 
physically turned towards one another and away from me to discuss another aspect of the work 
in which they were involved.  
In broaching the potential for disappointment I had, unintentionally, challenged the discourse 
of hope and positivity. As in the case with Tom at the start of this chapter, public participants 
could and did express their disappointment or frustration with the research process. In this 
instance, however, I was left in no doubt that questions about negative responses were not 
appropriate in this context. In the sense developed by Goffman, I had threatened the front stage 
performance everyone was participating in (1956). This threat had the potential, however slight, 
to damage the greater social performance taking place. My identity ‘within’ the research 
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community, at this moment, was spoiled and I was politely, but firmly shut out of causing any 
further harm. 
The anxiety expressed by researchers was linked not only to how the public responded to them, 
it was also linked to how they imagined the public were likely to respond. Whilst some members 
of the public vocalised their frustration, others were more tolerant of what they understood to 
be the very difficult problem of dementia research: 
 
What I was thinking about was, if all this research was easy then the drug-
companies would have done it, because it’s a very big market. I think that I started 
off looking at the question as a businessman and saying to myself ‘Yeah, that’s 
right. Why are we failing?’ But I don’t think that the researchers should beat 
themselves up too much, certainly not people researching for the Alzheimer’s 
Society, because ‘blue-sky’ research is equally as important as practical, focused 
research. So, perhaps the number of successes that have been had, are only an 
indication of the fact that the easy bit have been done and you’re now looking at 
the difficult bits. 
 
Comment from the floor during the debate ‘Why has dementia research failed’ 
Alzheimer’s Society Research Network (2011) 
 
This comment suggests that the reflexive anxiety of researchers was not purely a response to 
external public pressure, but also part of an internal struggle to make sense of the competing 
scientific, political, social, economic logics within which their work is suspended.  
‘Science takes time, I think the public understand that’ 
 
From this interaction, and from those with other researchers and at public events, the issue of 
expectation in the dementia research process was a tangible source of anxiety, and one which 
needed to be managed. I discussed this with Steven, a research co-ordinator working in another 
regional dementia research network. He initially responded that, ‘science takes time; I think the 
public understand that’. His experience, he said, was that the public were very aware of how 
complex and difficult the problem of dementia is. However, as we talked he described several 
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high profile failures in drug trials he had been aware of, and the ‘erosion’ of the amyloid 
hypothesis in the case of AD. He also mentioned that he was aware of trials where negative 
findings had been supressed, and covered by confidentiality clauses which prevented those 
involved in disseminating the information. So I asked again, how he felt public participants in 
the research process dealt with such problems, given the high level of expectation evolving 
around the dementia research agenda: 
We were running a study, but at the time people were like, “we just don’t 
understand why this isn’t already available.” So I think people do get a bit pissed-
off with the researchers when there is some kind of a consultation process. The 
science is not immediate, that’s the thing. 
Researcher’s experience of public understanding of and response to dementia science was not 
monolithic but plural and mutable. Whilst researchers felt the public appreciated the complexity 
of the process involved in scientific research, this did not preclude them expressing their 
frustration about the time it takes to achieve translational results.  
 
This movement between hope and frustration was well illustrated by a discussion around what 
one clinician saw as a lack of research on dementia for people with Down’s syndrome: 
 
Practitioner: What I want to ask is that nothing has been said about people with 
down-syndrome and down-syndrome dementia. I have worked with a lot of 
people who have down-syndrome with the onset of dementia and it is a problem. 
Researcher 1: I heard it in the news last week about people with down-syndrome 
getting dementia. And in fact as you probably know downs syndrome is a 
chromosomal disorder and on this chromosome is the gene for APP that is the 
gene for the production of amyloid. So Down’s patients [sic patients with downs 
syndrome] get a lot of amyloid and eventually when they get older they get also 
tangles, and this is one of the reasons it was believed that amyloid was one of the 
causes of the Tau pathology that we see in Alzheimer’s patients. But for people 
like me who work in the field this is nothing new at all, we know that people with 
Down’s get dementia much sooner than other Alzheimer patients, so I was really 
astonished when this came as a new thing. 
Researcher 2: I don’t think that is the point though. The point that is being made 
is not about the cause, but this is again going back to what I said before, we have 
known now for more than thirty years that people with Down’s syndrome are at 
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increased risk of developing dementia, yet there is still virtually nothing in terms 
of targeted interventions or particular services for this very, very vulnerable group.  
Researcher 3: Can I just make a point about diagnosing people with down-
syndrome with dementia, and there’s the Down’s Syndrome dementia scale that 
was adapted for people with down-syndrome and I think that that was one of the 
major achievements, because many of the people with down syndrome were 
inappropriately diagnosed with dementia for behavioural problems. Down south 
as far as I know, especially in Cambridgeshire, there is a lot of work being done 
with elderly people with down-syndrome. So there are cases where something has 
been done. 
Practitioner: I just want to know, I mean with all this obviously wonderful 
research going on, how does that get fed into strategic development across health 
and social care? Because I don’t think you can see either in isolation, it’s about 
good quality care wherever it is delivered for people who have a dementia and 
their carers. And how does this happen? Because carers and people will still say 
to me, ‘You are still disjointed, we still go to the clinic, we still see the psycho-
geriatrician, but actually you’re not listening to things about care?’ How do you 
feed those things, those disappointments into the social care system? 
 
Thus, researchers themselves expressed this dual tolerance and frustration about temporality in 
clinical research. On the one hand, things were being done and there was better understanding 
of the diagnostic process for people with Down’s syndrome dementia than ever before. However, 
the increased risk for this group has been known for more than thirty years and yet there 
remained no effective interventions and few specialised services available. One gerontologist 
described this frustration what she saw as a perpetual cycle of knowledge: 
 
If we go by pharmacology, we go into another cycle: The same people who told 
us some seven, eight, ten years ago not to use neuralgic medication, now are at 
the front line of recommending the same drugs that they have banned us from 
using ten years ago. This is in the new policies, even from the Alzheimer’s Society.  
 
So I think that we literally could ‘find’ as professionals, what we have been 
preaching some ten years, twenty years ago. Being in this field for more than 
twenty-five, thirty years now, it seems every 7 to 10 years that we discover the same 




I think it is the time just to look outside the circle, outside the box and think 
about individually targeted care. Each of us, maybe will have tangles and plaques, 
maybe we will have identical tangles and plaques in the same brain areas as your 
people with Alzheimer’s have, but that clinical pathology of how we present with 
those tangles and plaques could be very different, because each of us is very 
different. 
 
Local gerontologist speaking at an ARUK Meeting 2011 
 
New information might emerge and then seemed to become lost in the wider research process, 
only to resurface in new research. Implementation may only occur after many turns of the 
research cycle, by which time ‘good knowledge’ may have fundamentally altered. As scientific 
research constantly develops, ‘old’ knowledge can become ‘new’, and past failures be reshaped as 
current successes. Such narratives of time and complexity suffuse scientists’ anxieties and public 
frustrations. These concerns are nicely summed up in the following DeNDRoN poster. On a 
simple black background is centred a translucent black and white image of the human brain. 
The brain is composed of a mass intertwined ghostly white tangles representing neuronal 
networks. The title announces: 
 
Use your brain to help untangle dementia 
 
The image used plays on the tangles of Tau proteins which are thought to be central to the 
progression of Alzheimer ’s disease. At the same time, the rhetoric hints at the complexity of the 
disease and the science required to understand and address it. It captures the non-linear, lengthy, 
messy process which is the reality of science, particularly in the relatively ‘young’ field of dementia 
research. At the same time, the poster addresses ‘you’ the viewer, as someone who might 
experience directly or indirectly the effects of a dementia. ‘You’ become a potential collaborator 
in the research process whether as a supporter, participant in a clinical trial, or as a person 
pledging donation of their brain after their death. 
211 
 
Conclusion: clinical research at play - managing the borderlines of 
science 
 
In this chapter I have been describing how researchers make sense of what is perceived by many as the 
‘poison chalice’ of the growing success of the dementia research community. The attention and 
accountability which come with substantial funding and a high profile research agenda have created a 
particular environment. This environment is one which is hopeful and full of potential, yet anxious and 
reflexive about when that potential might be realised, and what form it will take. What Konrad describes 
as the ‘radically deterritorialised’ nature of the modern scientific process is particularly apparent in 
researcher’s encounters with public participants (Konrad 2002). These exchanges highlight the 
interaction of different perceptions about what constitutes successful dementia research. These 
boundaries between success and failure, expectation and actuality are managed by narratives which 
perform in cycles. These cycles create hope and potential, only to deconstruct them with reference to 
challenges of the complexities of research.  
 
To conclude I want to reflect briefly on how the cyclical process of the production of knowledge in 
clinical research is reflected in the rhetorics of research policy more broadly. Following Fischer, I argue 
that the cyclical framework enables researchers to manage the plurality involved in the structure of 
contemporary socially engaged clinical science.  
 
 




Figure 41: ‘Research Changes Lives’  
MRC scientific goals 2009-2014 
 
In the foreword to the MRC 2009-2014 Strategic Review shown above, the plural aims and 
identities of contemporary clinical science become visible (2009: 2-3). Written by Sir John 
Chisholm, Chairman and Sir Leszek Borysiewicz, Chief Executive MRC, the document sets out 
what is expected from researchers working in UK science during this period. Whilst the 
document never discusses the fears of failures explored above, the patterns in rhetoric reflect the 
cyclical arguments which dominate the anxious conversations I have been discussing. 
 
In particular, the writers reflect the different temporalities within which research functions. The 
document emphasises the need for the early career support to ensure the best opportunities to 
attract ‘young’ scientific talent, to work with the best and newest technologies. At the same time, 
the document places particular emphasises on ‘the biology of ageing and how it relates to frailty 
and disease’ (MRC 2009: 3) Researchers are asked build for the ‘future’ whilst drawing on an 
internationally prestigious scientific past, to build on an enduring legacy whilst meeting 
continually changing problems.  This comment is emblematic of what began with in the opening 
chapter of this thesis, that a movement between the historical and the emergent, fundamental to 
the shape of scientific knowledge at any one time. 
 
Researchers are tasked with responding to the needs of publics and populations and to 
communicate with all parts of society, whilst at the same time ensuring that research remains 
driven by ‘scientific excellence’. The writers suggest that ‘we must remain driven by the needs of 
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populations, individuals and patients and the desire of scientists to strive for new discoveries to 
improve human health through prevention and treatment’ (MRC 2009: 3). There is at once a 
sense of public-scientific mutuality here, and also a clear potential for the ‘needs’ of the public to 
be incompatible with the ‘desires’ of the scientist. This is seen again in this discussion of basic 
science: 
This not only delivers discoveries but provides the basis for translation of research 
into patient benefit. We must ensure that scientists supported by the MRC have 
confidence that, even in difficult economic circumstances, science of the highest 
quality and excellence can and will be supported and sustained, as it takes many 
years before discoveries achieve their potential in patient care. 
 
MRC 2009-2014 Strategic Review (2009: 2) 
 
Thus scientists are required to ‘respond quickly’ and ‘deliver discoveries’, whilst acknowledging 
that results may be many years away. I would suggest that this pattern has emerged as a 
consequence of an increasing interaction between mode I and mode II science. It is made visible 
through intensifying methods of public engagement and an increasing involvement of ‘publics’ 
and ‘patients’ in the research process. 
 
The narratives of research I have identified repeat these cycles. Researchers emphasise the 
positive developments and successes of the dementia movement, whilst at the same time 
regretting the failures which are often linked to underinvestment in the field. For research to 
continue it can never be truly successful or have a distinct end-point. Nor can research be truly 
flawed or it risks support being withdrawn. In this world failures can be read as successes, and 
future successes may not be achievable without prior failure to guide them. Fischer likens such 
tensions and contradictions to the mobius strip or the ouroborus, the snake eating its tale; they 
twist and turn and resist efforts to pin them down (Fischer 2013: 191-192). 
 
This constant game of the creation and destruction in the realm of dementia science echoes the 
kind of process described in Schechner’s theory of performance (1998, 2004). In order to make 
the social performance ‘real’, that is, to fully embody the role being portrayed, the actor must be 
at once themselves and the character they are creating. The tension and persuasiveness of the 
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performance lies in the skill of the performer to maintain a balance between acting the role and 
becoming the role. Researchers in science practice and engagement are similarly maintaining the 
equilibrium between multiple roles. Suspended between a transparent, trustworthy and 
authoritative role, capable of imminent scientific success; which is, at the same time, presented 
as underfunded, underdeveloped and vulnerable to complexity, risk and failure, researchers are, 
what Schechner informed by Turner (1974, 1982), describes as existing in the subjunctive, the 
‘as if’ (Schechner 1989, 2004:19). Like the ‘mights’ and ‘coulds’ of scientific discourse, research 
is neither truly one thing, nor the other; neither completely capable of success, nor completely 
open to failure. As such, the audience, the participants, funders and politicians, are caught up 
in an unfolding scientific drama. This suggests that it is useful for science to maintain itself in a 
state of rhetorical suspension (Bloch 1986, Miyasaki 2004). 
 
This cyclical structure enables the researcher to move between different orders of knowledge, 
that of: the researcher, the clinician, the local infrastructure, the national political-economy, and 
global scientific-market relations. I have used exchanges with public participants to illustrate 
occasions when this rhetoric appears to have reached its limits. As I have shown, this has resulted 
in very tense and anxious moments in which definitions of success and value were questioned 
both by public participants and by researchers themselves. Whilst these challenges create anxiety 
they do not break the chiastic-cycle of discussion. They may stretch it, push at the boundaries, 
but such is the flexibility of the discourse, the mutability of concepts such as ‘success’, that they 
can be reabsorbed and provide momentum for the next twist and turn in shaping contemporary 
dementia science. Managing these moments of tension result in the reflective and creative social 
dramas from which the community of dementia research is being formed. However, in the next 
turn of the cycle, public participants cannot be pushed out or ignored, indeed, they themselves 
have become part of the cycle which is increasingly shaping biomedical research in the UK. 
 
In the concluding chapter of this thesis I return to the framework of my original question, how 
is biomedical research enacted in dementia science, and what types of relations are implicated in 
this process. Finally, I reflect on the implications these relations have for shape of biomedical 





Chapter 8 Conclusion: tension and suspension in a 
community of research 
 
The principal aim of this thesis has been to describe the relations involved in the emergence of 
a dementia research community in the UK. The account I have given demonstrates how 
collaborative scientific, biomedical, political and public networks are collectively mobilised 
around the concept of dementia as a national crisis. Biomedical researchers are working hard 
to define themselves as the authoritative source of knowledge for an effective solution. However, 
I have shown that the concept of collaborations does not imply a unified community. Rather 
this ethnography demonstrates relations characterised by implicit fractures and tensions. Such 
fractures are particularly apparent in the way dementias and the research process itself is 
understood to exist and to function. I suggest therefore, that the role of such relations in 
dementia research is to maintain a state of suspension in the scientific process. By using the 
term maintained suspension I refer to the processes and practices by which research is kept 
open-ended and incomplete. This incompleteness creates space to respond to criticism of the 
failures of existing science, whilst sustaining trust and hope in the potential of future science.  
 
In this conclusion, following Beck (1992, 1994) and Fischer (1999, 2005, 2007) I build on this 
argument, demonstrating how research knowledge is kept in a state of perpetual suspension, 
the end point continually shifting as the bases for that knowledge continues to evolve. Drawing 
on the work of Nowotny, Scott and Gibbons (2001) I argue that the relations which I describe 
as maintaining suspension in dementia research can be thought of as ‘transgressive’. By using 
the concept of transgressive relations I argue that these are relations which make partial 
connections across scales (Strathern 1991, 1995a). Through institutions, technologies and 
discourses, such relations form and mediate between and across the boundaries of scientific 
practice. At these boundaries, interstitial research organisations and patient advocacy groups 
employ rhetorical imagery and language which both construct and blur the boundaries between 
dementia science and the roles of dementia and science in society. The role played by the public 
within science is shaped by these practices of blurring. This study thus presents a timely case-
study of the strategic connections between contemporary science and society. I raise questions 
about the important future of this relationship, are they relations of collaboration or persuasion? 
This study supports the need for a dynamic and contextual approach to understanding 
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contemporary scientific practice and knowledge making and building on existing work which 
scrutinises the evolving relationship between dementia science and society.  
 
Transgressive relations: boundary crossing in the interplay between 
science and society 
 
The narratives, discourses and rhetorics of contemporary dementia science that I have presented 
in this thesis act as a snapshot of a scientific moment. In this moment the shape of knowledge 
about the diseases that cause dementia is rapidly changing and unfolding. This unfolding is 
marked by tensions evident in discourses that both validate and contest the role of age and aging 
in representations of dementia as a condition and as a social crisis.  Furthermore, the boundaries 
and definitions of the conditions which cause dementia are both asserted and questioned. 
Dementias must be at once made concrete and stable objects for investigation and at the same 
time collapsed as incomplete and inadequate models of understanding.  
 
This ethnographic study can, therefore, be described as an example of techno-scientific 
knowledge production made under the conditions of what Beck (1992) describes as the ‘risk 
society’. In taking this approach, I am understanding knowledge formation as a process shaped 
by the increasing blurring of institutional and organisational boundaries, which lead to and 
emerge from conditions of ‘intellectual and social volatility’ (Nowotny, Scott & Gibbons 2001: 
30). The pluralistic and ambivalent discourses that surround contemporary narratives of 
dementia in research reflect broader changes in the co-evolution of science and society. In this 
environment, knowledge-making processes are explicitly open ended and continual, rather than 
leading toward discrete or defined end points of knowledge. This process reflects what Nowotny, 
Scott and Gibbons describe as ‘the production of the New in an open-ended process of moving 
towards a plurality of unknown futures’ (2001:36). 
 
Nowtony et al. (2005) argue that alongside this environment of uncertainty and plurality there 
has been a loss of public trust in science and scientific authority. Implicit in this change in the 
relationship between science and society are the increasingly blurred boundaries between science 
and industry that occur in large scale biomedical and biotechnological innovation (Nowotny 
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2005). Although important, the mistrust of this relationship is visible throughout my account of 
dementia research. Here relations with industry are viewed as fundamental to the research 
process, but are also a source of deep anxiety around who controls access to resources and 
information and to what ends. Such relations are perceived by both academic and clinical 
researchers to have the potential to compromise the autonomy and independence of scientific 
practice. As a consequence, there are ever increasing demands for scrutiny, transparency, 
accountability and public involvement in scientific, policy, funding and decision-making.  
 
In this ethnography, these demands are realised in a particular way. Public engagement is 
understood by research leaders and policy makers as key to their strategy for managing the 
tensions, anxieties and competing expectations which emerge in the increasingly diffuse and 
interconnected landscape in which biomedical research takes place. In the cases I have described 
here, public involvement is part of the process of ensuring the social acceptability and success of 
an agenda which focuses clinical research on early diagnosis and early clinical intervention. As a 
result, the research process I have described is one of multiple and cross-cutting connections 
between researchers, academic institutions, and national and regional NHS research 
infrastructures (NIHR, MRC, UKCRNP, DeNDRoN,), and key elements of the patient and 
disease advocacy community (Alzheimer’s Society, ARUK).  
 
These connections are visible in the relationships formed by key scientific and clinical research 
leaders in the formation of, and involvement with, dementia advocacy and charity groups. As 
such, patient advocacy groups are shown to be a critical site for creating connections between 
potential recruits and clinical trials. In this relationship, biomedical research is identified as the 
fundamental tool for changing how we live with dementia. As such, patient advocacy groups can 
be understood to be what Epstein (1996) describes as para-political organisations. Such 
organisations conduct key boundary work, with senior scientists holding posts across social, 
scientific and political domains during their careers. To play on Epstein’s concept, such 
organisations might, therefore, also be usefully thought of as para-scientific. By this I recognise 
the process of co-production at work (Jasanoff 2004, 2005, 2007). ‘Para’-work not only flows 
from science to politics, but can also be see to affect the directions in which research practice 
and policy evolves. In bringing together experts and public / patient participants, such para 
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organisations are both a result of, and a driver for the further development of mode II science 
(Nowotny, Scott & Gibson 2001).  
 
Throughout the thesis I have drawn attention to examples of relationality mediated by digital 
and virtual tools. Such domains of engagement play a critical role in the development and 
maintenance of these boundary crossing networks. For instance,: The Alzheimer’s Society 
website provides links to the DeNDRoN groups in England, Wales, Northern Ireland and 
Scotland. Through the society’s website a lay visitor can, at the click of a button, access the 
Clinical Research Network Study Portal (UKCRNP). The UKCRNP enables a visitor to view 
disease specific research taking place in their local region. The visitor can select a particular 
project and find out its aims, objectives, inclusion and exclusion criteria. The language of the 
UKCRNP is clearly biomedical and there are important questions to be asked about the 
availability and accessibility of such technological interfaces across different demographics. 
However, what is of particular interest here is the practice of facilitating connectivity itself, 
however partial or mediated that process might be. The developing virtual nature of evolving 
biomedical research networks marks an important shift in the evolutions of research accessibility 
for society. In just three clicks of a button, a member of the public can send an e-mail to the 
academic or clinician who is designated as a study’s primary investigator. In three clicks a member 
of the public can start the process to see if they are eligible to participate in a clinical study for 
dementia. Such connectivity can be viewed as an example of what Nowotny, Scott and Gibbons 
(2001) describe as ‘transgressive’ technologies. That is, digital tools for research expansion are 
rapidly creating the potential for connectivity and collaborations which are ‘eroding the 
boundaries between different forms of rationality’ (Nowotny, Scott & Gibbons 2001: 32).  
 
Dementia research has continued to be resilient in the competing market of disease movements, 
with a growing profile in the national health agenda between 2010 and 2014. The current scale 
and intensity of marketing and media campaigns for dementia awareness is unprecedented. The 
integration and potential of new forms of hypermedia and mainstream media are being used to 
full advantage to connect this field of research to national awareness. As I explored in chapter 
five, despite the often radically different situated knowledge involved (Starr 1988, 2010, Starr & 
Griesemer 1989, Starr & Bowker 1999), scientific images and images of science in such media 
further erodes the boundaries between researchers and public participants. Such images become 
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a tool for mediating between scientific practice and scientific engagement. The scientific images 
such as MRI, fMRI, PET and SEM used in public engagement suggests to relate concrete practices 
in the laboratory, to the much more open ended and future oriented goal of knowledge 
production which will affect real-world treatment practices. This is particularly true in the use of 
images of science, where generic images of the scientist at work are used to connect what happens 
today in the laboratory to the potential for a ‘cure’ for dementia tomorrow. This process of 
relating the concrete present to the intangible future, resonates with what Nowotny, Scott and 
Gibbons (2001) describe as a fundamental tension in social relations with science and technology 
more broadly: 
 
Science and technology are valued for their capacity to create new knowledge and 
deliver an apparently endless stream of new products, but they are also an equally 
limitless source of new desires and wishes - which can only be satisfied by 'more' 
science and technology. In this sense science and technology dominate in a double 
sense - by delivering 'real', or tangible, results; and by creating insatiable images. 
(Nowotny, Scott & Gibbons 2001: 31) 
 
Images of scientific practice and the brain, are used to convey the potentiality of research 
innovation, in spite of the uncertain nature of the scientific process and complex shape that any 
future intervention for dementia might take.  
Engaging, persuading and collaborating 
 
What does this description of a science characterised by transgressive relations mean for science 
and society? By recognising that public and patient engagement has become folded into the policy 
strategy for successful biomedical research how should it be viewed? Is it a tool for creating 
transparent engagement and better science, or a tool for persuading people to become involved 
in clinical research?  
 
The idea that public engagement in science is a pragmatic strategy and a tool for making willing 
and compliant subjects is well described in the existing literature (Callon 1999, Callon et al 2009, 
Caron-Flinterman, Broerse & Bunders 2005). This approach situates public engagement firmly 
in a Foucauldian framework of power relations within which society becomes complicit in the 
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reification of the hegemony of biomedical authority to define the value of the person (Foucault 
1990, 1992, 1997; Rabinow 1996, Rabinow & Rose 2006, Rose 1991, 1996, 2007). Arnstein 
(1969) for example argued that ‘engagement’, particularly when supported by the state, 
demonstrate relatively limited levels of equity and exchange. Thus, the reality of engagement can, 
at worst, be viewed as what Epstein termed ‘recruitmentology’ (2008). In this framework, 
engagement maintains the appearance of social responsibility, whilst unilaterally supporting the 
aims of the scientific establishment. The practice fulfils the letter of ethical governance without 
necessitating a response to the needs or concerns generated by patient-public perspectives (c.f. 
Callon et al 2009). 
 
Whilst the examples I have presented provide evidence for this imbalance of power, they also 
hint at the limits of this argument. I show at both the start and the end of the thesis three distinct 
examples where participants’ voice their concerns about the aims and goals of dementia research, 
and the failure of research to translate into realisable products to improve the experience of 
people with dementia. It can be argued that these countering discourses are raised and quickly 
submerged by the narrative that researchers cannot simply override the complexity of the 
scientific process, rather dementia research is uniquely complex, under-resourced and takes time.  
 
However, these moments of engagement do demonstrate that public engagement is not as 
controlled or controllable as an instrumentalisation approach would, at first, imply. Whilst 
dementia research charities undoubtedly bring powerful clinical and scientific influences into 
the process of patient advocacy and research agenda, they inevitably bring the public into the 
research processes. In doing so, they create new avenues and expectations for the public to exert 
pressure on how science is scrutinised, funded, approved, and conducted. As such, public 
engagement, being formed of many cross-cutting relations, cannot be wholly contained within 
the power structures of biomedical research. Exchanges between researchers and participants 
increasingly take place in the public domain and via virtual and social media. These exchanges 
are open to immediate scrutiny and comment by a range of actors. Interactions are recorded in 
perpetuity, and can be rapidly re-disseminated or re-used by an uncontrolled range of ‘others’, 
for their own independent aims or agendas. It therefore becomes increasingly difficult for 
scientists not to engage with or respond to these small challenges to the authority of biomedicine. 
The anxiety of researchers during these conversations in which the rehearsed narratives of 
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dementia science are resisted and challenged, suggest that public engagement is far from a 
perfectly controlled scientific tool. Rather, as Nowotny puts it, public engagement has become 
part of a dialogic environment of contemporary science: 
 
‘[A]n increasingly vociferous civil society is questioning the authenticity of the 
public nature of science. In the demand for greater lay participation, science as 
an institution comes under pressure to be more accountable to citizens and less 
closely linked to the interests of politics, the state, and the market’. 
Nowotny (2005:3) 
 
As I have demonstrated here, public engagement, has become increasingly important in shaping 
how scientists construct and re-tell the story of dementia research. Echoing the processes of co-
evolution (Nowotny, Scott & Gibbons 2001) and the co-production of science and society 
(Jasanoff 2011), the process of public engagement, has the capacity to influence processes in 
science by constitutionally altering the shape of society. Thus, access to, and participation in, 
clinical research for dementia is increasingly reframed as both a social ‘right’ and a moral 
responsibility (Harris 2005). The combination of biomedical, public health and national 
economic agendas, with public engagement and political activism suggest clinical research is 
moving toward science as a form of ‘social good’, and participation as a normative social duty. 
By mobilising the moral and social responsibility to participate in the development of new 
medical treatments and biotechnological developments, research participation becomes 
embedded in the idea of social contract. However, the different organisational groups involved 
in this contract - clinical researcher, laboratory researcher, advocate groups and patient groups - 
retain distinct identities whilst coming together to work on the collective theme of dementia 
research. Such groups can have very different perspectives on, and interests in, dementia 
research. The resulting dialogues are made up of plural agendas and competing rhetorics. 
Competition becomes particularly apparent when researchers and participants seek to define 
‘good’ science.  
 
Thus the case of transgressive relations I describe in dementia research, can be seen to create a 
complex network of connections. These are connections which are not clean and linear, but 
messy and incomplete. To adapt to and influence the changing environment of clinical research, 
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stakeholders in the dementia research community both collaborate and compete. Their interests 
coalesce and diverge in dynamic, transitory and fragmented ways. Whilst engaged in 
collaboration and dialogue, researchers and public participants are driven by independent 
interests which can also bring them into social conflict. Collaborations and collective ties are 
used to mobilise social and moral rhetorics. As a result, the notion of ‘good’ science which 
emerges in dementia research is used to exert persuasive pressure in a range directions, leading 
to competing definitions of the aims, outcomes, products and processes of the science involved. 
Thus, this study of dementia science is indicative of the tensions, anxieties and uncertainties of 
contemporary biomedical research. This uncertainty, I argued is highly challenging to negotiate, 
but provides a key space for the rhetoric of hope and futurity which provide the momentum for 
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